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Abstract 
The role of poly(ADP-ribose)polymerase-1 (PARP-1) in the 
cellular response to topoisomerase I poisons. 
P ARP-l inhibitors enhance DNA topoisomerase I (Topo n poison-induced cytotoxicity 
and anti-tumour activity in vitro and in vivo but the underlying mechanism has not been 
defined. Two hypotheses have been proposed to explain this a) PARP-I modulates topo 
I activity via poly(ADP-ribosylation), or b) P ARP-l participates in the repair of topo 1-
induced DNA lesions. To explore these mechanisms we have investigated the cellular 
effects of a novel potent P ARP-l inhibitor, AG 14361 (Ki < 5 nM), in combination with 
the topo I poisons, camptothecin and topotecan. 
PARP-l null mouse embryonic fibroblasts (MEFs) were 3-fold more sensitive to 
topotecan than P ARP-l wild type MEFs. AG 14361 significantly enhanced topotecan-
induced growth inhibition by 3-fold in PARP-l wild-type cells but not PARP-l null 
cells. This confirms that P ARP-l activity promotes survival after topo I poison-induced 
cytotoxicity and the cellular effects of AG 14361 are due to P ARP-l inhibition. 
AG 14316 also increased camptothecin-induced growth inhibition in human K562 cells 
~2-fold. AG14361 did not affect topo I-DNA cleavable complexes or topo I relaxation 
activity. In contrast, AG 14361 increased camptothecin-induced DNA strand breaks by 
20% and significantly retarded DNA repair following camptothecin removal, (620/0 
inhibition of repair 10 mins). These data indicate a role for PARP-l in the repair of 
topo I poison-mediated damage. The repair pathways by which P ARP-l acts to repair 
this damage was investigated using repair-deficient cells. AG 14361 significantly 
potentiated the cytotoxicity of camptothecin in AA8 repair-proficient and V3 non-
homologous end joining-deficient cells, but not the irs 1 SF homologous recombination-
deficient or EM9 base excision repair-deficient cells. AG 14361 also failed to retard the 
repair of camptothecin-induced DNA damage in EM9 cells. This suggests that P ARP-l 
may act via BER and possibly HR to repair topo I poison-mediated DNA damage. 
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Chapter 1 
Introduction. 
1 
1.1 Cancer 
Cancer is a major cause of morbidity in the UK, with one in three people being 
diagnosed with cancer during their lifetime and a quarter of all deaths attributable to 
cancer. There are over 200 different types of cancer of which the four main types, lung, 
breast, prostate and colorectal account for over half of all cases diagnosed. Lung cancer 
accounts for a quarter of all cancer deaths. A major cause of cancer is exposure to 
environmental carcinogens, e.g. natural and synthetic chemicals, radiation and viruses. 
Diet is also a large factor in predicting likelihood of developing cancer. Cigarette 
smoking has been identified as the single most important cause of preventable disease 
and premature death in the UK and accounts for one third of all deaths from cancer 
(www .cancerresearchuk.org). 
Cancers are largely caused by changes in the DNA as a result of exposure to agents in 
the environment or spontaneous events. A single change may have little effect 
however, these changes accumulate and eventually may activate proto-oncogenes, or 
inactivate tumour suppressor genes. Some individuals have inherited genetic defects 
that predispose them to certain forms of cancer, these include some forms of breast 
cancer characterised by loss of the BRCAI gene, and loss of the APC gene 
(adenomatous polyposis coli) found in familial colon cancer (Bale and Brown, 2001). 
Loss of the p53 tumour suppressor gene in Li-Fraumeni syndrome is associated with the 
development of tumours at a variety of sites including breast, brain and adrenal gland at 
and early age (Bale and Brown, 2001). Inherited genetic defects account for a minority 
of cancer cases and it is generally accepted that cancers are more common in the 
elderly; 65 % of cancer cases occurring in those over 65 years, due to the accumulation 
of several genetic changes. It is now recognised that epigenetic changes such as 
silencing of tumour suppressor genes by promoter hypermethylation and chromatin 
remodelling (acetylation/methylation) also playa role (Rountree et ai., 2001). 
Cancer is characterised by uncontrolled cell growth that is the result of accumulating 
genetic and/or epigenetic changes. Cancer is thought to be clonal in origin with a single 
altered cell proliferating to form a tumour. The growth of this tumour may be slo\\ and 
is not necessarily life-threatening. However, due to the inherent genetic instability of 
tumour cells, accumulating changes cause the development of heterogeneity and some 
tumour cells can metastasise from their primary site to form tumours in other tissues. 
As the tumours grow they develop their own blood supply by the process of 
angiogenesis. The condition becomes life threatening when the primary tumour and the 
metastases invade the neighbouring tissues and essential organs. 
1.2 Cancer treatment 
Cancer treatment most commonly compnses of surgery, radiotherapy and 
chemotherapy. More recently, immunotherapy, hormone therapy and gene therapy are 
being developed for use in the treatment of cancer. The type of treatment received 
depends on the size and location of the tumour. Most anti-cancer therapies target 
dividing cells. Because of the high turnover of these cells they have less time to repair 
the damage caused by chemotherapy or radiotherapy, this is detected by the cell and 
may lead to cell death. Unfortunately, normal cells such as bone marrow and hair 
follicles also undergo frequent cell division, therefore leading to the side effects of 
myelosupression and hair loss. Many cancers are intrinsically resistant to chemo- and 
radiotherapy or acquire resistance during treatment. Increasing efforts are being made 
to develop new therapies using new targets and drug combinations to overcome drug-
resistance, and to reduce the side effects of the treatments currently in use. 
1.2.1 Surgery. 
Surgery is the most effective treatment for cancer if the tumour is detected before it has 
metastasised and if all of the tumour mass can be removed. Therefore primary tumours 
are normally treated by surgical removal, and this is followed up with chemotherapy, 
and/or radiotherapy, to remove residual tumour. If the tumour is in an area that is not 
accessible to surgery other therapies must be used (reviewed by Rosenberg, 2001). 
1.2.2 Radiotherapy. 
Radiotherapy is often used in combination with surgery or chemotherapy. Radiation 
therapy is useful if the tumour is in a location where surgery is difficult to perform and 
if the tumour is locally confined. Radiotherapy is also useful as it can be focussed on 
the tumour thereby reducing damage to healthy tissues. This therapy can also be used to 
ensure that all of the tumour is removed following surgery by targeting the radiation to 
the margins of the tumour. Radiotherapy works by generating reactive oxygen species 
3 
that cause significant levels of DNA damage in the target cells. This DNA damage is 
detected by the cell and can result in cell death (reviewed in Hellman, 2001) 
1.2.3 Hormone therapy. 
Honnone therapy can be used III the treatment of hormone-dependent breast and 
prostate cancers. Cells in the breast and prostate require oestrogens or androgens for 
their proliferation. Therefore inhibition of the synthesis of these hormones or blocking 
the honnone receptor on the target cells can slow tumour growth and lead to tumour 
regression. Tamoxifen is one of the most widely used forms of hormone therapy. It is 
an antioestrogen, that binds to the oestrogen receptor without activating gene 
transcription and so preventing the normal substrate oestrodiol from stimulating 
proliferation. (reviewed in Erlichman and Laprinzi, 2001) 
1.2.4 Gene Therapy. 
Gene therapy is being investigated as an approach for cancer therapy. Gene regulation 
can be achieved using nucleotides that are complementary to the mRNA sequences for 
over produced proteins. These sequences bind the overproduced mRNA sequence and 
target it for degradation. An alternative approach is to introduce a gene to replace a 
defective one or that down regulates growth. An example is the delivery of p53 into 
tumour cells by adenoviral vectors. This would function to restore the tumour 
suppressor function of p53 that is often lost in tumour development. Such therapies are 
still in development. (reviewed in Hwu, 2001) 
1.2.5 Immunotherpy. 
In order to increase the specificity of the chemotherapy for the malignant cells, the use 
of antibodies to target drugs to tumours using specific tumour markers is being 
developed. In antibody directed pro-drug therapy (ADEPT) the drug is given in a form 
that is inactive. Using antibodies, the enzyme that can activate the pro-drug is targeted 
to the tumour; therefore the drug only becomes active at the required location. 
(reviewed in Weiner et ai., 2001) 
1.2.6 Chemotherapy. 
If the tumour has spread from its primary site then systemic therapy, most usually 
chemotherapy, is required. Chemotherapy can be used on its own or in combination 
with surgery, radiotherapy or other chemotheraputics. It can be used in the adjuvant 
setting to kill undetected tumour cells remaining following other treatments such as 
surgery, to slow disease progression and give better quality of life. The drugs used 
largely act by damaging DNA, inhibiting its synthesis or processing, or interfere with 
the progression of cells through the cell cycle e.g. tubulin binders. DNA-directed 
chemotherapy can be divided into agents which interact with DNA directly, i.e. the 
DNA alkylating agents, and DNA intercalators, agents which inhibit DNA synthesis i.e. 
the antimetabolites, and agents which interfere with DNA processing e.g. the 
topoisomerase poisons. Alkylating agents were one of the first classes of drug used to 
treat cancer. They can be subdivided into the monofunctional agents, such as 
temozolomide, and the bifunctional agents such as 1,3-(bis(2-chloroethyl)-I-nitrosourea 
(BeNU) and the platinum agents such as cisplatin. These agents form adducts on DNA 
bases leading to DNA inter and intra-strand cross-links. Antimetabolites have also been 
used to treat cancer for the past 50 or more years. These are analogues of natural 
products involved in DNA synthesis and can be subdivided into nucleoside or base 
analogues and antifolates. One of the earliest base analogues is 5-fluorouricil (5-FU), 
This analogue of thymine may be converted to the triphosphate and incorporated into 
RNA, or through metabolism to deoxynucleotides 5FdUMP and 5FdUTP which can 
inhibit thymidylate synthase, the rate limiting step for dTTP biosynthesis and hence 
DNA synthesis, and be incorporated into DNA in place of dTTP (reviewed in Longley 
et al., 2003). More recent nucleoside analogues include gemcitabine, a cytosine 
analogue, which following conversion to its triphosphate is inserted into the DNA, 
causing chain termination. Antifolates such as methotrexate (first introduced in the 
1950's) are analogues of folic acid and inhibit the folate-dependent enzymes e.g. 
dihydrofolate reductase, required for the synthesis of purine and thymine nuceotides 
(reviewed in various chapters of de Vita, 2001). 
Another major class of DNA-directed chemotherapeutic agents are the topoisomerase 
poisons. These have largely been identified from screening natural products e.g. those 
derived from fungi and plants used in herbal medicines, and their semi-synthetic 
derivatives. These agents inhibit the DNA processing activity of topoisomerase I and II 
converting these essential cellular enzymes into cellular poisons. The topoisomerase II 
inhibitors, such as doxorubicin (derived from Streptomyces pellcetics) and etoposide 
(derived from Podophyllum peltatwn, mayapple), were the first to be developed and, by 
stabilising the normally transient topo II-DNA cleavable complex lead to persistent 
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DNA double strand breaks. The exclusive target of the camptothecins (deriyed from 
Camptotheca acuminata) such as topotecan and irinotecan now widely used in the 
treatment of colon and ovarian cancer has been identified as topoisomerase I. 
Topoisomerase I and its inhibition are described in the following sections. 
1.3 Topoisomerases. 
The topoisomerases are a family of proteins that catalyse the breakage, unwinding and 
religation of DNA to relieve torsional strain associated with the processes of replication 
transcription, recombination and DNA repair. The topoisomerase family is divided into 
three groups based on their mechanism of action; these are type 1-3', 1-5' and II. Type 1-
3' topoisomerases include human DNA topoisomerase I, and cleave a single strand of 
DNA via a 3 '-phosphotyrosine intermediate relieving torsional strain by one tum. Type 
1-5' topoisomerases include bacterial DNA topoisomerase I and cleave single stranded 
DNA via a 5'-phosphotyrosine intermediate (Champoux, 1978). Type II topoisomerases 
cleave double stranded DNA via two 5'-phosphotyrosine intermediates (Sander and 
Hsieh, 1983). They act as a homodimer and lead to unwinding of DNA by two turns 
and are also able to catenate and decatenate DNA. These type II topoisomerases require 
ATP as an energy cofactor. The topoisomerases have been reviewed by Wang et al., 
(1996). As only human DNA topoisomerase I is discussed in this study a detailed 
description of the other topoisomerases is not included. 
1.3.1 Human DNA Topoisomerase I. 
Human DNA topoisomerase I (Topo I, EC 5.99.1.2) is a nuclear protein which is 
present in all cells at levels of between 106 and 107 molecules per cell (Roca et al., 
1995). It is expressed throughout the cell cycle, with a slight increase in activity at S-
phase (Heck et al., 1988). 
1.3.2 Structure of Topoisomerase I. 
Topoisomerase I is a 100 kDa monomeric protein consisting of 765 ammo acids 
encoded by a gene located on chromosome 20q 11.2-13.1 (Juan ct al., 1988). The 
structure of DNA topoisomerase I has been extensively reviewed by Berger (1998). 
Human topoisomerase I comprises of 4 domains; a 24 kDa N-terminal domain, a 56 
kDa core domain, divided into subdomains I, II and III, a 7 kDa linker domain and a 6 
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kDa C-tenninal domain (see Figure.I.1) (Champoux et al., 1998, Stewart et al., 1996). 
The 210 residue N-tenninal domain contains 90% polar and 72% charged residues, and 
is largely disordered, and most inter-species variation is seen in this region. This 
domain is thought to be important for interactions with other proteins and contains a 
nuclear localisation sequence, although this domain can be removed from the enzyme 
without significant effect on the activity of the enzyme. The C-tenninal domain is the 
most conserved region of topoisomerase I across species and contains the active site Tyr 
723 residue responsible for catalysis. The core domain is also highly conserved and 
binds preferentially to supercoiled DNA. Core sub domains I and II fonn the upper half 
or "cap" of the clamp-like confonnation fonned on binding of the topoisomerase I 
molecule to DNA. Core subdomain III and the C-tenninal domain form the lower half 
of the clamp making interactions with the DNA and wrapping completely around the 
DNA. The linker domain is between subdomain II and the C-tenninal domain, it 
protrudes out from the core of the molecule, and is thought to control the rotation of the 
uncleaved strand during relaxation. The linker region is less well conserved and is not 
essential for catalytic activity (Redinbo et al., 1998, Stewart et aI., 1998). 
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Figure.I.1 Crystal structure of mammalian DNA topoisomerase I in complex with 
DNA. (from Redinbo et al., 1999) 
1.3.3 Topoisomerase I mechanism. 
The main role of topoisomerase I is to remove excessive positive supercoils, as well as 
negative supercoils arising during DNA replication and transcription. The mechanism 
by which topoisomerase I achieves this is shown in Figure 2. Topoisomerase I wraps 
completely around the DNA and buries it in a DNA-binding pore of 15-20 A diameter. 
Topoisomerase I binds to the DNA over a 10 bp sequence, with the cleavage site 
centrally placed (Stevnsner et al., 1989). The enzyme contacts the DNA almost 
exclusively by protein-DNA phosphate interactions, and appears to make only one base 
specific interaction adjacent to the site of cleavage and covalent attachment using 
lysine 532 in the core domain III (Stewart et al., 1998). DNA topoisomerase I clea es 
one of the DNA strands via a nuc1eophillic attack of the phosphodiester bond in D A. 
This forms a covalent linkage between a tyrosine group (Tyr 723 In human 
topoisomeras I) at the acti e site of topoisomerase I and a 3'-phosphate group n th 
DNA backbone. This is t m1ed th clea able compl . Onc the cleavable c mph.: ' 
has been fonned the DNA can be unwound. Stewart et al., (1998) proposed a controlled 
rotation mechanism for relaxation by mammalian topoisomerase I. In this model, the 
rotation of the DNA duplex downstream of the cleavage site about the intact strand is 
controlled or hindered by interactions with the "cap" of the enzyme, as well as the linker 
domain. The flexibility of these domains was proposed to aid the relaxation mechanism 
(Redinbo et al., 1999). Following relaxation of the DNA, the DNA strand is religated 
and and the active tyrosine is released from the end of the DNA. Topoisomerase I then 
dissociates from the DNA. 
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Figure 1.2 Unwinding of DNA by topoisomerase I (from Pommier et al., 1998) 
1.3.4 Regulation of topoisomerase I by other proteins. 
Topoisomerase I can be modified post-translationally by a number of different 
mechanisms. Interaction with other proteins may also have an effect on the activity of 
topoisomerase 1. In this section the modifications and interactions that are relevant to 
this study are discussed. 
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Phosphorylation. 
Topoisomerase I has been shown to be phosphorylated in vitro and in vivo. In \'itro 
experiments have shown that phosphorylation of serine residues enhances acti\'ity 
where as phosphorylation of tyrosine residues, causes inactivation (Tse-Dinh et al., 
1984, Pommier et al., 1990). In vivo studies have shown that topoisomerase I is 
phosphorylated in response to a number of different stimuli including epidermal growth 
factor and insulin (Samuels et al., 1994). Topoisomerase I is phosphorylated by caesin 
kinase II, and protein kinase C on serine or threonine residues under the influence of 
different stimuli. Protein kinase C and caesin kinase II may regulate topoisomerase I 
activity, stabilise the cleavable complex, or influence the recruitment of to poi some rase I 
to other proteins. The level of phosphorylation may also determine the sensitivity of 
cells to camptothecin (Pommier et at., 1990). 
Poly(ADP-ribosylation}. 
PARP-1 has been shown to poly(ADP-ribosylate) topoisomerase I in vitro and in whole 
cells, causing inhibition of topoisomerase I relaxation activity (Jongstra-Bilan et at., 
1983, Ferro and Olivera, 1984, Krupitza and Cerutti, 1989). This is thought to be due to 
an increase in the negative charge of topoisomerase I associated with (ADP-ribose) 
polymers resulting in repUlsion of topoisomerase I from DNA. Poly(ADP-ribosylation) 
of topoisomerase I also occurs following treatment with ionising radiation (Boothman et 
al., 1998). Po1y(ADP-ribosylation) of topoisomerase I is described in detail in chapter 
4. 
p53. 
Topoisomerase I interacts directly with the tumour suppressor protein p53, as shown by 
co-immunoprecipitation studies (Gobert et al., 1996, and 1999). This interaction serves 
to increase the activity of topoisomerase 1. There is a difference in the interaction 
between topoisomerase I and p53 in cells containing wild type and mutant p53. In HT-
29 cells expressing mutant p53, the two proteins are always associated where as in 
MCF-7 cells with wt p53 the association is tightly regulated, taking place only during 
periods of genotoxic stress (Gobert et at., 1999). The topoisomerase I-p53 complex has 
also been shown to be poly(ADP-ribosylated) in response to y-irradiation (Smith and 
Grosovsky, 1999). It is thought that the p53 response to DNA damage may involve 
topoisomerase 1. 
10 
Ubiquitination and Sumoylation. 
Topoisomerase I has been shown to be ubiqutinated and sumoylated in response to 
treatment with topoisomerase I poisons (Desai et aI., 1997, Mao et aI., 2000). 
Ubiquitination of topoisomerase I results in its degradation by the 26S proteosome and 
may be a factor in determining drug resistance (Desai et al., 2001). Sumoylation 
involves the conjugation of small ubiquitin-like modifiers (SUMas) to the target 
proteins in a process called sumoylation. Sumoylation requires UBC9, an E2 enzyme 
involved in the formation of a covalent bond with lysine residues on the target protein. 
It is thought that SUMas may compete with ubiquitin to target the protein for 
degradation. Mo et al., (2001) have shown that the sumoylation of topoisomerase I is 
associated with its nuclear delocalisation, and suggest that SUMO may be an address 
tag for this process. Sumoylation may act as a rescuing mechanism to prevent further 
DNA damage mediated via topoisomerase 1. 
1.4 Topoisomerase I poisons. 
Topoisomerase I poisons are an exciting class of chemotherapeutic agents that are used 
in the treatment of a number of malignancies including colorectal and ovarian cancers. 
Topoisomerase I poison sensitivity has been reported to be related to the levels of 
topoisomerase I in the cell and, since topoisomerase I is frequently present at higher 
levels in some tumour cells compared to normal cells from the same tissue, a degree of 
selective anti-tumour activity is predicted. For example, colorectal and prostate tumour 
cells have been shown to have 2 to 35-fold higher levels of topoisomerase I protein 
corresponding to similar increases in gene expression and catalytic activity compared to 
normal cells from the same origin (Husain et al., 1994, Madden and Champoux, 1992). 
Combine this with the fact that tumour cells are dividing and therefore conducting 
replication and transcription (processes that topoisomerase I is involved in) and this 
makes topoisomerase I a promising target for anticancer therapy. Topoisomerase I 
poisons used today are derivatives of the natural product camptothecin, and include 
topotecan and irinotecan. The structures of these compounds are sho\vn in Figure 
1.3""] and have been described most recently by Ulukan and Swaan, (2002), and 
Pizzolato and Saltz (2003). 
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Figure 1.3 Structure of the Camptothecins. 
1.4.1 Camptothecin. 
Camptothecin is a plant alkaloid that was first isolated from stem wood of Camptotheca 
acuminata (family Nyssaceae) during a National Cancer Institute screen searching 
thousands of plants for steroids (Wall et al., 1966). All of these extracts were tested for 
their antiviral, antibacterial and anti tumour activity. The extract from C. acuminata had 
significant anti tumour activity in a standard in \'i\'O test system as well as in murine 
leukaemic L 121 0 cells. Therefore this agent was seen as a possible anti-tumour agent. 
Canlptothecin was approved by the Food and Drug Administration (FDA). for use 
against colon carcinoma in the 1970s. It was also evaluated against other forms of 
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cancer and showed impressive anti tumour activity In patients with gastrointestinal 
cancer. However it was shown to cause unpredictable and severe adverse effects 
including myelosupression, vomiting, diarrhoea, and severe haemorrhagic cystitis. 
Because of these findings clinical trials of camptothecin were terminated in 1972 
(Moertal et al., 1972). 
DNA topoisomerase I was shown to be the sole molecular target of camptothecin in 
purified systems and in cultured mammalian cells (Hsiang et al., 1985, Hsiang and Liu, 
1988). Both of these studies showed that camptothecin increased the level of protein-
linked DNA strand breaks, and that these breaks were reversible on removal of 
camptothecin. Immunoblot analysis of camptothecin-treated cell lysates showed that 
there was a dose-dependent decrease in the amount of topoisomerase I detectable on the 
blot with increasing concentrations of camptothecin. The explanation for this was that 
there was an increase in the number of topoisomerase I-DNA complexes, which were 
too bulky to run through the gel, presumably due to stabilisation of the cleavable 
complex. This was proved by the digestion of the extracts with DNase I and subsequent 
immunoblotting which resulted in the reappearance of topoisomerase I bands. This 
therefore showed that camptothecin interferes with topoisomerase I by trapping the 
reversible enzyme-DNA cleavable complex. 
Once the intracellular target of camptothecin had been discovered there was renewed 
interest in this class of compounds. It was shown that administration of the water 
soluble sodium salt of camptothecin resulted in much less of an antitumour effect, and 
more severe side effects compared to the natural product of camptothecin (Gottleib et 
al., 1970). This was related to the open lactone ring present in this structure 
(Slichenmyer et al., 1993). Therefore this heralded the development of camptothecin-
derivatives, based on structure activity relationships, containing a closed lactone ring. 
Of these compounds, topotecan and irinotecan were the most promising anticancer 
agents in phase I clinical trials although exatecan, and rubitecan are currently in phase II 
clinical trials. lrinotecan and topotecan are described in detail below and all 
topoisomerase I poisons have been extensively reviewed by Ulukan and Swaan, (2002), 
Pizzolato and Saltz, (2003), and Koh and Nishio, (2000). 
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1.4.2 Topotecan 
Topotecan (TP, 9-[(dimethylamino)methyl]-10-hydroxy-camptothecin, Hycamtin©) is a 
water-soluble camptothecin derivative that acts without further modification to inhibit 
topoisomerase I. Topotecan has impressive anti tumour activity in vitro and in tumour 
xenograft models covering a wide range of tumour types (Houghton et at., 1992, 
Kingsbury, 1991). The FDA approved it for use in 1996 in patients with cisplatin-
refractory ovarian carcinoma and as second-line therapy for non-small cell lung cancer 
(Takimoto 1997, ten Bokkel Huinink et at., 1997). Topotecan has been accepted for use 
in these refractory malignancies, however no randomised trial has ever shown a survival 
benefit with topotecan compared to other therapies. Topotecan is currently in clinical 
trials for a number of different malignancies on its own and in combination with 
ionising radiation, paclitaxel, etoposide, cisplatin and cytarabine. 
1.4.3 Irintotecan. 
lrinotecan (CPT-II, 7 -ethyl-l 0-[ 4-( I-piperidino) ]carbonyloxycamptothecin, 
Camptosar©) is a potent semi-synthetic water-soluble analogue of camptothecin. 
Irinotecan acts as a pro-drug and has to be converted in vivo into the active compound 
SN-38. This conversion involves the cleavage of the dipiperidino side chain of 
irinotecan by carboxylesterase found in the gut and liver (Takasuna et a/., 1996). SN-38 
is 1000-fold more potent than irinotecan in cells, although the actual concentrations of 
SN-38 may be 1000-fold lower than irinotecan, therefore irinotecan itself may 
contribute some way towards anti-tumour activity (Kawoto et a/., 1991). 
lrinotecan was developed in Japan and was first approved for use against lung cancers 
in Japan in 1994. Subsequently it was approved for use as a second-line agent against 
colon cancer in Europe in 1995, and this remains the largest use for this compound 
today. Irinotecan is being studied for use against other malignancies including 
mesothelioma, ovarian cancer and some forms of head and neck cancers. 
Although the camptothecins have impressive anti-tumour activity there are limitations 
to the use of these drugs, including the rapid reversibility of the cleavable complex and 
the instability of the lactone form of canlptothecin at physiological pH. Therefore other 
non-camptothecin topoisomerase I inhibitors are being developed. These compounds 
are intercalators or minor groove binders and therefore may interact with other proteins. 
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Non-camptothecins such as rebeccamycin, intoplicine and ecteinascidin, are currently in 
clinical trials. 
1.4.4 Topoisomerase I Poison Mechanism of Action. 
Topoisomerase I poisons act by reversibly stabilising the topoisomerase I-DNA 
complex by inhibiting the religation step of the enzymes catalytic cycle, converting 
topoisomerase I into a cellular poison (Hsaing et al., 1985, Svejstrup et al., 1991) 
although there is evidence that the camptothecins may inhibit the cleavage step as well 
(Kjeldson et al., 1992). This cleavable complex is reversible on removal of drug and is 
not itself a cytotoxic lesion. Cytotoxity of topoisomerase I poisons is largely S-phase -
specific. D'Arpa et al., (1990), showed that in V79 cells treated with camptothecin, 
cytotoxicity increased with progression of the cells from G 1 to S-phase and decreased 
on progression to G2. When DNA synthesis was inhibited by treatment with 
aphidicolin, camptothecin was ineffective. It is thought that the S-phase specific 
cytotoxic lesion caused by camptothecin is generated following the collision of the 
camptothecin-stabilised cleavable complex with the progressing replication fork. This 
collision results in the production of DNA double strand breaks and an irreversible 
topoisomerase I-DNA complex (Zhang et al., 1990) (Figure 1.4). This damage is 
detected by the cell and triggers other cellular processes, which lead to cell cycle arrest 
in the G2 phase, and eventually cell death. 
There is also an S-phase independent mechanism of cytotoxicity, demonstrated by the 
ability of high doses of camptothecin to kill cells treated with aphidicolin to inhibit 
replication (Goldwasser et al., 1996, Barrows et al., 1998). EM9, base excision repair 
(BER) deficient cells, have been shown to be hypersensitive to camptothecin even when 
treated with aphidicolin suggesting that BER might be important for the non-S-phase 
component of camptothecin-toxicity (Barrows et al., 1998). Wu and Liu, (1997) 
proposed a "Transcription Collision Model" to explain replication independent-
camptothecin toxicity. In this model it is thought that collision between the 
topoisomerase I cleavable complex located on the template strand and the elongating 
RNA polynlerase results in transcription arrest and the conversion of the cleavable 
complex into irreversible strand breaks (Figure 1.5). Further explanations for S-phase 
independent cytotoxicity are discussed in Barrows et aI., (1998). 
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Figure 1.4 "Replication fork collision model" of topoisomerase I poison-mediated 
cytotoxicity . 
The topoisomerase I-DNA complex is stabilised by camptothecin, to form the stabilised 
cleavable complex and a single strand break. Collision with the progressing replication 
fork results in the generation of single and double DNA strand breaks. 
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Figure 1.5 "Transcription collision model" (adapted from Wu and Liu, 1997). 
Collision of RNA polymerase with a stabilised cleavable complex located on the 
template strand results in the formation of an irreversible single strand break. The 
transiently broken 5'-OR end is shown displaced from the duplex by the DNA helix 
tracking activity of the RNA polymerase. 
1.4.5 Binding of camptothecin to the cleavage complex. 
Topoisomerase I binds DNA in a sequence specific manner. Under normal conditions a 
T is preferred at the -1 position i.e. the 3'-terminus of the cleaved DNA. There is no 
sequence preference at the +1 position i.e. the base at the 5' terminus of the break. 
Camptothecin only traps topoisomerase I-DNA complexes at certain cleavage sites. In 
the presence of camptothecin there is a strong preference for a G at the + 1 position. 
This suggests that camptothecin interacts with the G at the 5' terminus of the cl a age 
site or th C on the non-clea ed strand (J axel et a/., 1991, Tanizawa et a/ .. 1993). 
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The stacking model has been proposed as a mechanism for the interaction of 
camptothecin with the cleavable complex following investigation of the crystal structure 
of topo I bound to camptothecin (figure 1.6, Redinbo et al., 1998). In this model 
camptothecin is stacked between the terminal + 1 guanine on the scissile strand of DNA 
and the side chain of asparagine 722 of topoisomerase I in the major groove of the 
DNA. There are sites for H-bond interactions, particularly with the asparagine 533 and 
the arginine 364 residues that are found to protrude into the DNA major groove. These 
residues interact with the double bonded lactone oxygen in the E-ring of camptothecin 
and the hydroxyl group at the 20S chiral centre. Camptothecin is also thought to 
interact with the active site of topoisomerase I, as mutations in the catalytic site confer 
camptothecin-resistance (Fujimori et al., 1995). 
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Figure 1.6. Proposed model for camptothecin binding. (A) A schematic 
representation of the key hydrogen bond and ring-stacking interactions made between 
the human topoisomerase I-DNA covalent complex and camptothecin in the proposed 
camptothecin binding mode. The atomic nomenclature for camptothecin is also 
indicated. (From Redinbo ct al., 1998). 
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1.4.6 Resistance to topoisomerase I poisons 
Mechanisms of resistance to topoisomerase I poisons can be divided into 3 categories: 
(i) pre-target events such as accumulation of camptothecin in the cell, 
(ii) drug-target events such as altered topoisomerase I levels, activity and mutation, 
(iii) post-target events such as DNA repair. 
Drug accumulation. 
Passive diffusion may playa role in the uptake of camptothecins, although it has also 
been shown that energy-requiring processes may be involved in their accumulation. 
Several ATP-binding cassette (ABC) proteins are able to pump camptothecin out of the 
cell and overexpression of P-glycoprotein can confer resistance to topoisomerase I 
poisons. A screen to identify mutations that lead to camptothecin-resistance in yeast 
identified two ABC proteins, Snq2 and Pdr5. In addition the Bcrp/Mxr was shown to be 
overexpressed in cells resistant to topotecan and SN-38, and inhibition of Mrp2 by 
antisense oligonucleotides increased sensitivity to SN-38 and irinotecan (Saleem et al., 
2000). 
Topoisomerase I activity. 
Topoisomerase I expression has been shown to be a good predictor of cellular or tumour 
sensitivity as elevated levels of topoisomerase I were related to increased sensitivity to 
topoisomerase I poisons (Madden and Champoux, 1992, and Husain et al., 1994). 
However a direct link between topoisomerase I activity and tumour response remains 
controversial with a number of authors reporting no clear link between the two factors 
(Goldwasser et al., 1995, Voigt et al., 1997). Voigt et al., evaluated the effect of 
topoisomerase I activity on the cytotoxic response to topoisomerase I poisons and 
demonstrated that topoisomerase I activity was not a good single predictor of 
sensitivity. A correlation between activity in cells and drug response was seen 
following a 2 hour exposure but not after 24 hours. This correlation was only between 
cell lines of the same origin and there was no trend when cell lines from different 
origins were considered. However as these cells were all from a different background 
there may be many factors determining their differential sensitivities. Similar results 
were obtained by Goldwasser et al.. (1995) using a panel of cell lines with different 
sensitivities to camptothecin. This study showed that the levels of cleavable complexes 
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fonned in response to camptothecin were the best indicator of the growth inhibitory 
effects of camptothecin. However, some cell lines displayed differences in growth 
inhibition that were not accompanied by similar differences in cleavable complex levels. 
This study also showed that p53 status was not a detenninant of response. These 
authors concluded that the factors detennining sensitivity to topoisomerase I poisons are 
numerous and may depend on other factors downstream of the cleavable complex as 
well as cleavable complex fonnation itself. Nevertheless, in studies comparing cells of 
the same parental background there is a clear link between sensitivity to topoisomerase I 
poisons and topoisomerase I activity. In such experiments there are fewer differences 
between the cell lines that may account for differences in sensitivity between parental 
and derivative cell lines. 
Some studies have shown that camptothecin-induced down regulation of topoisomerase 
I is defective in a number of tumour cell lines (Desai et al., 2001). There was an inverse 
correlation between the amount of down regulation and the degree of sensitivity in the 
cell. This suggests a role for topoisomerase I degradation in the development of 
resistance to topoisomerase I poisons. Ubiquitination and degradation by the 26S 
proteasome pathway is stimulated in response to treatment with camptothecin, therefore 
it is possible that this pathway may be involved in cellular resistance to topoisomerase I 
pOIsons. 
Topoisomerase I mutations are probably not relevant for camptothecin resistance in a 
clinical setting as mutations in topoisomerase I are not commonly found in resistant 
tumours and are often a late event in the development of camptothecin resistance in the 
laboratory. Of the mutations that have been studied, most of these seem to cluster 
around the catalytic tyrosine 723 residue. For example, in the camptothecin-resistant 
CCRF-CEM line, mutation of asparagine 722 to serine confers camptothecin-resistance. 
Resistance inducing mutations are found in other conserved regions of topoisomerase I, 
these are thought to be brought close to the active site by protein folding (Kubota et aI., 
1992). 
DNA Repair. 
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The repair of topoisomerase I-DNA complexes has an impact on the sensitivity to 
camptothecin. The exact nature of the repair of the topoisomerase I-DNA complex is 
unclear. The first step is thought to involve a 3'-specific tyrosyl DNA 
phosphodiesterase that specifically cleaves the phosphotyrosyl bond between the 
enzyme and the DNA (Pouliot et al., 1999). As topoisomerase I is ubiquitinated and 
sumoylated, mainly while attached to DNA, following treatment with camptothecin, this 
may also be a mechanism of repair or damage limitation (Desai et al., 2001). The single 
stand break can be repaired by base excision repair (BER) or nucleotide excision repair 
(NER). The DNA strand breaks produced on collision with the replication fork may be 
repaired by either of the double strand break repair pathways, homologous 
recombination (RR) or non-homologous end-joining (NHEJ). Cells deficient in various 
components of these pathways have been shown to be hypersensitive to camptothecin. 
Similarly, some camptothecin resistant cells have been shown to exhibit enhanced NER 
capacity (Fujimori et al., 1996). The repair of top I poison induced DNA damage is 
described in detail in chapter 6 and has been reviewed by Pourquier and Pommier 
(2001). 
1.5 DNA repair. 
DNA damaging agents cause a number of different types of damage that have to be 
repaired using different strategies. The normal cellular response to DNA damage is to 
signal to halt the cell cycle, inhibit transcription, replication and chromosome 
segregation and either repair the DNA or execute apoptosis. Long-term, failure to 
repair the DNA or to apoptose may lead to accumulation of mutations and chromosome 
aberrations, which may cause cancer. Cells have multiple pathways for repairing the 
various types of DNA damage. Defects in any of these pathways predisposes to 
malignancies. There are a number of damage repair pathways in mammals. Nucleotide 
excision repair (NER), and base excision repair (BER) repair damage to single strands 
of DNA whereas homologous recombination (RR) and non-homologous end-joining 
(NHEJ) repair double strand breaks. Mismatch repair is responsible for the repair of 
replication errors such as mismatches, deletions and insertions. DNA damage can also 
be repaired by direct reversal of the modified base using specific alkytransferases such 
as 0 6 -methylguanine DNA methyltransferase (MGMT). Only the repair pathways that 
are relevant to this thesis have been described in detail in the following sections. 
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1.5.1 Base excision repair (BER). 
Base excision repair is the major pathway for the correction of damage caused by X-
rays, oxygen radicals, and alkylating agents. The lesions caused by these agents include 
abasic sites, 8-oxoguanine, and single strand breaks. These lesions mayor may not 
impede transcription or replication but frequently cause small mutations and only affect 
one of the DNA strands. The BER pathway has been reviewed in detail by Hansen and 
Kelly (2000), Krokan et al., (2000) and Hoeijmakers (2001). 
BER is divided into two sub-pathways determined by the length of the resynthesised 
patch. The major pathway in mammals is the short patch pathway. Short patch repair 
deals with the repair of single base alterations. Long patch repair, the minor pathway, 
involves the resynthesis of 2-8 nucleotides and repairs damage that is not able to be 
processed by the short patch pathway. However there may be crossover between these 
pathways. Both pathways are summarised in Figure 1.7. 
Damage caused by methylation, deamination, or exposure to reactive oxygen species 
results in base modification. Such damage is recognised by glycosylases specific for 
individual base alterations (Lindahl, 1974). These recognise suspect bases, and flip 
them out of the helix by DNA backbone compression. The base is cleaved out by 
hydrolysis of the N-glycosyl bond linking damaged bases to the sugar-phosphate 
backbone to leave an abasic site (Dodson et al.,1994). AP endunclease 1 (APE1) causes 
a nick in the DNA strand at the abasic site and generates a 3' hydroxyl and a 5'-
deoxyribosephosphate (Kane and Linn, 1981). Following this step, repair can continue 
by either of the two sub-pathways. The major pathway followed (the short patch 
pathway (Dianov et al., 1998)), involves the recruitment of DNA pol P to repair the 5'-
deoxyribosephosphate (DRP) terminus created by APE 1 inserting a single nucleotide to 
fill the gap. The remaining nick is sealed by DNA ligase III (Srivastava et al., 1998). 
Abasic sites can also occur due to spontaneous hydrolysis or exposure to ionising 
radiation resulting in single strand breaks. Under these circumstances there is no need 
for the removal of bases, instead it is thought that polynucleotide kinase (PNK) and 
P ARP-l may be involved and act to trim the ends for repair synthesis PNK or APE-l 
modify the DNA so that there are 5'-phosphates and 3'-hydroxyl ends. PARP-l binds as 
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a dimer, to the DNA breaks which activate the enzyme leading to addition of PAR 
polymers to P ARP-1 itself and other acceptor proteins. The automodification of 
poly(ADP-ribose) may recruit XRCC1-DNA ligase III complex. DNA polP and ligase 
III then fill and religate the gap. 
Under some circumstances repair may not be able to continue via the short patch 
pathway. For example, DNA pol P may not be able to repair the DRP produced in the 
short patch pathway if it is reduced or oxidised. Under these circumstances the long 
patch pathway is used. This is thought to involve the recruitment of P ARP-1, PCNA 
and FEN-1 in addition to the short patch pathway BER components, and stimulates the 
extension of the gap to 2-8 nucleotides and the cleavage of the flap by FEN-I. DNA pol 
P and possibly DNA pol 8/E repair the remaining gap and the ends are rejoined by ligase 
I (Klugland and Lindahl, 1997). As indicated in Figure 1.7, there may be cross over 
between the long and short patch pathways. 
BER protein interactions. 
XRCC 1 is the scaffold protein of the BER pathway and interacts with many of the 
proteins involved in this pathway (reviewed by Caldecott, 2003). XRCC1 interacts with 
P ARP-1, pol P and ligase III (Caldecott et ai., 1996) and PNK (Whitehouse et ai., 
2001) XRCC1 binds to the BRCA-1 C-terminal (BRCT) domain of PARP-1 via its 
own BRCT domain (Masson et ai., 1998). It is thought that P ARP-1 may recruit 
XRCC 1 to sites of damage as XRCC 1 preferentially interacts with ADP-ribosylated 
PARP-1 (Schreiber et ai., 2002). XRCC1 may then recruit the other enzymes in tum. 
XRCC 1 is known to stimulate the kinase and phosphatase activities of PNK, and has 
been shown to interact with PNK in a yeast-2-hybrid screen (Whitehouse et al., 2001). 
XRCC1 interacts with DNA pol-P via its N-terminal domain, and it is thought that this 
complex may surround the DNA and prevent further damage to the undamaged strand 
(Marintchev et al., 2000). DNA ligase III and XRCC 1 interact via their BRCT domains 
(Nash et ai., 1997), and it is thought that this interaction functions to stabilise DNA 
ligase III and to target it to sites of damage. 
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Figure 1.7 Base excision repair. (Picture adapted from Hoeijmakers, 2001). 
Description of the pathway is included in the text arrows indicate cross over between 
the two pathways may occur at these points. 
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1.5.2 Nucleotide excision repair (NER). 
NER repairs DNA damage that distorts the DNA helix, interfering with base pairing 
(Global genome-NER; GG-NER) and obstruction of transcription by blocking the 
progress of RNA polymerases (transcription-coupled NER; TC-NER). The lesions 
repaired by NER are mainly caused by exogenous sources such as UV light, causing 
distortions in DNA such as thymidine dimers. Polycyclic aromatic hydrocarbons and 
cisplatin induced damage is also thought to be repaired through the NER pathway. 
Defects in the NER pathway can result in extreme sun sensitivity as seen in the 
Xerodemum Pigmentosum syndrome increasing the likelihood of developing cancer 
1000-fold. (reviewed in Hoeijmakers, 2001). 
Around 25 proteins participate in NER. The detection of DNA damage is carried out by 
different proteins in each of the sub pathways. In GG-NER XPC-hHR23B detects the 
damage where as two proteins associated with Cockayne Syndrome, CSA and CSB, are 
used in TC-NER. Following detection, XPB and XPD helicases open the DNA around 
the site of damage and this open intermediate is stabilised by Replication protein A 
(RP A). XPG and ERCC1/XPF are endonucleases that cleave the 3' and 5' ends of the 
damaged strand leaving a 24-32 bp gap, which is filled by the regular replication 
machinery (de Laat et aI., 1999). 
1.5.3 Double strand break repair. 
DNA double strand breaks (DSB) arise from exposure to ionising radiation, free 
radicals, chemicals such as cisplatin, and during the replication of a single strand break. 
Following detection of a DSB a complex cascade of reactions is initiated to halt the cell 
cycle and recruit repair proteins. The Ataxia telangiectasia-mutated (ATM) protein is 
one of the early initiators of this process. ATM, Ataxia telangiectasia related (ATR) 
and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) are serine/threonine 
kinases which phosphorylate histone H2AX in the DNA domain next to the DSB, this 
may result in modulation of the chromatin structure allowing access of the DNA repair 
proteins. ATM and ATR also signal the DNA damage by phosphorylating p53, 
resulting in its stabilisation. p53 halts the cell cycle in G 1 by inducing the expression of 
genes such as p21 (which lead to growth arrest), or bax (leading to apoptosis). There 
are two mechanisms of DSB repair described in the following sectons. When a second 
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copy of the DNA is available homologous recombination (HR) is the mechanism of 
choice; otherwise the more error-prone non-homologous end-joining pathway (NHEJ) is 
used. HR is the most accurate as it uses a template, and NHEJ is more error-prone as 
end-joining mechanisms may involve the deletion of bases that can lead to mutations. 
Mammalian cells repair the majority of DSBs by NHEJ, although this pathway may be 
coupled to HR to generate accurate repair of strand breaks. The mechanisms are shown 
in Figure 1.8. (Reviewed in Hoeijmakers 2001 and Kanaar et aI., 1998). 
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Figure 1.8 Mechanisms of Double Strand Break Repair (Hoeijrnaker 2001). 
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1.5.3.1 Homologous recombination (HR). 
This pathway repairs double strand breaks using the sister chromatid as a template to 
provide a perfect copy. Therefore this pathway is conducted in the S and G2 phases of 
the cell cycle where the second copy is present. To allow strand invasion into 
homologous sequences, the 5'-3' exonuclease activity of the RAD50IMREI1INBS 1 
complex exposes both of the 3' ends at the double strand break. This complex can be 
phosphorylated by ATM. RP A aids the assembly of a RAD51 nucleofilament that may 
include XRCC2, XRCC3, RAD51B, C and D. This nucleoprotein filament searches for 
the homologous duplex DNA. When the correct sequence has been located, DNA 
strand exchange creates a joint molecule between the homologous damaged and 
undamaged DNA duplexes. The gap is filled by a DNA polymerase and the strand 
rejoined by a ligase. Finally the so-called Holliday junctions are resolved by resolvases 
(Hoeijmakers, 2001, and Kanaar et al., 1998). 
1.5.3.2 Non-homologous end joining (NHEJ). 
NHEJ is a more error-prone mechanism of double strand break repair occurring in the 
G 1 phase of the cell cycle. Cells in G 1 only have the homologous chromosome to use 
as a template for repair, which may be difficult to find, and is dangerous to use as may 
lead to homozygosity for recessive mutations. In NHEJ, the ends of the breaks are 
simply rejoined without a template, sometimes with the loss or gain of a few 
nucleotides. This process is carried out by the Ku70/80 complex and DNA-PKcs, 
which bind the ends that are religated by XRCC4-ligase I (Khanna and Jackson, 2001). 
1.6 PARP-1. 
A major component of BER is P ARP-l, which was discovered in the 1960's although 
the first description of a NAD+ consuming enzyme was made by Riott et al., in 1956. In 
this early study it was observed that treatment of cells with the alkylating agent 2,4,6,-
triethyleneimino-l ,3,5,-triazine resulted in the inhibition of glycolysis that was mediated 
via a depletion in NAD+. This was followed by the first reports of the formation of 
polymers of ADP-ribose. Chambon et al., (1963) reported the incorporation of C4C]-
adenine-labelled A TP into an acid-insoluble fraction of a nuclear preparation of chicken 
liver and that this could be enhanced 1000-fold by the addition of nicotinamide 
mononucleotide. It has since been shown that the enzyme, poJy(ADP-
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ribose )polymerase-l (P ARP-l) is activated in response to alkylating agents and IS 
responsible for the synthesis of (ADP-ribose) polymers (Whish et aI., 1975). 
PARP-l (EC 2.4.2.30) is a 113 kDa nuclear enzyme containing 1014 amino acids, 
encoded by a single copy gene at the q41-q42 position of chromosome 1. P ARP-l is 
found in most eukaryotic cells at levels of between 105 and 106 copies per cell, in a 
dimeric form. P ARP-l activity is low under "normal" cellular conditions but is 
stimulated by more than 500-fold in the presence of DNA strand breaks (Benjamin and 
Gill, 1980, reviewed by de Murcia et al., 1994). 
1.6.1 PARP Homologues. 
To date 15 P ARP homologues have been identified by sequence homology. P ARP-l 
was the original poly(ADP-ribosylating) protein identified in the 1960s and has been 
followed by the discovery of others more recently. The characteristics of the more 
extensively studied P ARP homologues are described below; these have been reviewed 
in de Murcia and Shall (2000), Smith (2001) and Bouchard et aI., (2003). 
PARP-2 
P ARP-2 was discovered after the observation that P ARP-l null cells still showed 
residual P ARP activity following DNA damage (Arne et aI., 1999). P ARP-2 is a 
nuclear protein similar to PARP-l (60 % homology) and is activated in response to 
DNA damage. This protein is 64.8 kDa and shares considerable homology to the 
catalytic domain of P ARP-l and has the ability to bind DNA even though it does not 
have the zinc finger-binding domain found in P ARP-l. P ARP-2 has been shown to be a 
member of the BER repair complex, interacting with XRCCl, DNA pol~ and DNA 
ligase III. P ARP-2 forms a dimer with itself and P ARP-l. P ARP-2 null cells have been 
shown to be deficient in strand break resealing following treatment with MNU, similar 
to that observed in P ARP-l null cells (Schreiber et aI., 2002). Therefore P ARP-2 seems 
to playa role in BER, and may compensate for lack ofP ARP-l. 
PARP-3 
PARP-3 is a 60 kDa protein, whose gene is located on chromosome 3. This P ARP has 
neither a DNA binding domain (DB D) or automodification domain. This protein has 
been shown to localise to the centriole throughout the cell cycle. (Johanssen el al., 
1999) 
PARP-4 (PH5P or VPARP) 
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P ARP-4 is a multifunctional 192 kDa protein belonging to the inter-a-inhibitor family. 
This protein has been isolated as one of those found in the Vault ribonucleoprotein 
particle. This protein contains a P ARP catalytic domain. (Jean et al., 1999) 
Tankyrase 1 (PARP-5) 
Tankyrase is a 142 kDa protein localised in the telomeres. It contains a PARP-l 
catalytic fragment. Its function is to negatively regulate the TRF-l protein involved in 
telomere elongation. Thus poly(ADP-ribosylation) of TRF-l by tankyrase-l functions 
to regulate telomere length.(Smith 1998, 2000) 
Tankyrase 2 (PARP-6) 
Tankyrase 2 is more than 80% homologous to tankyrase 1 and has a similar function. It 
is expressed in the cytoplasm and can be recruited to the telomeres to bind TRF-l. It 
associates with the Golgi apparatus. Overexpression of this protein leads to necrosis. 
Ti PARP 
Ti P ARP is a 75 Kda P ARP that is inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxine. 
sPARP-l 
This is a short form of P ARP-l possibly resulting from an alternative start site in the 
P ARP-l gene. It is a 55-kDa protein containing the catalytic domain of P ARP-l. It is 
located in the nucleus and is stimulated by genotoxic stress. Strand breaks are not 
needed for activation of sP ARP. 
1.6.2 Structure of PARP-1. 
PARP-I can be divided into three domains by proteolytic cleavage, a 46 kDa, DNA-
binding domain, a 22 kDa automodification domain and a 54 kDa C-terminal substrate 
binding domain (Kamishita et al., 1984). The domain structure of P ARP-l is shown in 
Figure 1.9 and has been extensively reviewed by reviewed Masutani et at., 2003, and de 
Murcia and Shall 2000). 
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Figure 1.9 Schematic representation of the structure of P ARP-l. Adapted from 
Masson et ai., (1998). NLS, Nuclear localisation sequence; BRCT, BRCA1 C-terminus 
motif. 
DNA binding domain. 
The N-terrninal DNA-binding domain contains two zinc-finger motifs, a basic amino 
acid sequence, a nuclear localisation sequence, and a cysteine rich sequence. The zinc 
fingers share the same sequence motif of Cysteine-X2-Cysteine-X28_30-Histidine-X2-
Cysteine, where X is any amino acid. This motif binds a zinc atom in a tetrahedral 
complex using the Cys and His residues. It was originally thought that the second zinc 
finger was essential for the recognition of the single strand breaks, however it has since 
been shown that both of the zinc fingers are capable of single strand break recognition 
(Gradwohl et ai., 1990, de Murcia and Shall, 2000). However the first zinc finger is 
essential for activation of P ARP-1 in response to DNA damage, whereas deletion of the 
second zinc finger does not prevent activation of P ARP-1 (Ikejima et al., 1990). This 
zinc-finger region detects DNA single-strand breaks and interacts with one and a half 
turns of the DNA helix, protecting seven nucleotides either side of the break 
independently of DNA sequence (Menissier de Murcia et al., 1989). A basic amino 
acid sequence present down stream of the zinc fingers also contributes to non-specific 
DNA binding activity (Ikejima et al., 1990). The DNA binding domain also contains 
regions for protein-protein interactions. Proteins found to interact with this area of 
PARP-1 include histones, PARP-1, XRCC1 (Masson et al., 1998), DNA pol a (Dantzer 
tat., 1999), and the transcription factors TEF-1 and RxRa. The DNA binding domain 
also contains a bipartite NLS that ensures that P ARP-1 is transported through the 
nucl ar membrane into the nucleus. 
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Automodification domain. 
p ARP-l fonns homodimers with itself and is able to ADP-ribosylate the adjacent 
P ARP-l molecule at sites within the automodification domain. This auto poly(ADP-
ribosylation) takes place mainly on 15 conserved glutamate residues and interferes with 
DNA binding due to charge repulsion between the negatively charged polymer and 
DNA. The automodification domain contains a BRCT motif commonly found in DNA 
repair and cell cycle checkpoint proteins. This motif binds ubc9 (ubiquitin-conjugating 
enzyme-9) (Masson et al., 1997), Oct-l (POU-homeodomain-containing octamer 
transcription factor-I) (Nie et al., 1998), YYl (Yin-Yang-l) (Griesenbeck et al., 1999), 
as well as P ARP-l and P ARP-2 (Schreiber et al., 2002). 
C-terminal catalytic domain. 
The C-tenninal domain of P ARP-l is the most highly conserved region of the P ARP-l 
protein. It is conserved 100% in vertebrates and shows 92 % homology amongst other 
speCIes. The C-tenninal catalytic domain is responsible for all of the catalytic activity 
associated with the P ARP-l protein; NAD+ hydrolysis, initiation, elongation, branching 
and tennination of polymer. Initiation involves the attachment of ADP-ribose to a 
protein acceptor. Elongation involves the addition of more ADP-ribose polymers, and 
polymer length can range from a few to 200 residues. It is thought that for every 
initiation step P ARP-l catalyses over 200 elongation and 5-7 branching reactions. 
1.6.3 PARP-1 reaction mechanism. 
Poly(ADP-ribosylation) is a post translational modification of nuclear proteins. In 
response to DNA damage, P ARP-l binds the DNA strand break through the N-tenninal 
DNA binding domain and catalyses the transfer of an ADP-ribose unit from its substrate 
NAD+ to a nucleophillic acceptor protein, releasing nicotinamide. This reaction 
involves the breakage of the glycosidic bond between the Cl' atom of ribose and the 
nicotinamide in NAD+ (Figure 1.10), and the fonnation of a new glycosidic bond to the 
nucleophillic acceptor. Glutamic acid, aspartic acid, or lysine residues act as acceptors 
for poly(ADP-ribosylation) on the target protein. For elongation, the ADP-ribose is 
added to the 2'-hydroxyl of the nicotinamide ribose (a), or adenine ribose (P) for the 
fonnation of branched polymers. In the case of automodification P ARP-l acts as a 
homodimer where each monomer poly(ADP-ribosylates) glutamate residues on the 
other P ARP-l molecule (Mendoza-Gonzalez and Alvarez-Gonzalez, 1993; reviewed by 
de Murcia cf a/., 1994 and Lindahl ef ([/., 1995). 
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Figure 1.10 Synthesis of poly(ADP-ribose) by PARP-1. Addition of ADP-ribose to 
growing polymer chain and release of nicotinamide. (Picture provided by N. Curtin, 
NICR) 
1.6.4 Poly(ADP-ribose) degradation. 
Poly(ADP-ribose) is degraded within approximately 2-5 minutes of polymer formation 
by poly(ADP-ribose) glycohydrolase (PARG). PARG specifically splits ribose-ribose 
bonds of linear and banched forms of poly(ADP-ribose) degrading polymer down to the 
protein-bound ADP-ribose residue. The last residue may be removed by ADP-ribosyl 
protein lyase (Hatakeyama et al., 1986), however more recently it has been shown that 
the last residue may be removed by P ARG (Jacobson et al., 2003). 
1.6.5 Acceptors of poly(ADP-ribose). 
PARP-l catalyses the formation ofpoly(ADP-ribose) polymers on PARP-l itself and a 
number of other DNA binding proteins. Poly(ADP-ribose) binding can be very strong 
and covalent poly(ADP-ribose)-histone (HI and H2B) complexes resist strong acids, 
detergents and high salt concentrations. The other major acceptors are HMG proteins, 
lamin B, topoisomerase I, DNA-PK, and p53. The existence of a 20 amino acid 
poly(ADP-ribose) binding motif consisting of two conserved regions, a cluster rich in 
basic amino acids and a pattern of basic anlino acids interspersed with basic residues 
has been reported by Pleschke et al., (2000). The disco ery of this sequence has 
allowed screening of proteins for the poly(ADP-ribose) binding motif and has identi fi d 
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a number of proteins involved in DNA damage that may be poly(ADP-ribosylated . 
These include p21 , xerodera pigmentosum group A complementing protein, MSH6 
DNA ligase III, XRCC1 , and the DNA-PKcs and Ku70 subunits of DNA-PK. The 
poly(ADP-ribose) binding motif was found to interfere with domains that were 
associated with protein-protein interactions, DNA binding, nuclear localisation, nuclear 
export and protein degradation suggesting a role for P ARP-1 in the regulation of these 
processes. 
1.6.6 Consequences of poly(ADP-ribosylation). 
Poly(ADP-ribosylation) of DNA-interacting proteins generally causes inhibition or 
reduction in activity of the target protein due to the repulsion of the enzyme away from 
the DNA. This is due to the negative charge of the (ADP-ribose) (1.7 -ve charges per 
monomer). As shown in Figure.1.11, poly(ADP-ribosylation) of his tones or PARP-1 , in 
response to strand breaks, results in their repUlsion from DNA and may serve to alter the 
chromatin conformation allowing access to repair enzymes (the histone shuttle model, 
Althaus et al., 1994). Poly(ADP-ribosylation) of PARP-1 may act to remove the 
P ARP-1 from the site of the DNA damage again allowing access for repair enzymes. 
One exception is DNA-PK, where poly(ADP-ribosylation) of DNA-PKcs leads to an 
increase in activity. It is thought that the poly(ADP-ribosylation) of the catalytic 
subunit could enhance the interaction between DNA-PKcs and the Ku70/80 heterodimer 
via the non-covalent poly(ADP-ribose)-binding site on the Ku70 protein (Ruscetti et aI. , 
1998). 
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Figure.I.II Mechanism of action of PARP-I. DNA damage stimulates PARP-1 
(blue) and recruits it to the site of damage. PARP-1 poly(ADP-ribosylates) itself and 
histones (green) causing repulsion from the DNA leading to dissociation of P ARP-1 and 
chromatin remodelling allowing access for DNA repair enzymes to the site of damage. 
Picture provided by N. Curtin, NICR. 
1.6.7 PARP-1 and DNA repair. 
The role of P ARP-1 in DNA repair was initially proposed following the observation that 
PARP-1 activity was increased -SOO-fold following stimulation by DNA strand breaks 
(Benjamin and Gill, 1980). More direct evidence followed when it was shown that an 
early inhibitor of PARP-1, 3-aminobenzamide (3-AB) dramatically slowed the ligation 
of single strand breaks and greatly increased cytotoxicity induced by the methylating 
agent dimethyl sulfate (DMS) (Durkacz et al., 1980). Many other authors have shown 
similar findings using P ARP-1 inhibitors such as 3-AB with other alkylating agents, 
including, methyl methanesulfonate (MMS), N-methyl-N'-nitro-N-nitrosoguanidine 
(MNNG) , ionising radiation, the radiomimetic bleomycin and oxidating agents such as 
H20 2 (reviewed by Griffin et al., 1995). The general conclusion from these studies was 
that P ARP-1 plays a role in BER in some capacity, as damage caused by such agents 
would normally be repaired by BER. 
As the early inhibitors of P ARP-1 were shown to affect other cellular processes apart 
from P ARP-1, activity such as de novo purine biosynthesis (Milam et al., 1986), more 
specific molecular approaches were sought to elucidate the role of P ARP-1. Antisense 
RNA expression was used to deplete HeLa cells of 90% P ARP-1. These cells were 
shown to have limited DNA repair in recovery from nitrogen mustard and MMS-
induced strand breaks, this corresponded to a reduced NAD+ consumption. At later 
time points these cells displayed normal levels of repair, showing that the involvement 
ofPARP-1 was an early response (Ding and Smulson 1994, Ding et al., 1992). 
The effect of trans-dominant P ARP-1 inhibition by overexpression of the DNA binding 
domain (DBD) has also been reported. cDNA encoding the wild-type P ARP-1 DBD 
was cloned into a pECV23 expression vector and transfected into CV -1 cells. The 
ovcrexpression of the DNA binding domain inhibited PARP-1 activity by competing 
with it for DNA strand breaks, and irrevcrsibly binding to the DNA. This trans-
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dominant inhibition of P ARP-l in intact cells inhibited unscheduled DNA synthesis that 
occurs during BER and inhibited the repair of MNNG-induced DNA damage (Molinette 
et al., 1993, Kupper et al., 1995). 
P ARP-l-deficient mouse and cell studies. 
P ARP-l deficient V79 cells derived by selection in NAD+ deficient medium were 
shown to be hypersensitive to a range of alkylating agents, camptothecin, and y-
irradiation (Chatterjee 1990, 1991). Although this suggested a role for PARP-l in 
repair, as these cells may also be defective in other NAD-requiring processes and have a 
vastly reduced proliferation rate, better models were sought. P ARP-l knockout mice 
have been developed by homologous recombination, and immortalised cell lines have 
been derived from these mice. This has allowed verification of the previous results and 
has been reviewed by Shall and de Murcia (2000). Three independent groups have 
created P ARP-l knockout mice by disruption of the P ARP-l gene at exons 1, 2 and 4 
(Masutani et al., 1999, Wang et al., 1995, Menissier de Murcia et al., 1997, 
respectively). These mice develop normally and are fertile, demonstrating that P ARP-l 
is dispensible for development. However, all of the P ARP-l knockout animals have a 
serious defect in response to DNA damage caused by alkylating agents (MNNG, MNU, 
MMS) and y-irradiation, which can be attributed to a defect in the BER process. They 
have a high level of genomic instability, including increased level of sister chromatid 
exchanges and chromatid breaks (Menissier de Murcia et al., 1997, Wang et al., 1995). 
P ARP-l deficient mice have been exposed to a number of genotoxic agents that have 
been shown to stimulate P ARP-l activity. P ARP-l null mice treated with the alkylating 
agent MNU (75 mg/kg) , died within 2-4 weeks of administration, compared to 60% 
survival of the wild type mice 8 weeks after exposure (Menissier de Murcia et al., 
1997). Similarly most of these P ARP-l null mice exposed to 8 Gy of y-rays died within 
4-6 days of exposure compared to 50% at three weeks post exposure for the wild type 
mice. Similar results were obtained using mice from the Wang laboratory where all of 
the P ARP-l null mice that had been exposed to 8 Gy of y-irradiation had died within 10 
days of exposure compared to 100% survival of the wild type mice (Wang et al., 1997). 
The P ARP-I null mice from the de Murcia laboratory have also been shown to be 
hypersensitive to CPT-II. 64% of P ARP-l null mice had died within 2 weeks of 
exposure to 140 mg/kg CPT-II while all of the wild type mice were alive at 8 weeks 
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(Burkle et aI, 2000). Immortalised cell lines derived from these mice have been shown 
to display a dramatic delay in DNA strand break rejoining following exposure to the 
DNA alkylating agent MMS. Six hours after treatment with 0.15 rnM MMS, 95% of 
strand breaks were repaired in the wild type cells, whereas only 36 % of the strand 
breaks were repaired in the P ARP-l null cells although the damage was repaired 
eventually (Trucco et al., 1998). These data show that in the absence of P ARP-l there 
is a defect in the repair of those lesions repaired by the BER pathway, therefore adding 
further support to the proposal that P ARP-l is involved in DNA repair. 
The BER pathway consists of two overlapping pathways; long and short patch repair 
see section 1.5.1). To determine whether PARP-l was involved in the long or short 
pathways the pathways have been reconstructed in vitro. The effect of P ARP-l 
deficient cell extracts on these pathways was investigated. Using two different AP sites, 
uracil and 8-oxoguanine it was shown that the absence of P ARP-l had dramatic effects 
on long patch repair of uracil or 8-oxoguanine derived AP sites (> 90% reduction), but 
only moderate effects on short patch repair (50% reduction). The defect was shown to 
be associated with the polymerisation step of the pathway and P ARP-l protein and 
catalytic activity was demonstrated to take part in the repair process (Dantzer et al., 
2000). 
All of the above data suggests that P ARP-l is involved in the response to DNA damage 
but an exact role was disputed until interactions with other proteins in the BER pathway 
were demonstrated. P ARP-l has already been shown to contain a BRCT domain that is 
a common motif in DNA repair and DNA damage responsive cell cycle checkpoint 
proteins (Callebaut et al., 1997). Using immunoprecipitation, co-purification and yeast-
2-hybid techniques, P ARP-l has been shown to physically interact with a number of 
proteins in the BER pathway. P ARP-l has been shown to associate with XRCC 1 in a 
yeast-2-hybrid screen and this has been confirmed in mammalian cells by 
immunoprecipitation. XRCCI interacts with the PARP-l via its BRCT domain. This 
interaction can be via the BRCT domain or zinc finger domains of the P ARP-l protein. 
XRCC 1 interacts preferentially with automodified P ARP-I and this interaction 
negatively regulates PARP-l activity (Masson et at., 1998, Trucco et a/., 1998). This 
suggests that P ARP-l recruits XRCC 1 and the interaction of the two proteins serves to 
remove P ARP-I. This proposal was supported by the observation that PARP-l null 
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cells were unable to form XRCCI foci in response to treatment with H20 2 and MMS 
(El-Khamisy et al., 2003). P ARP-1 also interacts via its BRCT domain with the C-
terminal domain of DNA pol~ (Dantzer et aI., 2000). An interaction between P ARP-l 
and DNA ligase III has also been demonstrated by affInity chromatography. PARP-1 
binds to the N-terminal region of DNA ligase III. DNA ligase III has also been shown 
to bind directly to poly(ADP-ribose) and preferentially associates with automodified 
P ARP-l (Leppard et al., 2003). Thus P ARP-l activation may function to recruit DNA 
ligase to the BER complex. Further characterisation of the role of P ARP-1 in the long 
patch pathway showed that P ARP-1 has also been shown to be involved in strand 
displacement during DNA synthesis by DNA pol~. This is dependent on the presence 
of FEN-I. Therefore there may be some interaction between these two proteins to 
activate long patch repair (Prasad et al., 2001). Therefore as P ARP-l associates with 
many of the proteins involved in the BER process it is possible that poly(ADP-ribose) 
synthesis by P ARP-l regulates the BER process, possibly in a cyclic manner, by 
regulating the association and dissociation of proteins from the BER core complex 
(fIgure 1.12, Dantzer et aI., 2000). 
Figure.1.12 Interaction of P ARP-l with components of the BER pathway at sites of 
DNA damage. PARP-1 binds the break as a dimer via its Zn fIngers. PARP-l makes 
interactions with XRCCI via common BRCT domains, P ARP-l also interacts with 
DNA pol~. Poly(ADP-ribosylation) of P ARP-l removes P ARP-I from the strand 
breakage site allowing pol ~ to repair the break and DNA ligase to religate the DNA. 
Adapted from de Murcia and Shall (2000). 
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It has also been proposed that P ARP-l might supply ATP to the long patch BER 
pathway by local production of poly(ADP-ribose) under conditions of ATP shortage. 
This would involve the degradation of poly(ADP-ribose) by PARG and generation of 
ADP-ribose units. These could combine with the pyrophosphate liberated by the action 
of pol P to generate ATP. The production of ATP may be necessary for the completion 
of the repair process, as ligase III requires ATP (Oei and Zeigler, 2000). 
The evidence for the role of P ARP-l in repair is overwhelming although its actual 
function has not been absolutely defined. P ARP-l may be involved in several steps of 
the BER pathway. P ARP-l preferentially binds to a sugar phosphate at the 5' margin of 
a single -stranded DNA nick suggesting that P ARP-l binds a BER intermediate that is 
formed before a choice of sub-pathway has been made (Lavrik et at., 2001). Therefore 
P ARP-l may playa role in the selection of pathways. P ARP-l and its catalytic activity 
are required for BER, its catalytic activity may be required for chromatin remodelling 
via poly(ADP-ribosylation) of histones. This high concentration of negative charge 
from the poly(ADP-ribose) may cause repulsion of histones away from the DNA 
allowing the DNA repair proteins to access the damaged DNA. Poly(ADP-ribosylation) 
may also be required for activation of the BER proteins such as XRCCI. As PARP-l 
preferentially binds to the automodified form of XRCC 1 (Masson et ai., 1998, Trucco et 
ai., 1998) it is possible that P ARP-l binds the DNA strand break via the zinc fingers 
and the increase in negative charge caused by automodification may attract XRCCI. 
XRCCI may then become attached to the DNA via its interaction with the BRCT 
domain of P ARP-l. These two proteins may then recruit the other BER proteins. The 
role of P ARP-l as a nick sensor in response to DNA damage may protect DNA from 
accidental recombination events. This could be by prevention of access of exonulceases 
or other enzymes that may facilitate recombination by the rapid and tight binding of 
PARP-l. The negatively charged poly(ADP-ribose) polymers would also repel DNA 
preventing exchange of DNA sequences (Lindahl et aI., 1995). P ARP-l may detect the 
break and signal for the start up of the repair process, informing the cell of the level of 
damage via poly(ADP-ribosylation) of other proteins; this process may involve other 
DNA repair proteins such as DNA-PK and ATM. 
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There is evidence suggesting that P ARP-l may not have an essential role in BER and 
that BER can function in the absence of P ARP-l. Using an in vitro BER system, it was 
shown that repair of strand breaks was stimulated by NAD+ and induced poly(ADP-
ribose) formation. BER was not efficient in the presence of competitive inhibitors of 
P ARP-l such as 3-AB or in the absence of NAD+. However the repair was still 
effective when >980/0 of the P ARP-l activity of the cell extracts used had been depleted 
by affinity chromatography suggesting that P ARP-l was not essential for BER. Taken 
together these data suggest that BER can proceed independently of P ARP-l, but if 
PARP-l is present then it must be active. In the absence ofNAD+ or the presence of3-
AB, P ARP-l is still able to bind to DNA, however as it is unable to poly(ADP-
ribosylate) itself it is unable to dissociate, becoming an obstruction to DNA repair. This 
may suggest that the effects of P ARP-l inhibition may be more severe than lack of 
P ARP-l. However it should be noted that these assay were conducted using plasmid 
DNA in the absence of his tones, and therefore these results may not be representative of 
chromosomal DNA (Satoh and Lindahl 1992, Satoh et al., 1993). Other groups have 
shown that P ARP-l deficient cells are able to conduct BER effectively (Vodenicharov 
et al., 2000, Allinson et al., 2003). Vodenicharov et al., showed that extracts made 
from P ARP-l null cells were able to repair plasmid DNA damaged by MNNG or y-
irradiation and similarly that P ARP-l null cells could repair this damage as efficiently 
as the wild type cells. Allinson et al., showed similar findings, that P ARP-l null cell 
extracts could efficiently repair abasic sites in DNA, although this was shown to be 
independent ofNAD+. The repair in the PARP-l null cell was also faster than that seen 
in the wild-type cells. There are a number of explanations for the ability of the P ARP-l 
null cells to repair SSBs. It may be that P ARP-l itself is not involved in repair but is 
required to poly(ADP-ribosylate) proteins involved in this process. It is also possible 
that PARP-2 may be performing the role of PARP-l in these cells. PARP-2 is 
stimulated by DNA damage and can also interact with XRCC1, pol B and DNA ligase 
I II in the BER complex. P ARP-l and 2 can act together in heterodimers as well as 
individual homodimers (Schreiber et al., 2002). It is interesting to note that P ARP-l/2 
knockout mice are embryonic lethal, suggesting that these two enzymes together play an 
essential role (Menissier de Murcia et al., 2003). 
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1.6.8 Role of PARP-1 in cell death. 
P ARP-1 is activated in response to DNA damage, but the extent of damage detennines 
the eventual fate of the cell (see Figure 1.13). In response to mild DNA damage 
P ARP-1 is activated and is recruited to sites of DNA damage and may serve to recruit 
other DNA repair enzymes. Indeed 3-AB sensitised Jurkat cells to apoptosis, 
suggesting that at low levels of DNA damage P ARP-1 protects against apoptosis (Payne 
et aI., 1998). At higher levels of DNA damage, the repair machinery is not able to 
perform repair and apoptosis follows. An early event in apoptosis is the cleavage of 
P ARP-1 into 85 and 23 kDa fragments by caspases; caspase-3 and 7 being the most 
efficient (Kaufman et al., 1993). The cleavage occurs in the DNA binding domain of 
P ARP-1. The remaining 85 kDa fragment containing the automodification and catalytic 
domains, has basal PARP-1 activity equivalent to that of the whole enzyme in the 
absence of stimulation by DNA ends, but is not inducible by DNA strand breaks. 
Route 1 Route 2 Route 3 
1.-----------11 DNA djmage II------~l 
Mild Unrepairable Excessive 
~ ~ ~ 
PARP activation PARP activation overactivation 
PARP-~~ ______ , 
inhibition I 
DNA repair L - - .. DNA repair (insufficient) 
of PARP PARP-1 
:- - - - - - -~ ~inhibition 
NAD,J, , ATP ,J, 
Cell survives 
~ 
p53-mediated ..... - - - - - -' 
apoptosis 
~ 
rapid clearence 
of apoptotic cells 
by macrophages 
~ 
necrosis 
cell leakage 
promotes 
inflammation 
Figure 1.13 Role of PARP-l in cell death. Picture from Virag and Szabo. (2002). The 
three different response pathways used to combat varying degrees of DNA damage. 
The dotted lined represents the crossover between pathways induced by P ARP-I 
inhibition. 
Excessive levels of DNA damage caused by inflammation, or shock lead to P ARP-l 
hyperactivation. This causes a massive depletion of the NAD+ pool causing depletion 
of ATP, and glycolysis and mitochondrial respiration become impaired. ATP is used to 
try to rcsynthesise the NAD+ leading to a futile and lethal cycle. Cell death follows by a 
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caspase-independent pathway. (the Suicide hypothesis; Berger et al., 1985, Chiarugi 
2002, Virag and Szabo 2002). These observations have led to the study of the use of 
P ARP-l inhibitors for use in myocardial infarction, cerebral ischaemia and insulin 
dependent-diabetes where there is massive DNA damage leads to over-activation of 
P ARP-l. Use of P ARP-l inhibitors to treat these conditions may reduce the extent of 
the damaging death response, increasing survival or causing apoptosis (reviewed by 
Tentori et al., 2002, Southan and Szabo, 2003). 
Recent findings have shown that P ARP-l may be involved in caspase-independent fonn 
of cell death, involving apoptosis inducing factor (AIF) (Yu et al., 2002). AIF 
translocates from the mitochiondria to the nucleus in response to damage, and this is 
dependent on P ARP-l activity. This translocation causes nuclear condensation and cell 
death. AIF also causes the release of cytochrome C from the mitochondria. This 
pathway may pre-date caspases on an evolutionary scale and has been shown to act 
following growth factor deprivation and in early development. 
1.7 Development of PARP-1 inhibitors. 
Early inhibitors were developed to enable the study of the mechanism of P ARP-l, 
These compounds were analogues of the by-product of P ARP-l catalysis, nicotinamide; 
nicotinamide itself being a weak P ARP-l inhibitor. Benzamide, an isostere of 
nicotinamide was shown to be an inhibitor of P ARP-l in 1975 (Shall, 1975). Following 
this the investigation of benzamide analogues led to the discovery of more specific 
P ARP-l inhibitors including the "benchmark" inhibitor 3-aminobenzamide (3-AB) 
(Purnell and Whish, 1980). 3-AB was shown to cause 96 % inhibition of P ARP-l and 
has a Ki of 4 J.lM. However, these early benzamide compounds were shown to lack 
specificity and interfere with other cellular processes such as inhibiting de novo purine 
biosythesis (Milam et al., 1986, Eriksson et al., 1996, Cleaver et al., 1984). They could 
not be used clinically as they were far too weak; 3-5 mM 3-AB was required for 
potentiation in vitro. 
3-AB has been shown to potentiate the cytotoxicity of a range of alkylating agents, 
ionising radiation and bleomycin (see section 1.6.7 and 1.7.1). The promising ill vitro 
studies using 3-AB prompted further investigation and the development of more potent 
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P ARP-1 inhibitors. The study of a large number of compounds for their potential 
PARP-1 inhibition by Banasik et al., (1992), aided in the determination of the essential 
features of a P ARP-1 inhibitor. This study showed that a carboxamide group 
constrained within a ring structure conjugated to an aromatic ring was a common 
feature of the PARP-1 inhibitors screened. Some compounds were 100-fold more 
potent than benzamide. The biologically active conformation has the carbonyl group of 
the carboxyamide orientated anti to the 3-bond of the heteroaromatic ring (Suto et al., 
1991). 
The majority of P ARP-1 inhibitors are analogues of nicotinamide and are competitive 
with respect to NAD+. Structure-activity studies have indicated which are the desirable 
features for potent PARP-1 inhibition as summarised in figure l.14. These include an 
unsubstituted aromatic or poly aromatic heterocyclic system and the presence of a 
carboxamide group, as those compounds without this group have no activity. The 
carboxamide moiety must be constrained to the anti conformation, as those derivatives 
with unrestrained carboxamides were less active. An amide proton is required for 
putative hydrogen bonding. Finally a non-cleaved bond is required at the position 
corresponding to the 3-position of the benzamide (Griffin et at., 1995). 
anti - Conformation 
to 1,2-bond 
Electron-ric~ 
aromatic ring 3 
Good donor 
/ carbonyl group 
At least one 
free NH group 
X ,'--- Non-cleavable 
bond 
X = H, OH, OMe, Nii 
Figure 1.14 Features of a PARP-1 inhibitor. Picture from Griffin et al., 1995 
A number of classes of compounds were discovered to have P ARP-I inhibitory activity. 
These include benzimdazole carboxamides such as NUl 085, quinazolinon-4-[3H]-ones 
such as NU1025 and isoquinoline derivatives such as PD128763. NUI025 and 
PO 128763 incorporate the carboxamide into a ring system to lock the essential groups 
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in to the optimal confonnation. In NUI085, the carboxamide is locked in the favoured 
confonnation through intramolecular hydrogen bonds between the imidazole nitrogen 
and one of the carboxamide hydrogens (Figure 1.15). These inhibitors showed increased 
affinity for P ARP-l compared to the original compounds but they still required 
concentrations of 10-100 JlM to achieve chemopotentiation (Table 1.1) (Boulton et al., 
1995, Bowman et al., 1996 and Delaney et al., 2000). 
3-AB PD128763 
o NUI025 y(NHl 
I-N 
AG 14361 
NUI085 
OH 
Figure1.15 Structure of PARP-l inhibitors. AG14361 (the inhibitor used in this 
thesis) is shown in bold. 
Ki (nM) Relative potency 
(Compared to 3-AB) 
3-AB 4000 1 
PD128763 70 60 
NUI025 50 100 
NUI085 10 830 
AG14361 «6 >1000 
Table 1.1 PARP-l inhibitory activities of PARP-l inhibitors (Skalitzky et aI., 2003 
and N. Curtin, personal communication). 
The development of the tricyclic benzimidazoles, aimed to combine the best features of 
NUI025, NUI085 and PD128763. to fonn a PARP-l inhibitor with the restricted 
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carboxamide in a ring structure, resulted in much more potent P ARP-1 inhibitors. The 
development of these compounds is described by Skalitzky et at., (2003) and Canan 
Koch et al., (2003). The aim was to design structures that would restrict the benzamide 
rotation and allow optimum interaction with the P ARP-1 protein. These structures 
locked the carboxamide in the s-trans conformation via a ring connection such as a 
lactam, to an indole core. Modelling studies have shown that these tricyclic systems 
allow interaction with P ARP-1 via three critical hydrogen bonds of the lactam 
carbonyllN-H with glycine-863 and serine 904 in the active site (Figure 1.16). The non-
planar conformation of the seven-membered ring may prove to be ideal for interactions 
between the inhibitor and PARP-1, by allowing the lactam carbonyl and N-H to get 
closer to the amino acids involved in the H-bonding interactions. Tyrosine residues 
(907 and 889) nearby may also form 7t-7t-interactions with the indole core and C-2 aryl 
substituent. The indole N-H participates in hydrogen bonding between the ordered 
water molecule and the catalytic Glu-988 residue. The flexibility of the Gln-763 
accommodates the p-benzylamine substituent. The presence of the inhibitor is also 
thought to interfere with the intra molecular hydrogen bonding of P ARP-1 between Tyr-
889 and Asp-766 (Skalitzky et al., 2003, Canan-Koch et al., 2002). 
AG14361 (structure shown in bold in Figure 1. 15) is a tricyclic benzimidazole that has 
been chosen for further evaluation in cytotoxicity and in vivo studies, and is the subject 
of this thesis. The interactions made between AG 14361 and the catalytic site of chicken 
P ARP-1 and humanised by changing residue 763 from glutamine to glutamate, are 
shown in figure 1.16. AG 14361 satisfies the structural requirements for a P ARP-1 
inhibitor that have been revealed by structure-activity relationships and discussed in this 
section. The use of this inhibitor in chemo- and radio-potentiation studies will be 
discussed in the following section. 
Figure 1.16 Co-crystal structure of AG14361 in the catalytic domain of chicken 
PARP-l (provided by K Maegley, Pfizer GRD). 
1.7.1 Cherno and radio-potentiation by PARP-1 inhibitors. 
The early PARP-l inhibitors such as benzamide and 3-AB have been shown to 
potentiate the cytotoxicity of a number of alkylating agents and ionising radiation. One 
of the earliest studies by Durkacz et al., (1980) showed that four classes of P ARP-l 
inhibitor, nicotinamides, methylxanthenes, thymidine and benzamides, potentiated the 
cytotoxicity of the alkylating agent dimethyl sulfate in L1210 cells. Nicotinamide and 
3-AB have also been shown to potentiate X-ray-induced potentially lethal damage in 
V79 cells (Ben-Hur et al. , 1984). Similarly 3-AB potentiates the cytotoxicity of the 
radiomimetic drug, bleomycin (Huet and Laval 1985). 3-AB has also been shown to 
potentiate the cytotoxicity of a number of cytotoxics including M G, B 
etoposide and cisplatin (reviewed by Griffin et aI., 1995) pro iding opportunity ~ r th 
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development of P ARP-l inhibitors in combination with other chemotherapeutic agents. 
As the original inhibitors have been shown to lack specificity, new inhibitors were 
developed that were more potent and specific with the potential for clinical 
development. In this section the combination of P ARP-l inhibitor and anticancer 
agents will be discussed. 
6-[5H]-phenanthridinone is a potent P ARP-l inhibitor that was originally shown to have 
P ARP-l inhibitory activity along with a range of other compounds, by Banasik et aI., 
(1992). Phenanthridinone is an isoquinalone derivative that has been studied in 
conjunction with a range of cytotoxics including camptothecin in a panel of murine and 
human tumour cell lines. 6-[5H]-phenanthridinone was shown to enhance the 
cytotoxicity of SN-38 the active metabolite of irinotecan, taxotere, BCNU and cisplatin. 
This compound potentiated cytotoxicity of bleomycin in some cell types. Thus this 
P ARP-l inhibitor did potentiate the activity of chemotherapeutic agents, but this was 
dependent on the cell type and drug action (Holl et aI., 2000). 
The dihydroisoquinalone PARP-l inhibitor PD128763, has been used in combination 
with a number of alkylating agents and ionising radiation. PD128763 was able to block 
recovery and increase cell killing following exposure of Chinese hamster V79 cells to 
X-irradiation (Arundel-Suto et al., 1991). A 7 and 36-fold potentiation of cytotoxicity 
of the alkylating agent streptozotocin, and the nitroimidazole RSUI069, respectively 
was also seen in L1210 cells (Seebolt-Leopold et aI., 1992). In a separate study, 
PD128763 has been shown to potentiate the cytotoxicity 4 to 7-fold and increase the 
number of DNA strand breaks caused by temozolomide (Boulton et aI., 1995). 
A similar drug screen has been conducted using NUI025 in murine L1210 cells. Here it 
was found that NUI025 could potentiate the cytotoxicity of MITC (the methylating-
species derived from temozolomide), 4-fold as well as a 2.6-fold potentiation of 
camptothecin, and 1.4-fold potentiation of y-irradiation, and bleomycin. NUI025 did 
not potentiate the cytotoxicity of the topoisomerase II poison etoposide, the thymidylate 
synthase inhibitor, nolatrexed or the cytotoxic nucleoside gemcitabine (Bowman et aI., 
1998). 
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Further studies used NU1025 and NU1085 with topotecan and temozolomide in a panel 
of 12 cell lines that were chosen to be representative of the most common malignancies, 
lung, colon, ovarian and breast. In this study it was shown that the potentiation of 
growth inhibition by NU1025 and NU1085 varied between cell lines from l.5 to 4-fold 
for temozolomide and 1 to 5-fold for topotecan. Potentiation was independent of tissue 
of origin and p53 status of the cells (Delaney et al., 2000). NU1025 has been used in 
vivo in combination with temozolomide by Tentori et al., (2002). In this study, 
NU1025 significantly increased the survival of mice that had been injected 
intracranially with L5178Y lymphoma cells and treated with temozolomide. Mice 
treated with temozolomide alone were dead by day 24, whereas those treated with 
temozolomide and NUl 025 were still alive up to 90 days after treatment. 
Studies using the more potent inhibitor AG14361 found that 0.4 JlM AG14361 caused a 
5.5-fold enhancement of temozolomide-induced growth inhibition in LoVo colorectal 
carcinoma cells. A 2.1 to 2.3-fold potentiation of growth inhibition was also seen in 
A549 non-small cell lung carcinoma cells. In vivo studies using mice bearing human 
tumour xenografts also demonstrated that AG 14361 could reduce the anti-tumour 
activity of temozolomide. The most impressive activity was seen using SW620 (colon 
carcinoma) xenografts, where a 1000/0 complete remission rate was observed when 
temozolomide was used in combination with AG14361. This remission persisted for 60 
days at the lowest dose of AG 14361 (5 mglkg) and until the end of the study at 100 
days at the highest dose (15 mglkg) (Calabrese et aI., JNCI in press). In the same study 
the effect of AG 14361 on ionising radiation and topotecan was studied. Recovery from 
damage caused by irradiation in growth arrested cells (potentially lethal damage) was 
delayed by 730/0 in Lo Vo cells. Irradiation of mice bearing Lo Vo xenografts caused a 
19 day tumour growth delay that could be extended to 37 days by the co-administration 
of AG14316. AG14361 was able to enhance topotecan-induced growth inhibition in 
A549 cells, SW620 cells and LoVo cells and delay tumour growth in mice bearing 
LoVo and SW620 tumour xenografts compared to those mice treated with irinotecan 
alone (for more details see section 1.8). 
The combination of P ARP-l inhibitor, similar to AG 14361 but with improved 
solubility, and temozolomide has recently reached Phase I clinical trials in Newcastle. 
47 
1.8 PARP-1 and Topoisomerase I: Background to this project 
Previous studies have shown that P ARP-l inhibitors potentiate the cytotoxicity of 
topoisomerase I poisons (Bowman et al., 2001). Here it was shown that NUI025 could 
potentiate the cytotoxicity of camptothecin 2 to 3-fold in murine leukaemic L 1210 cells. 
This corresponded to a 2 to 3-fold increase in camptothecin-induced DNA single strand 
breaks. Similarly Calabrese et al., (JNCI in press) demonstrated that the novel potent 
PARP-l inhibitor AG14361 caused a 1.4 to 2-fold potentiation of the growth inhibitory 
effect of topotecan in human tumour cell lines. In vivo xenograft studies showed that 
the anti-tumour activity of irinotecan could be increased 2 to 3-fold by co-
administration of AG 1436l. These studies are described in more detail in chapter 3 
(See Figure 1.17, Calabrese et al., lNCI in press). 
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Figure 1.17 Effect of AG14361 on topo I poison-induced growth inhibition (A) and 
tumour growth delay (B). 
(A) Effect of 0.4 JlM AG 14361 on growth of SW620 cells treated with increasing 
cone ntrations of to po tee an for 5 days continuously. 
(B) Effect of AG 14361 on growth of SW620 tumour xenografts following daily 
treatment for 5 days with 2.5 mglkg irinotecan ± 5 mglkg AG 14316. 
Graph provided by N. urtin, p ronal communicati n. 
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1.9 Aims 
The aim of this study was to elucidate the mechanism by which P ARP-l inhibition 
potentiates topoisomerase I poison-mediated cytotoxicity using the novel P ARP-I 
inhibitor AG14361. Based on the previous data available there were two hypotheses 
proposed to explain this phenomenon. 
1. Modulation of topoisomerase I activity by P ARP-1. 
P ARP-l poly(ADP-ribosylates) topoisomerase I, and this causes inhibition of 
topoisomerase I (Ferro and Olivera 1984, Jongstra-Bilan et al., 1983, Krupitza and 
Cerutti et al., 1989). This inhibition is most likely to be mediated via an increase in 
negative charge on the topoisomerase I protein caused by the (ADP-ribose) polymers. 
Therefore inhibition ofPARP-l by AG14361 may release topoisomerase I from PARP-
1 mediated inhibition, providing more cleavable complex formation and hence targets 
for topoisomerase I poisons. Since topo I poison-mediated cytotoxicity is directly 
related to topo I activity P ARP-l inhibition increases the cytotoxicity of topoisomerase I 
poisons by activation of topo I. 
2. Repair of topoisomerase I poison-induced DNA damage by P ARP-1. 
P ARP-l is involved in the repair of DNA single strand breaks via the BER pathway 
(reviewed in section 1.6.7). Cells deficient in BER are hypersensitive to topoisomerase 
I poisons, suggesting that this damage is repaired by the BER pathway. Cells deficient 
in BER are hypersensitive to camptothecin. Therefore it is possible that P ARP-l is 
involved in the repair of topoisomerase I poison induced DNA damage. Thus inhibition 
of P ARP-l by AG 14361 would result in the inhibition or delay of the repair thereby 
increasing cytotoxicity. 
PARP-I wild type and null cells were studied in addition to the use of AG14361. This 
determined whether inhibition of P ARP-l was equivalent to lack of P ARP-I and 
investigated the possibility that when P ARP-I was inhibited it may act as a poison, by 
binding DNA and preventing DNA repair. 
The studies described in the following chapters were designed to test these hypotheses 
to investigate the effect of P ARP-l on topoisomerase I poison-induced cytotoxicity. 
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2.1 Materials. 
All reagents were provided by Sigma (Poole, Dorset, UK) unless otherwise stated. 
AG 14361 (1-( 4-dimethylaminomethylphenyl)-8-9-dihydro-7H-2, 7,9a-benzo[ cd]azulen-
6-one)) was provided by AgouronJPfizer Pharmaceuticals GRD, La Jolla, CA, USA. 
AG14361 was stored as powder at 4°C or as 10 mM stocks in DMSO at -20°C. 
AG14361 was used at 0.4 !J.M in all experiments unless otherwise stated. 
Topo I poisons, Camptothecin (CPT, Sigma) and Toptecan (TP, Hycamptin© 
SmithKlineBeecham Pharmaceuticals Philadelphia, PA) were stored as powder at 4°C 
or as 10 mM stocks in DMSO at -20°C. 
All radiolabelled compounds (e2p]-NAD+, [3H]-thymidine and C4C]-thymidine) were 
supplied by Amersham (Bucks, UK). Wallac Optiphase HiSafe scintllant (Fisher 
Chemicals) was used with the radioactive samples prior to counting 
Tissue culture media, supplements, antibiotics and trypsin were supplied by Invitrogen 
(Paisley, UK) unless otherwise stated. 
2.2 Equipment. 
All tissue culture plastic-ware was purchased from NUNC (Fisher Scientific, 
Loughborough, UK). Routine centrifugation was carried out using either a MSE Mistral 
5000 bench topo centrifuge, or an Eppendorf centrifuge 5417R with 45-30-11 rotor 
depending on sample size (Fisher Scientific). The pH of buffers and solutions was 
measured using an Orion Model 420A pH meter (Fisher Scientific). A Titretek 
Multiscan MCC/340 (Flow Laboratories, Rickmansworth, UK) plate reader was used to 
measure the absorbance of XTT or SRB stains and BCA reagent in protein assays. 
Where samples were warmed or mixed a shaking water bath was used (Grant OLS200, 
Fisher Scientific). Perkin Elmer Lambda 2 UV Vis spectrophotometer was supplied by 
Perkin Elmer (Beaconsfields, Bucks UK). A Wallac 1409 DSA ~-counter (perkin Elmer) 
was used to measure levels of radioactivity in samples. 
2.3 General Tissue Culture. 
All cell lines were maintained at 37°C in a humidified atmosphere containing 50/0 CO2 
in a Haraeus incubator (Haraeus, Essex, UK). All manipulation of cell lines was carried 
out using sterile equipment and reagents within a class II safety cabinet. 
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All cell lines were routinely tested for mycoplasma using an enzyme immunoassay 
(Mycoplasma Detection Kit, Roche Diagnostics, Sussex, UK) for the detection of the 
most common mycoplasmalacholeplasma species found in cell cultures. Testing was 
conducted at approximately 3 month intervals and the cells used in this study were 
found to be free of mycoplasma at all times. 
2.3.1 Cryogenic Storage of Cell Lines. 
Cells were kept in liquid nitrogen for long-term storage in the presence of DMSO. 
DMSO is a cryoprotective agent, which prevents the formation of ice crystals within the 
cells on freezing which would damage the cells. Cells were spun down at 1500 rpm for 
5 mins and resuspended in freezing medium (DMEM or RPMI containing 10% (v/v) 
DMSO and 20% (v/v) foetal calf serum) to give a final concentration of approximately 
1-2 million cells per ml. Cryovials containing 1 ml of cell suspension were then frozen 
at -80°C for --24 hours before transfer into liquid nitrogen stores (-180°C). This slow 
freezing reduces the amount of damage sustained by the cell. 
To retrieve cells from the frozen stocks the cells were thawed rapidly in a water bath, to 
37°C, thus reducing the amount of damage to the cells. The cell suspension was then 
centrifuged, the medium was aspirated off to remove the DMSO, and the cells were 
resuspended in a large volume of fresh medium. The cells were than seeded into flasks 
at the appropriate cell density. Cell lines were passaged at least twice before they were 
used in any experiment to ensure that they were growing optimally. 
2.3.2 Cell Lines. 
PARP-l wild type and null eel/lines. 
Immortalised P ARP-1 wild-type and null mouse embryo fibroblasts (MEFs) cell lines 
were derived by isolation of embryos from the P ARP-1 wild type and null mice by E. 
Notriani at the University of Newcastle upon Tyne using standard methodology 
(Robertson et al,. 1987) and continuos cell culture. P ARP-1 wild type and null mice 
were kindly provided by Gilbert de Murcia (Ecole Superieure de Biotechnologie de 
Strasbourg, France). Deletion of the PARP-1 gene was achieved by homologous 
recombination (Mennissier de Murcia et aI., 1997) (see Figure 2.1). It was found that 
whereas the P ARP-I null cells expressed wild type p53, the P ARP-l wild type cells 
expressed high levels of transcriptionally inactive mutant p53, which was the result of a 
base change at codon 278 which corresponded to an Asp to Glu substitution. This 
mutation was found to be within a conserved region of the DNA binding domain of p53 
(P. J owsey PhD thesis, 2003). 
Xb 
Targeting Vector pGK-neo 
X X 
PARP wild type locus 
3 4 5 6 7 
probe 
9.6 
... • 
Targeted allele 
EXb f 
I I ~_---IIIII--" , pGK-neo r-r----
3.3 
Figure 2.1 Inactivation ofPARP-l by homologous recombination. 
Gene inactivation was achieved by insertion of PGk-neo into the fourth exon of the 
P ARP-l gene. EcoRI (E) restriction was used to detect the targeted gene as indicated. 
(B, BamHI; X, XhoI; Xb, XbaI; pG-neo, neomycin-resistance gene driven by the pGK 
promotor; HSV -Tk, thymidilate kinase gene driven by the herpes simplex virus 
promoter). Diagram adapted from Menissier de Murcia et al., (1997). 
PARP-l nulfR_ 
PARP-I nullTR cells are PARP-1 null cells that have been re-transfected with human 
PARP-I, to create a PARP-1 wild-type cell line that expresses wild-type p53. PARP-I 
null cells were transfected with the pP ARP31 plasmid using FuGENE 6. These cells 
were also co-transfected with a plasmid containing a neomycin resistance gene, to 
enable selection of transfectants. These P ARP-1 nullTR cells have been shown to 
express P ARP-1 protein, which was activated in response to DNA double strand breaks_ 
This activity could be inhibited by AG 14361. Southern blotting was used to show that 
the original P ARP-I gene was still inactivated, by the presence of the 3.3 kb fragment 
(data not shown, P.1owsey PhD thesis 2003). 
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K562. 
The K562 cell line is an erythroleukaemic line derived from pleural effusion of a 53 
year old female Caucasian with chronic myelogenous leukaemia. (Lozzio and Lozzio, 
1975). p53 is homozygously deleted in these cells via an N-terminal truncation of the 
gene. Cells were obtained from the ATCC (Manassas VA, USA). 
AA8. 
A parental Chinese hamster ovary cell line that was isolated as a spontaneous clone that 
is functionally heterozygous at the adenine phosphoribosyltransferase locus (Thompson 
et a/., 1980). Cells were obtained from the ATCC. 
EM9. 
Derivative of the AA8 cell line. These cells were isolated on the basis of their 
hypersensitivity to killing by ethyl methanesulfonate (EMS) (Thompson et al.,1980). 
These cells are hypersensitive to alkylating agents, UV radiation, X-rays and 
camptothecin. They also have a reduced rate of DNA-strand break rejoining following 
treatment with X-rays, EMS or methyl methanesulfonate (MMS), as well as a high 
baseline frequency of sister chromatid exchange compared to the parental AA8 cell line 
(Thompson et al.,1982). It had been demonstrated that this hypersensitivity could be 
corrected by complementation with XRCC 1, thus these cells were deficient in base 
excision repair (Thompson et al., 1990). The gene coding for XRCCI in the EM9 cells 
has been shown to contain a C to T base change in codon 221, which introduces a 
termination codon one third of the way into the sequence. This results in the expression 
of a truncated XRCC 1, which does not contain either of the BRCT domains (Shen et al., 
1998). Cells were obtained from the ATCC. 
V3. 
Derivative of the AA8 cell line that does not express DNA-PKcs due to an inactivating 
mutation in the C-terminal region of one allele of the DNA-PKcs gene (XRCC7). This 
results in a deficiency in NHEJ (Blunt et al., 1995). Cells were a kind gift from PJeggo, 
University of Sussex. 
irs} SF. 
A derivative of the AA8 cell line with a mutated XRCC3 gene. This results in 
inactivation of HR (Tebbs et al.,1995). These cells have been shown to be 
hypersensitive to AG 14361 (S Kyle, personal communication). Cells were a kind gift 
from T. Helleday, University of Sheffield. 
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2.3.3 Maintenance of cell lines. 
P ARP-l mouse embryo fibroblasts (MEFs) were grown as mono layers in plastic tissue 
culture flasks. They were maintained in Dulbeccos Modified Eagle's medium 
containing non-essential amino acids and glutamine. This was supplemented with 10 % 
(v/v) foetal calf serum, 100 units/ml penicillin, 100 Jlglml streptomycin, 15 mM hepes 
and 1 mM sodium pyruvate. 
K562 cells were grown as suspensions in RPMI 1640 plus L-glutamine, supplemented 
with 10 % (v/v) foetal calf serum, 100 units/ml penicillin, 100 Ilglml streptomycin. 
AA8, EM9, V3 and IRS 1 SF cell lines were maintained as mono layers in RPMI 1640 
plus L-glutamine supplemented with 10 % (v/v) foetal calf serum and 100 units/ml 
penicillin, 100 Jlglml streptomycin. 
All cell lines were passaged twice a week or when 80% confluent. 
2.3.4 Subculture of cell lines. 
K562 suspension cells were subcultured by dilution of a volume of cell suspension in 
fresh medium to maintain the culture at a density of between 1 x 105 and 1 x 106 
cells/ml, up to passage ~ 25. 
Monolayer cell lines had to be removed from the tissue culture dishes prior to sub-
culture or use in cell assays. To achieve this the medium was aspirated from the cells 
and the cells were washed in Dul A (Dulbecco' s Phosphate Buffered Salts, modified 
without Ca2+ and Mg2+). An appropriate volume (enough to cover the cells) of 0.25%, 
trypsin in DulAiEDT A (0.02% (w/v), disodium salt) was added and the cells were 
incubated at 37°C until the cells had detached from the plate. Fresh medium was added 
to neutralise the trypsin and dilute the cell suspension to the desired cell density. 
2.3.6 Cell counting. 
To enable the seeding of the cells at known cell densities the number of cells in a 
suspension was measured using a haemocytotmeter or a Coulter counter. 
57 
Haemocytometer. 
A haemocytotmeter consists of two mirrored counting chambers on a glass slide. A 
coverslip is placed on to the haemocytometer to form a counting chamber with a depth 
of 0.1 mm. The chamber is divided into 9 x 1 mm2 squares. Therefore the volume of 
each square is 1 x 10-4 ml. Cell suspensions can be added to this chamber using a 
pasteur pipette, and cells counted under a microscope (Olympus CK2 Microscope). By 
counting the cells seen in the 1 mm2 squares and taking the dilution factor into account 
the number of cells in the original suspension can be calculated using the equation 
below. 
Mean cell count per 1 mm2 square x dilution factor = cells/ml x 104 
Coulter Counter. 
In clonogenic and cell counting assays a Coulter counter was used to determine cell 
numbers. The Z 1 Coulter counter (Beckman Coulter, Bucks) is an electronic cell 
counter. Cells were firstly fixed in an equal volume of Camoys fixative (75% methanol, 
250/0 acetic acid (v/v)). The fixed cell suspension was then diluted 1110 in Isoton 
(Becton Dickinson, Oxford, UK) and transferred to the counting chamber of the Coulter 
counter. Electrolyte is drawn through a small orifice, across which a current passes. 
The entrance of a cell into the aperture, displaces its own volume of electrolyte and 
modulates the current flowing between two electrodes across the aperture. The machine 
detects this as a voltage pulse that is proportional in height to the volume of electrolyte 
displaced and therefore cell size. Voltage pulses are counted by the machine to give an 
accurate determination of cell number. Aperture size a can be altered to account for 
differences in cell size and was used at 8-24 J.lm for the cells used in this study. Using 
this aperture size gave reproducible cell counts that were consistent with those obtained 
using a haemocytometer. 
2.3.7 Determination of cell doubling time. 
To measure cell doubling times cells were harvested and diluted into suspensions that 
contained 200, 500, 1000, 2000, 5000 and 10000 cells/ml. These were seeded into rows 
on seven 96-well plates. At 24 hour intervals a plate was fixed and growth was 
measured using the SRB assay, or XTT assay described in the next section. Absorbance 
values obtained from the assays were plotted against time using GraphPad Prism 
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software (San Diego CA, USA) and the doubling time of the cells calculated using 
linear regression on the exponential part of the plot. 
2.4 Growth inhibition and cytotoxicity assays. 
A variety of methods were used to assess the growth inhibitory and cytotoxic effects of 
drugs on cells. The choice of which assay to use was detennined by the cell type, i.e. 
whether monolayer or suspension and the desired biological endpoint. The assays base 
their detennination of growth on the amount of protein bound to a plate, cell number, 
metabolic activity or cell viability. As cytotoxic agents may prevent growth but mayor 
may not affect cell viability it is important to use more than one type of assay to 
detennine the effect of the drug on the cells. 
In preparation for all of these assays, cells were seeded into dishes at a known cell 
number that did not become confluent during the course of the experiment and were 
therefore growing exponentially throughout the period of drug exposure. Monolayer 
cells were seeded a day before drug exposure to allow the cells to adhere to the plates. 
Cells were exposed to various concentrations of camptothecin or topotecan in the 
presence or absence of 0.4 J.lM AG14361; control cells were exposed to an equivalent 
concentration of DMSO to account for any growth inhibitory effects of DMSO. The 
final concentration of DMSO in an experiment was always less than 1 % to prevent any 
growth inhibitory effects of DMSO from interfering with drug effects. In some 
experiments the drug was removed from the cells after a period of time and cells were 
washed with Dul A. Specific details of each experiment are included in figure legends. 
2.4.1 Sulforhodamine B (SRB) assay. 
Staining with SRB is a rapid, sensitive and inexpensive method for measuring cellular 
protein content of adherent cells. SRB is an aminoxanthene dye that binds basic amino 
acid residues under acidic conditions; this is reversible under alkali conditions allowing 
quantification of the dye. Therefore absorbance of SRB measured at 570 nm is directly 
proportional to the amount of cellular protein in the well. This method has limitations 
in that an increase in cell size in response to a drug could be interpreted as an increase in 
cell number, and therefore is only accurate as long as the cell size remains constant 
(Skehan ct aI, 1990). 
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Cells were seeded and exposed to drugs as required. After the desired time, usually 
corresponding to 3 cell doublings, cells were fixed with 50% (w/v) trichloroacetic acid 
(TCA), and cooled at 4°C for at least 1 hour. The medium was removed and the plates 
washed five times in water, then dried at 60°C. Plates were then stained in 0.4% (w/v) 
SRB dissolved in 1 % (v/v) acetic acid and left for 20 mins before washing in 1 % (v/v) 
acetic acid and drying at 60°C. Stain was solublised using 10 mM Tris base (PH 10.5) 
before reading on a Titretek Multiscan MCC/340 plate reader at 570nm. 
Average absorbance values were obtained for each drug treatment and expressed as a 
percentage of the related untreated or AG 14361-treated control. Growth inhibitory ICso 
values (GIso, the concentration that results in 50% growth inhibition) were calculated 
using a point to point curve on GraphPad Prism software. The potentiation factor (PF), 
a measure of the increase in growth inhibition in the presence of AG 14361, was also 
calculated as stated below. 
PF so = GIso drug alone 
GIso drug + AG14361 
2.4.2 XTT cell proliferation assay. 
This assay determines the growth and viability of cells using a tetrazolium salt that is 
metabolised by mitochondrial dehydrogenases in active cells to form a spectrally 
different formazan salt. The conversion of the yellow XTT to the orange formazan dye 
therefore only occurs in viable and metabolically active cells (Scudiero et al.,1988). 
This assay was used for determination of cell doubling times of suspension cells. 
Cells were exposed to drugs for the required duration. The XTT assay was conducted 
as instructed using the Cell Proliferation Kit II (Roche Diagnostics, GmbH). The XTT 
reagent (1 mgimL) was mixed with the electron-coupling reagent (phenazine 
methosulfate) at a ratio of 5011 (v/v). 50 /11 of the XTT reagent mixture was added to 
each well of the 96-well plate and incubated in a humidified atmosphere for 4 hours at 
37°C, 5% CO2 to allow the dye to be metabolised. The 4 hour incubation time had been 
previously optimised for use with the K562 cells by A. Jobson, CAMB, University of 
Newcastle upon Tyne. The absorbance was then read on a Titretek Multiscan MCC/340 
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spectrophotometer at 450 run. To determine doubling times the mean absorbance for 
each cell density was plotted against time and doubling time calculated using linear 
regression on the exponential part of the plot using GraphPad Prism software. 
2.4.3 Cell counting. 
Growth inhibition can be measured by counting the number of cells present after the 
drug treatment and comparing this with untreated control. This assay does not give a 
measure of the viability of these cells, just the number of cells. This assay was most 
suitable for use with suspension cells. Cell lines were treated and left to grow for the 
desired period of time, then fixed using an equal volume of Carnoys fixative (75% 
methanol, 25% acetic acid, (v/v)). The fixed cell suspensions were diluted 1 in 10 in 
Isoton, before a 1 ml sample was counted in duplicate using a ZI Coulter counter 
(Beckman Coulter, Bucks) as described in section 2.3.6. 
Mean cell numbers for each sample were calculated and expressed as a percentage of an 
untreated or AGl4361-treated control. GI50 values were calculated using the GraphPad 
Prism software as described in section 2.4.1. 
2.4.4 Clonogenic survival assay. 
Clonogenic assays measure the cytotoxicity of a drug i.e. cell kill. Some agents may 
cause cytotstatic effects, inhibiting cell growth, however the cells still remain viable and 
are able to reproduce when returned to drug-free medium, therefore these agents do not 
necessarily kill the cell. As the clonogenic assay involves drug exposure followed by a 
long colony forming period in drug free medium this assay exclusively measures cell 
viability. This assay also allows the measurement of very low levels of cell survival e.g. 
at much higher concentrations of drug than the growth inhibition assays, as greater 
numbers of cells can be exposed and seeded to account for several orders of magnitude 
of cell kill (reviewed in Brown and Boger-Brown, 1999). 
Following drug exposure, monolayer cell lines were trypsinised and then counted by 
Coulter counter as described in section 2.3.6. The cells were diluted in fresh medium to 
give a suspension of Ix 1 04 cells/ml. The cells were then seeded at low densities onto 60 
mm dishes (100 and 200 cells for controls and increasing to 10,000 for the highest drug 
concentrations). This ensured that there were cells surviving to form colonies at each 
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dose level. The plates were grown for 7 days for AA8, EM9 and V3 cell lines and 10 
days for irs 1 SF cells. 
When colonies were visible they were fixed using Carnoys fixative, and then stained 
with 0.4% (v/v) crystal violet in water. Colonies containing more than 30 cells were 
counted. Plates containing less than 10 colonies or over 300 colonies were not included. 
Each colony is assumed to be derived from a single cell and therefore the colony count 
is an estimate of the number of cells that survived the drug treatment. The plating 
efficiency of the cells was calculated as the percentage of colonies formed on the plates 
compared to the number of cells originally seeded. The clonogenic survival of drug 
treated-cells was calculated as the plating efficiency of treated cells expressed as a 
percentage of the plating efficiency of the DMSO alone or AG 14361-treated controls. 
Mean percent survival curves were plotted and LCso values (concentration that results in 
500/0 cell kill) calculated using GraphPad Prism software using a point to point curve 
plot. 
2.4.5 Sloppy agar clonogenic survival assay. 
The sloppy agar technique enables clonogenic assays to be performed with cells that 
grow in suspension e.g. K562 rather than monolayers. The cells are trapped in an 
agarose matrix to hold the cells in suspension allowing colony formation without 
migration through the gel. To visualise the colonies in the gel the tetrazolium dye MTT 
(methylthiazoletetrazolium) is used. MTT is a yellow dye that is reduced to a blue 
formazan by mitochondrial reductases in the cell in viable cells. The blue colonies can 
then be counted to determine cell survival. 
K562 cells were treated, counted and diluted to a cell density of 1 x 104 cells/ml as 
described in the clonogenic assay (section 2.4.4). Using this suspension a known 
number of cells was transferred into 8 ml polyurethane tubes. Three cell densities were 
used per drug concentration, typically in the range of 100-200 for controls and up to 
10000 at the highest drug concentrations. The cell suspension was then made to 1 ml 
with fresh medium and then to a final volume of 7 mls with 0.15% SeaKem ME agarose 
firstly dilutred in PBS, then diluted in pre-warmed RPMI to give a final concentration of 
0.1250/0 agarose. The tubes were mixed by inversion, cooled to room temperature to 
allow the agarose to set and the lids loosened, and holes punctured in them to allow gas 
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flow. The tubes were then incubated at 37°C in a humidified atmosphere for 10-12 days 
to allow colony formation. 
When colonies were visible the cell suspensions were poured out of the tubes into 
dishes containing 1 ml freshly prepared MTT (0.5 mg/ml in sterile water). Cells were 
left to stain overnight in the dark at 37°C in a humidified atmosphere. Survival was 
measured by colony counting. Only dishes containing greater than 10 and less than 300 
colonies were counted. Mean percent survival was calculated as described in section 
2.4.4. 
2.5 50S-polyacrylamide gel electrophoresis and Western blotting. 
This is a method that can be used visualise proteins in a cell extract. Proteins are 
separated on the basis of size by running them through a SDS-polyacrylamide gel. The 
proteins are then transferred to nitrocellulose under the influence of an electrical 
current. The protein of interest can be detected using antibodies specific for that protein 
followed by the use of the appropriate horseradish peroxidase-conjugated (HRP) 
secondary antibody. Enhanced chemiluminescence (ECL) can then be used to visualise 
the presence of the protein on X-ray film. The band corresponding to the protein of 
interest can then be quantified if desired using densitometry. 
2.5.1 Sample preparation. 
Preparation of Whole cell lysates. 
Cells were grown to 80% confluence before being lysed by addition of SDS lysis buffer 
(6.25 mM Tris HCI pH 6.8, 2% SDS, 10% glycerol) and harvested by cell scraping. 
The lysate was sonicated for 10 seconds using a MSE Soniprep Sonicator 150 (Fisher 
Scientific) and heated to 90°C for 5 mins. If the lysates were still sticky after this, the 
procedure was repeated to ensure that all of the cells were lysed. 
Preparation of Nuclear extracts. 
For the detection of topo I protein nuclear extracts were prepared. This was 
recommended by TopoGen (Colombo OH), the suppliers of the topo I antibody, in order 
to achieve the best results with their product. 1-2 x 107 cells were required per sample. 
The medium was decanted from exponentially growing cells and washed with TD 
buffer (100 111M NaCI, 20 mM KCL 0.5 mM Na2HP04, 20 mM Tris). The cells were 
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then scraped into 2 ml TD buffer and then spun at 1000 xg for 10 mins at .f°C. The 
supernatant was discarded and the pellet was resuspended in 2 ml Buffer A (100 mM 
NaCI, 50 mM KCI, 0.1 mM EDTA, 20 mM Tris-HC1, pH7.5, 0.1 mM PMSF, 10% 
Glycerol, 0.2% NP-40, 0.1 % Triton-X 100). The extract was then incubated on ice for 
10 mins. The nuclei were then pelleted by centrifugation at 1000 xg for 10 mins at 4°C. 
The supernatant was then discarded and the nuclei resuspended in 180 f.ll Buffer A. The 
extracts were inspected for nuclei under the microscope. Finally 20 f.ll 10 % SDS was 
added to the nuclei. Following this the extracts were sonicated and heated as for whole 
cell extracts. 
BCA Protein assay. 
To determine the amount of protein in each sample therefore enabling equal amounts of 
protein to be loaded onto the gel, a protein assay was conducted on all samples. The 
Pierce BCA Protein Assay Kit (Pierce, Rockford IL) was used. This assay is based on 
the reduction of Cu2+ to Cu 1+ by protein in an alkaline medium (Biuret reaction). BCA 
(bicinchoninic acid) chelates with the Cu 1+ in a ratio of 2: 1 to form a purple reaction 
product. The absorbance of this product can be measured on a spectrophotometer at 
560 nm. To conduct the assay a standard curve of known concentrations of BSA 
(0.125-2 mg/ml) is set in quadruplicate on a 96-well plate. Samples are applied to the 
plate in quadruplicate, these may be diluted 1110 in lysis buffer if necessary. The BCA 
reagent was mixed in a ratio of 25: 1 reagent A to reagent B and 200 f.ll added to each 
well. The plate was incubated at 37°C for ~30 mins. The absorbance of the wells was 
measured at 560 nm on a plate reader. Protein concentration was calculated by 
comparison to the standard curve and correction for the dilution of the samples. 
The cell lysates were diluted in the relevant buffer (SDS lysis buffer or TD buffer) to 
the desired protein concentration and 5% (v/v), 0.5%) (w/v) bromophenol blue and 5% 
p-mercaptoethanol were also added. Samples were heated to 80°C for 5 mins to allow 
reduction of the protein and ensure that the samples were homogeneous. 
2.5.2 Electrophoresis. 
Samples and molecular weight markers (SeeBlue Pre-Stained Standard; Invitrogen, 
Paisley, UK) were loaded onto 5-200/0 Tris-glycine SDS-PAGE pre-cast gels 
(Invitrogen). Typically between 20 and 50 f.lg protein was loaded per sample. 5 f.ll pre-
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stained markers were added to provide a ladder of molecular weight standards to aid 
identification of the protein. Gels were run at 120-200V for 1-1.5 hours in Iris-Glycine 
running buffer (25 mM Tris, 200 mM Glycine 0.1 % SDS) in a NOVEX Mini cell gel 
rig (Invitrogen) and a Bio-Rad PowerPac 300 (BioRad, Herts UK). 
2.5.3 Western blotting. 
The proteins were transferred to nitrocellulose membrane (Hybond C, Amersham, 
Bucks, UK) in transfer buffer (25 mM Tris, 100 mM Glycine, 20% Methanol) at 30V 
overnight, using a Bio-Rad Mini Protean II Blot Module. The membrane was then 
blocked in 5% (w/v) dried milk in TBS Tween (50 mM Tris, 150 mM NaCI, with 0.050;() 
Tween 20 added on day of use) for 1 hour. The antibodies used in this thesis are 
described in Table 2.1. The primary antibody was applied to the membrane diluted 
111000 in 5% milk in TBS Tween and mixed for at least an hour using a Roller mixer 
SRTI (Stuart Scientific, UK). The membrane was washed three times in TBS Tween 
before application of the appropriate secondary antibody, at III 000 dilution, in 5% milk 
(as above). These were mixed for 1 hour as above. The membrane was washed in TBS 
Tween for at least one hour with frequent changes of TBS Tween to reduce non-specific 
binding of the antibody. Proteins were detected using an ECL kit (Amersham) or Pierce 
SuperSignal West Pico Chemiluminescent Substrate (Pierce) depending on the protein 
being detected. The ECL reagent was added to the membrane for the required length of 
time and the excess removed. The membrane was then exposed to Fuji Medical X-ray 
film Super RX for a number of exposure times to ensure that the protein bands are 
visible. The film was then developed using a Fuji X-ray film processor RGII. Equal 
loading of the membrane was determined either by re-probing the membrane with anti-
actin antibody AC-40 (DAKO, Ely, UK), or by staining with Ponceau S. 
Densitometry. 
Bands that were visible on a film were quantified using densitometry. A Fuji LAS-3000 
camera (Raytech, Milton Keynes, UK) was used and data obtained using AIDA version 
3.28 according to manufacturers instructions. The density of the protein band was given 
in arbitrary units. 
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Antibody Details 
Topo I Polyclonal anti-human topo I isolated from Sclerodenna 
patients (#2012) supplied by TopoGen. 
PARP-1 Rabbit polyclonal anti P ARP-1 (H-2S0) supplied by Santa 
Cruz Biotechnology, Santa Cruz, CA. 
Actin Mouse monoclonal anti-actin (AC-40) supplied by Sigma. 
2° antibody to human HRP-conjugated goat anti-human antibody supplied by 
1 ° antibody Sigma. 
2° antibody to rabbit HRP-conjugated goat anti-rabbit antibody supplied by 
1 ° antibody DAKO. 
2° antibody to mouse HRP-conjugated goat anti-mouse antibody supplied by 
1 ° antibody DAKO. 
Table 2.1 Antibodies used in this study. 
2.6 PARP-1 activity assay. 
This method measures P ARP-1 activity stimulated by exogenously added DNA ends by 
the incorporation of e2p]-NAD+ into acid insoluble ADP-ribose polymer using a 
modification of the method by Halldorsson et al., (1978). The amount of radiolabel 
incorporated into the polymer is directly proportional to P ARP-1 activity. This assay 
should only detect P ARP-1 activity as a blunt ended double stranded oligonucleotide is 
used. P ARP-2, another member of the P ARP family that is stimulated in response to 
DNA strand breaks, is not stimulated by the type of DNA strand break represented by 
the oligonucleotide used here (G. de Murcia, personal communication). As the 
oligonucleotide used to stimulate P ARP-1 and the NAD+ cannot enter intact cells, the 
cells were permeablised prior to assaying for P ARP-1 activity. In this study digitonin 
was used to penneablise the cells. 
2.6.1 Preparation of cells 
Exponentially growing cells (approx. lSx106/per treatment) were treated with various 
concentrations of AG 14361 for 10 mins and harvested by trypsinisation where 
necessary (monolayer cultures). Cell suspensions were counted and pelleted by 
centri fugation as described in earlier sections. Cells were washed once in ice cold Dul 
A and then centrifuged at 1S000 rpm for S mins at ..f°C. Cells wcrc resuspended in 0.15 
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mg/ml digitonin (Boehringer-Mannhein, Mannheim, Germany) in Dul A to a density of 
3 x 10
7 
cells/ml, and left on ice for 10 mins. Permeablisation was stopped by addition 
of 9 volumes of isotonic buffer (40 mM Hepes, 130 mM KCI, 4% Dextran, 2 mM 
EGTA, 2.3 mM MgCI, 225 mM Sucrose pH 7.8; plus DTT to a final concentration of 
2.5 mM added immediately prior to use). The extent ofpermeablisation was verified by 
trypan blue exclusion; permeablised cells take up the dye and this can be seen under the 
microscope. Cell counts were taken of each sample to allow calculation of the amount 
ofNAD+ incorporated per cell. 
2.6.2 Preparation of radiolabelled NAO+. 
An approximately 6 mM NAD+ solution was prepared freshly on the day of assay. The 
exact concentration of this solution was calculated by measuring the OD of a 11100 
dilution of this stock solution at 260 nm in a 1 cm silica cell on a Perkin Elmer Lambda 
2 UV Vis spectrophotometer (Molar extinction coefficient for NADINADH at 260 nm = 
18000). The NAD+ stock was then diluted to give a 600 ~M NAD+ solution. To this 
approximately 10 ~Ci/~l e2pJ-NAD+ was added depending on the current specific 
activity of the radio label. 
The oligonucleotide used in this assay was the palindromic sequence CGGAA TTCCG 
synthesised by J Lunec (NICR, Newcastle upon Tyne). It was stored as a 200 ~g/ml 
solution in 10 mM Tris / EDTA pH 7.8 at -20°C. 
2.6.3 Assay. 
The reaction mixture containing a final concentration of oligonucleotide 2.5 ~g/ml, 75 
~M NAD+ /[32p]_NAD+, made to a final volume of 50 ~l in water was prepared in 10 
mL plastic test tubes (NUNC). The permeablised cells were warmed to 26°C for 7 mins 
in a shaking water bath. 300 ~l of pre-warmed cell suspension (3 x 106 cells/ml) was 
added at regular timed intervals to the pre-prepared reaction mixture. The tubes were 
vortexed and incubated at 27°C for 5 minutes with constant shaking. The reaction was 
stopped after 5 mins by the addition of 2 ml ice cold 10% trichloroacetic acid (TCA) (10 
% (w/v) TCA, 10% (w/v) sodium pyrophosphate). 10% TCA was added to blanks prior 
to cell addition, this enabled correction for non-specific binding of radiolabel to the filter. 
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Samples were left on ice for at least an hour to allow precipitation of acid insoluble 
material including poly(ADP-ribosylated) proteins. 
To separate the TCA-precipitated poly(ADP-ribosylated) proteins from the reaction 
mixture the samples were filtered through a Millipore filtration unit. Glass microfibre 
filters (GFIC 25mm; Whatman, Kent UK) were soaked in 10% TeA (as above) and 
placed rough side up on the filtration apparatus. Samples were applied to the filters and 
washed five times in 1 % TeA (1 % TeA, 1% sodium pyrophosphate) under gentle suction 
pressure, before they were air-dried. Filters were placed in 10 ml Optiphase HiSafe 
scintillant. Radioactivity on the filters was assayed using the Wallac 1409 DSA ~-counter 
and counting for 2 minutes. Triplicate controls containing 51-11 of 600 I-1M NAD+le2p]-
NAD+ in 10 ml scintillant were also counted. 
2.6.4 Calculation of results. 
The mean of the blanks was subtracted from the sample counts to remove non-specific 
background. The pmol NAD+ incorporated per sample was calculated by comparison 
with mean dpm of the standards (5 1-11 of 600 I-1M NAD+ is equivalent to 3000 pmol). 
This was then adjusted to account for the cell numbers in each sample, allowing the 
result to be given in the format pmol NAD+ incorporatedl1 06cells/5 mins. 
2.7 Measurement of Topoisomerase I activity by DNA Relaxation. 
Topoisomerase activity can be determined by measuring the relaxation of plasmid 
DNA. This measures the cleavage, unwinding and religation of DNA by topo I. The 
relaxation assay measures topoisomerase I activity by following the relaxation of 
negatively supercoiled DNA based on the different mobility of the supercoiled and 
relaxed plasmid DNA in agarose-gel electrophoresis. The assay is specific for 
topoisomerase I by virtue of omission of Mg + and A TP from the assay which are 
required by other members of the topoisomerase family. To determine topoisomerase I 
activity, ATP is omitted because ATP is required for topoisomerase II activity. 
Exclusion of Mg + from the assay buffer allows detection of type 1-3 enzymes (Stewart, 
2000) 
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2.7.1 Preparation of nuclear extracts. 
To ensure sufficient levels of protein in the cell preparation to allow quantification, 106_ 
107 cell were used per sample. Following drug treatment the cells were pelleted at 800 
x g for 3 mins at 4°C and resuspended in 3ml ice-cold TEMP buffer (10 mM Tris-HCI 
pH 7.5, 1 mM EDTA, 4 mM MgCh, 0.5 mM PMSF). This was repeated and the 
samples were then incubated on ice for 10 mins. Following this, cells were 
homogenised using a Dounce homogeniser. The cells were then inspected to ensure that 
nuclei were present under the microscope. The nuclei were then pelleted at 1500 x g for 
10 mins in the cold and washed again in TEMP. The remaining pellet was resuspended 
in less than 4 pellet volumes of TEP buffer (TEMP without MgCh). An equal volume 
of 1 M NaCI was added and then the samples were left on ice for 30-60 mins. The 
samples were then centrifuged at 15000 x g for 15 mins 4°C. The supernatant was 
removed and used in the relaxation assay. 
The protein concentration of each sample was determined using the Pierce protein assay 
as described in section 2.5.1, so that equal amounts of protein could be used in each 
reaction. 
2.7.2 Relaxation Assay. 
Each extract was diluted in TEMP buffer to give samples with a protein concentration 
of 0.1 /-Lg//-LI, this concentration had been shown to contain topo I activity in initial 
studies for this thesis. 1-8/-LI of sample extract or pure topoisomerase I (2 /-LI, TopoGen) 
was mixed with 2 /-LI R buffer (10 mM Tris-CI, pH 7.5, 100 mM KCI, 1 mM PMSF and 
1.0 mM p-mercaptoethanol, buffer supplied with pure topoisomerase I by TopoGen), 
l/-LI negatively supercoiled PUC19 plasmid DNA (1 /-Lg//-LI) and made to a final volume 
of 20 /-LI with water. The reaction components were pooled by centrifugation. After 
incubation at 37°C for 30 mins the reaction was stopped with 114 volume of stop buffer 
(0.5%) SDS, 0.1 % bromophenol blue and 25% glycerol). The samples were then loaded 
onto an agarose gel (0.8% in TBE; 89 mM Tris borate, 20 mM EDTA, pH 8.0). The gel 
was run for ~3 hours. DNA on the gel was visualised by staining with 0.25 /-Lg/ml 
ethidium bromide in TBE for 30-60 mins. A permanent image was visualised using a 
uv transilluminator and captured on camera with the GelDoc system. Supercoiled 
DNA has different mobility to relaxed DNA in agarose-gel electrophoresis; the 
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supercoiled DNA will travel further down the gel from the relaxed DNA as shown in 
Figure 2.2. Thus enzyme activity can be compared between samples. 
-
Relaxed DNA 
-
-
-
-
-
Supercoiled DNA 
Figure 2.2 Relaxation of DNA as visualised on an agarose gel. 
Relaxed DNA is less mobile than the supercoiled form therefore can be separated on a 
gel. Intermediate DNA species can be detected as the DNA unwinds as shown. 
2.8 Trapped in agarose DNA immunostaining (TARDIS). 
The TARDIS assay is an immunohistochemical method for the detection of drug-
stabilised topoisomerase-DNA cleavable complexes with isoform specific antibodies in 
individual cells. This assay is an adaptation of the assay used by Frank et al., (1996) for 
the detection of melphalan-DNA adducts in cells. It has been used to detect 
topoisomerase I and II a and ~ stabilised cleavable complexes in a number of cell lines 
formed in response to a wide range of topo I and II poisons. (Willmore et al.,1998, 
2002, Errington et al., 1999, Padget et al.,2000(a), 2000(b)) 
The T ARDIS assay does not use fixing techniques and therefore avoids co-precipitation 
of proteins that may hinder the access of antibodies. It relies on the immobilisation of 
cellular DNA in agarose and subsequent lysis of the cell to leave the DNA and 
covalently associated proteins. As topo I is covalently bound to DNA in the cleavable 
complex and can be stabilised by camptothecin, levels of the stabilised cleavable 
complex can be detected by the use of an antibody specific for topoisomerase I, and an 
appropriate FITC-conjugated secondary antibody. DNA is detected using a fluorescent 
Hoechst stain. Image analysis allows the quantification of topo I-associated 
fluorescence associated with DNA corresponding to individual cells. This method is 
summarised in Figure 2.3. 
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2.8.1 Slide Preparation. 
Following appropriate drug treatment, cells were harvested by centrifugation at 3000 
rpm in an MSE Mistral 5000 centrifuge. 50).11 of cell suspension was mixed with 50 ).11 
2% (w/v) agarose ("Sea Prep" ultra low melting-point agarose; BMA Rockland, ME) in 
PBS. This was smeared onto slides that had been pre-coated with 0.5% (w/v) low 
melting point agarose in water. Slides were placed on ice briefly to solidify the agarose, 
prior to incubation in lysis buffer, (10% SDS, 0.5 M potassium phosphate, 0.5 M 
EDT A, plus protease inhibitors; 1 mM PM SF, 1 mM benzamidine, 2 Ilglmlleupeptin, 2 
Ilg/ml pepstatin, 1 mM DTT added immediately prior to use) for 30 mins at room 
temperature, to lyse the cells and remove the cell membrane and soluble proteins. The 
slides were then transferred into 1 M NaCI (plus protease inhibitors as above) for a 
further 30 mins to remove non-covalently bound nuclear proteins, leaving only the 
drug-stabilised topo I complexes. The slides were washed three times in PBS before 
addition of the primary antibody. To detect Topo I complexes a polyclonal human 
antibody to human topoisomerase I was used (#2012, TopoGen). For use it was diluted 
111000 in PBS containing 0.1 % (v/v) Tween 20 and 1 % (w/v) BSA. Once the antibody 
had been added, the slides were incubated in a dark humidified atmosphere at room 
temperature for one hour. The slides were washed in PBST (PBS + 0.1 % Tween 20 
(v/v» before addition of the secondary antibody in a dark humidified atmosphere at 
room temperature, for an hour. The secondary antibody was an FITC-conjugated goat 
anti-human immunoglobulin G (Fab specific) (Sigma). It was diluted 111 00 in PBST + 
1 % (w/v) BSA. After exposure to antibodies the slides were washed twice in PBST and 
once more in PBS. Immediately prior to visualisaton the slides were stained with 
Hoechst 33258 (10 IlM in PBS) for 5 mins to stain the DNA. Coverslips were placed 
carefully onto each slide and secured using nail varnish. 
2.8.2 Microscopy 
A detailed description of the method for the microscopy and image analysis is described 
by Frank et al., (1996). Hoechst (blue) and FITC (green) associated fluorescence were 
visualised separately using an epifluorescence microscope (Olympus BH2-RFCA, 
Technical Lamp Supplies Ltd, Slough, UK) and appropriate optical filters (Omega 
Optical, Brattleboro USA). Images were visualised using a lOx objective and captured 
using a cooled slow-scan charge-coupled device (CCD) camera (Astrocam, Cambridge, 
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UK). A field of view was focussed under a blue filter to visualise the DNA and the 
image was captured using a 5 second exposure. The same field of view was then 
captured using a green filter and a 20 second exposure. 6-8 pairs of images were 
captured per dose from replicate slides to obtain data from 100-150 cells. 
2.8.3 Analysis of results 
Images were analysed using Imager 2 software (Astrocam, UK) based on Visilog 4 
(Neosis, France). The images were background corrected using slides containing PBS 
alone to correct for stray light and camera background. All of the sample images were 
subjected to blue and green shade correction to compensate for differences in the lamp 
intensity and non uniformities in light transmission using slides containing 3 11M 
fluorescein and 0.4 mM 4-methylumbelliferone. The corrected blue Hoechst image was 
used to define the areas containing the DNA in each cell and create a binary image. A 
series of functions were performed to remove objects on the edge of the image and 
remove small particles. The blue and green fluorescence intensities corresponding to 
the area occupied by the DNA were integrated. The values stated are integrated 
fluorescence, which is defined as the number of pixels in the cell multiplied by the 
surface of the cell. Integrated fluorescence data for each cell was plotted as scatter 
plots. Mean fluorescence was also plotted using GrapbPad Prism software. 
72 
0 0 Cells embedded in agarose 
0 ~ Lysis procedure 
~ DNA with covalently attached topoisomerase 
~ molecules remains 
~ ]tt., ~ Isoform specific antibody 
~ binds to covalently attached topoisomerase molecules 
~ 
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'~ the primary antibody ~ 
Areas occupied by DNA 
are defined using Hoechst 
dye blue fluorescence 
t 
FITC green 
immunofluoresc ence 
within each defined 
DNA area is quantified 
Figure 2.3 The T ARDIS assay. Diagram from Padget et a!., (2000a) 
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2.9 Potassium-50S assay for detection of enzyme-DNA complexes. 
The K-SDS assay is an established method for the quantification of protein-DNA 
covalent complexes (Rowe et al., 2000). The assay relies on the fact that SDS binds 
protein and dissociates non-covalent protein-DNA complexes but is unable to dissociate 
covalent interactions. On addition of potassium chloride insoluble crystals of potassium 
dodecyl sulfate [onn which co-precipitate free protein and protein covalently attached to 
the DNA. Using radiolabelled DNA, the levels of protein covalently bound to DNA can 
be quantified. As camptothecin stabilises the covalent complex fonned between topo I 
and DNA this method enables the quantification of protein-DNA complexes formed in 
response to treatment with topo I poisons which will correspond to an increase in topo 1-
DNA cleavable complexes. Increases in the level of cleavable complexes 
corresponding to exposure to increasing concentrations of camptothecin, have been 
measured by Beidler et al., (1996). 
2.9.1 Assay. 
Exponentially growing cells were radiolabelled with 0.04 JlCilmL C4C]-thymidine (53 
mCi/mol; Amersham) overnight. The label was removed by centrifugation and cells 
were grown in fresh medium for a further ~4 hours to chase the label into the high 
molecular weight DNA. Equal numbers of cells were treated with appropriate drugs for 
the desired time. Following drug exposure the cells were centrifuged at 1500 rpm for 5 
mins at 4°C. The cells were lysed in 2 mllysis solution (1.25% SDS (w/v), 0.4 mglmL 
herring spenn DNA (Promega, Hants, UK), 5 mM EDTA (PH S.O) heated to 65°C. 
This removes the cell membranes and soluble proteins. After a 10 min incubation at 
65°C in a waterbath the KCI concentration was adjusted to 65 mM by addition of 352 
mM KCI. The lysates were vortexed for 10 secs to fragment DNA. The lysate was 
cooled on ice for 10 mins to allow precipitation of the protein-DNA complexes, and 
then centrifuged for 10 mins at 10000g at 4°C. The pellet was resuspended in 1 ml 
wash buffer (10 mM Tris HCL pHS.O, 0.1 mglmL herring sperm DNA, 100 mM KCI, 1 
mM EDT A) and heated at 65°C for 10 mins with occasional mixing by inversion to 
resuspend the pellet. The samples were then cooled on ice for 10 mins to allow 
precipitation. The precipitate was recovered by centrifugation as before. The wash step 
was repeated. The washed pellet was resuspended in water pre-heated to 65°C and 
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added to 5ml Optiphase HiSafe scintillant. Samples were counted on a Wallac 1409 
DSA p-counter for 2 mins. 
2.9.2 Calculation of results. 
The average dpm for triplicate samples was calculated and then expressed as a 
percentage of the relevant controls. 
ISDS 
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~I --'--1 r--TI 1-'--1 -r--I ---r--I .----rl I---r-I 
Free DNA ~ (no Topo bound) + SDS denatured 
Free topo I 
Figure 2.4. The potassium SDS assay. 
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DNA is nicked (I nicklcovlent complex) 
Topo I binds to DNA covalently and forms a transient cleavable complex. On addition 
of SDS the topo I is denatured. Upon addition of KCL the SDS bound DNA is 
precipitated. Adapted from www.TopoGen.com. 
2.10 Measurement of DNA single strand breaks by alkaline elution. 
Alkaline elution provides quantitative analysis of DNA single strand breaks. 
Radiolabelled DNA from drug treated cells can be separated according to fragment size 
using polycarbonate filters which are neither protein or DNA adsorbent. This impedes 
the passage of larger DNA molecules allowing smaller ones to elute first. Therefore an 
increase in strand breaks will be signified by an increase in the rate of elution. Double 
strands of DNA are separated and apurinic/pyramidinic CAP) sites are re ealed by 
cleavage at high alkaline pH (PH 12.2) therefore re ealing both single strand breaks 
and AP sites. In this study protein adsorption was minimised by the use of low protein 
adsorption polycarbonate filters, the presence of SDS in the lysis and elution buffer and 
using a lysis buffer containing proteinase K. Elution of the DNA fragments 0 er time 
was measured by scintillation counting of elut d fractions . To increase the pr cision of 
75 
the assay the samples were co-eluted with an internal standard consisting of irradiated 
DNA. Comparison of the elution rate of the sample with the internal standard DNA 
enables correction for variation in pump channel efficiency (Kohn et al., 1981). 
2.10.1 Cell Preparation. 
Cells were seeded at a density that ensured at least 4x 1 05 cells per sample on the day of 
the experiment for both the sample and internal standard (IS) cells. Monolayer cells 
were seeded at least 24 hours prior to labelling so that they had adhered to the tissue 
culture dish. Sample cells were labelled for 24 hours with C4C]-thymidine (0.016 
j..lCi/mL). IS cells were labelled with 3H_ Thymidine (0.1 j..lCi/ml) for 24 hours. eH]-
thymidine damages DNA to a greater extent than [14C]-thymidine, therefore the samples 
were labelled with the least damaging isotope. After 24 hours the unincorporated 
radiolabel was removed from the cells by changing the medium on the monolayer cells 
and resuspending suspension cells in fresh medium for a further 2-4 hours. This was to 
chase the radio label into the high molecular weight DNA, thus ensuring that any strand 
breaks that were detected were in the mature DNA. 
Sample cells were treated as described in figure legends and control cells were treated 
with equivalent concentrations of DMSO. Cells were kept on ice to prevent repair and 
in the dark to prevent accumulation of further damage that may be caused by lighting 
etc, prior to elution. 
Prior to elution the IS cells were irradiated using a Gammacell 1000 elite irradiator 
(Nordion International Inc, Kanata, Canada) with a dose of 3 Gy to give uniform strand 
breaks in these cells. 
2.10.2 Preparation of Filters. 
Polycarbonate filters (2.0 j..lm pore size, 25 mm diameter, Whatman) were moistened in 
ice-cold PBS (1/10 dilution of lOx PBS without magnesium) and placed shiny side up 
onto 25 mm Swinnex polyethylene filtration funnels (Fisher Scientific). A rubber 
gasket was applied to the filter before the top was screwed into place to prevent leakage. 
Foil was wrapped around the barrel to prevent light penetration that could lead to further 
DNA damage. 50 ml syringe barrels were attached to the Swinnex apparatus. Cold 
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PBS was passed through the apparatus to ensure an even flow of liquid and air locks 
were removed. When there was -10 ml PBS remaining in the barrel the flow was 
stopped using a clip. The apparatus was kept at 4°C until use. 
2.10.3 Elution 
Equal numbers of cells (usually 4 x 105) from both the sample and IS cells were added 
to the PBS remaining in the barrels of the filter apparatus, at 4°C, in subdued lighting. 
The samples were allowed to drip freely through the apparatus. When all of the liquid 
had passed through, the syringe barrels were removed and the filters were washed twice 
with lysis buffer (69 mM SDS, 25 mM EDTA pH 10). The flow was stopped and the 
funnels filled with lysis buffer containing 0.5mglml proteinase K (Roche Diagnostics) 
and left for 1 hour at room temperature. Lysis of the cells removed the cell membranes 
and proteins bound to DNA. The filters were washed with 20 mM EDT A (PH 10) 
before being attached to elution apparatus via silicone tubing running through a 
peristaltic pump (Watson Marlow 205S, Watson Marlow, Falmouth, UK) to a fraction 
collector (LKB 2211 Superfrac Pharmaceia LKB Technology, Sweden). The swinnex 
apparatus was topped up with elution buffer (2 mM EDT A-acid form, 1 M 
tetrapropylammonium hydroxide (tetP), pH 12.0 with tetP and the syringe barrels 
reattatched and filled with 30 ml elution buffer. The pump was set at 2 mllhr and the 
fraction collector set at 90 min/fraction with 9 fractions per sample. The fractions were 
collected into scintillation vials containing 15 ml scintillant. 
2.10.4 Processing of filters 
When the filters had eluted the tubes were washed with 0.4 M NaOH. The filters were 
removed from the apparatus, and put into scintillation vials containing 0.4 ml 1 M HCI 
and baked for an hour at 60°C. This depurinates the DNA. To neutralise the acid, 2.5 
mL of 0.4 M NaOH was then added to the filter for a further hour at room temperature 
to convert the apurinic sites into strand breaks and thus fragmenting the DNA. 
Scintillant was then added and the tubes capped and shaken. The radioactivity in the 
vials was then counted using the liquid scintillation counter. Samples were counted for 
60 seconds to detect 10le and 3H. 
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2.10.5 Calculation of results and relative elution. 
For each sample the total amount of radioactivity applied to the filter was calculated by 
addition of the counts from the individual fractions. The number of counts remaining 
on the filter after elution of each fraction was calculated and then converted into the 
fraction of the counts remaining. Values were calculated for both the sample and the IS 
cells and plotted on a double log scale with reverse x-axis for fraction 3H retained and 
standard y axis for fraction 14C retained. Relative elution, i.e. the ratio of the rate of 
elution of the DNA after treatment compared with untreated control, as shown in 
Figure2.52.5 was calculated as described by Fomace and Little (1977) using the 
equation below. To calculate the RE the relative retention (RR) is required; this is the 
fraction of sample DNA retained when 50% of the IS DNA has been eluted. The RR 
can be calculated using GraphPad Prism software. 
Relative elution = [log Control RR - log sample RR] 
RR: Relative retention 
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Figure2.5 Sample Elution Plot. 
2.11 Statistical analysis. 
All experiments were repeated at least three times unless other wise stated and generally 
contained duplicate samples within the experiment, unless other wise stated. Mean and 
standard errors were calculated using Microsoft Excel software. The Student's 2-tailed 
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t-test was used to determine statistically significant differences between data sets. In 
this study p values at the 95% confidence level are given unless otherwise stated. A 
paired test was conducted if the two sample sets were paired i.e. a series of identical 
experiments with treated and controls within the same experiment e.g. K562 cells 
treated with camptothecin alone compared to K562 cells treated simultaneously with 
camptothecin + AG14361 in each of three independent experiments. An unpaired t-test 
was used to determine the difference between cell lines in unrelated experiments. 
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3.1 Introduction. 
The effect of P ARP-1 inhibition on topo I poison-mediated cytotoxicity was described 
in an early study by Mattern et al., (1987). This study showed that pre-incubation with 
5 mM 3-AB for 16 hours increased the cytotoxicity of camptothecin approximately 1.5-
fold (LDso camptothecin = 0.3 J.lM, camptothecin + 3-AB = 0.2 J.lM). These data 
corresponded to an increase in the number of protein-linked DNA strand breaks and 
single strand breaks. This study also showed that a 60 min incubation with 3-AB prior 
to exposure to camptothecin had no effect on cytotoxicty. Therefore this has shown that 
P ARP-1 inhibition could enhance topo I poison-mediated cytotoxicity, but only under 
certain conditions. From this study it was proposed that 3-AB exerted its effect by 
blocking the poly(ADP-ribosylation) of topo I, thus increasing topo I activity in the cell. 
Potentiation of topo I poison-mediated cytotoxicity by 3-AB has also been described by 
Beidler et aI., (1996). In this study camptothecin resistant and revertant cell lines 
derived from the human nasopharangeal KB cell line were used. The resistant KB cells 
were established by exposure to increasing concentrations of camptothecin for 8 
months, when resistant clones were isolated. The partial revertant line was established 
by culturing the resistant cells in camptothecin-free media for 5-6 months. The resistant 
cells were shown to be 32 to 54-fold resistant and the revertant cells were 2.5 to 3.2-fold 
resistant compared to the KB cell line depending on the concentration of camptothecin 
used in the establishment of the cell line. This was not due to the down-regulation of 
topo I protein expression or activity, as the levels of protein and topo I activity were 
similar in both resistant and revertant lines. It was shown that incubation with 1 mM 3-
AB for 4 hours increased camptothecin-induced cytotoxicity 6-fold in the resistant cell 
line but not the parental or revertant KB cell lines, implicating a role for P ARP-1 in 
camptothecin resistance. A subsequent study by Park et al., (2002) showed that levels 
of the BER scaffold protein XRCC1 were 5-fold higher in the resistant cell line 
although levels of other BER proteins including P ARP-1 remained unchanged. The 
increased level of XRCC 1 was related to the degree of resistance in the cell and 
potentiation by P ARP-I inhibition. These authors demonstrate that revertant cells that 
had been transfected with XRCC 1 at similar levels as the resistant cell lines were 2-2.5 
fold more resistant to camptothecin and that 3-AB could reverse this resistance. This 
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suggests that the role of P ARP-1 in camptothecin resistance may involve the BER 
pathway. 
Conclusions drawn for studies using 3-AB are compromised by the lack of specificity of 
3-AB. 3-AB has been shown to interfere with other cellular processes such a de novo 
purine biosynthesis as well as inhibiting P ARP-1 (Milam et al., 1986). Therefore more 
specific and potent P ARP-1 inhibitors have been used to try to clarify the role of P ARP-
1 in the response to cytotoxic drugs (see section 1. 7). 
6-[ 5H]-phenanthridinone is a potent P ARP-1 inhibitor that was originally shown to have 
P ARP-1 inhibitory activity along with a range of other compounds, by Banasik et al., 
(1992). Phenanthridinone is an isoquinalone derivative that has been studied in 
conjunction with a range of cytotoxics including camptothecin in a panel of cell lines. 
6-[5H]-phenanthridinone was shown to enhance the antiproliferative activity of SN-38, 
the active metabolite of irinotecan (Weltin et al., 1997). However, this inhibitor was 
found to act differently depending on the tumour or cell line used (see section 1.7). 
As many of the early P ARP-1 inhibitors lacked specificity and potency, there has been 
increased interest in developing novel P ARP-1 inhibitors. The Experimental 
Therapeutics group at the University of Newcastle upon Tyne has developed a number 
of more specific and potent compounds, as described in section 1.7. One of these 
inhibitors, NUl025, has been studied in combination with camptothecin in L12l0 cells 
(Bowman et al., 2001). Exposure to 200 ~M NUl025 potentiated the cytotoxic effects 
of a 16 hour exposure to camptothecin by 2.1 to 2.5-fold. This potentiation of 
cytotoxicity by NU1025 was shown to correlate to a 2.5-fold increase in the level of 
DNA single strand breaks. The ability of camptothecin-induced strand breaks to 
activate P ARP-1 was also measured. Concentrations of 120 nM and 1 ~M 
camptothecin caused significant activation of P ARP-l. These data demonstrated that 
P ARP-l was involved in topo I-mediated cytotoxicity, most probably through increased 
DNA strand breakage as P ARP-l was activated by camptothecin-induced damage and 
inhibition of P ARP-l enhanced levels of strand breaks and cytotoxicity. 
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Delaney et al., (2000) investigated the effect of NUI025 and another more potent 
P ARP-I inhibitor, NUI085, in combination with topotecan in a panel of human cell 
lines. The cell lines used were representative of the 4 most common malignancies; 
lung, breast, ovary and colon and had varying p53 status. It was found that NUI085 
potentiated topotecan-mediated cytotoxicity by 1.5 to 4 fold in II out of 12 of the cell 
lines. There was only one cell line that was not potentiated (LS 14 7T; ovarian) but this 
cell line was already extremely sensitive to topotecan. The cytotoxicity of these drugs 
was also studied by colony formation in 3 of the cell lines (Lo Vo, A549 and OA W -42). 
These cell lines gave results consistent with the growth inhibition data. Taken together 
these data suggest that inhibition of P ARP-I can potentiate the growth inhibitory effects 
oftopotecan independently of cell type or p53 status. 
More recently a range of even more potent P ARP-I inhibitors have been developed 
using a combination of structure activity relationships and crystal-based drug-design 
(Canan-Koch et aI., 2003, Skalitzky et al., 2003. A range of benzimidazole-4-
carboxamides and tricyclic lactam indoles with Ki values of less than 10 nM have been 
screened for their effect on topotecan induced growth inhibition by Calabrese et aI., 
(2003). In this study it was found that cellularly active compounds could elicit a 2-fold 
potentiation of growth inhibition caused by topotecan. 
Following this study, a related PARP-I inhibitor, the tricyclic benzimidazole AG14361, 
was investigated, in combination with topotecan in three human tumour cell lines. 
Potentiation of topo I poison-induced growth inhibition was determined by SRB assay 
following 5 day exposure to topotecan with and without at 0.4 JlM AG 14361. 
AG 14361 potentiated the growth inhibitory effect of topotecan in Lo Vo (colon 
carcinoma), SW620 (colon carcinoma) and A549 (NSCLC) by 1.7, 1.4 and 2 fold 
respectively. 0.4 JlM AG 14361 is < 5% GIso in these cells, therefore was not growth 
inhibitory, and did not alter gene expression, but did inhibit P ARP-I by greater than 
850/0 (Calabrese et aI., JNCI in press). 
In \'iva studies in mice bearing human xenografts showed that co-administration of 
AG 14361 increased the antitumour activity of irinotecan 2 to 3-fold without a detectable 
increase in whole animal toxicity. In mice bearing LoVo tumour xenografts, 2.5 mglkg 
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irinotecan daily for 5 days caused tumour growth delay of 4 days. Co-administration of 
AG14361 at 5 or 15 mglkg AG14361 increased the tumour growth delay to 9 days or 11 
days respectively. Similarly, in mice bearing SW620 xenografts the irinotecan-induced 
tumour growth delay of 8 days was increased to 14 or 16 days by co-administration of 
AG 14361 at 5 or 15 mg/kg (Calabrese et aI., INCI in press). 
Another potent P ARP-l inhibitor CEP-6800 (Ki = 5 nM) has been used in vitro and in 
vivo in combination with topo I poisons. 1 11M CEP-6800 was shown to potentiate the 
cytotoxicity of camptothecin in HT -29 colorectal tumour cells in vitro (Miknyoczki et 
aI., 2003). In vivo studies were conducted using irinotecan resistant HT-29 human 
colon carcinoma xenografts in nude mice. Treatment with irinotecan or CEP-6800 
alone had no effect on tumour growth delay. However combination of irinotecan (l0 
mglkg) and CEP-6800 (30mglkg) resulted in a 38% reduction in tumour volume 
compared to irinotecan alone, starting on day 19 extending to day 33, with a maximum 
tumour volume reduction of 66%. 
P ARP-l-deficient cells have also been used to examine the effect of P ARP-l on topo I 
poison-mediated cytotoxicity. Cells deficient in P ARP-l activity have been shown to 
be hypersensitive to topo I poisons. P ARP-l deficient cells have been derived from 
V79 Chinese hamster cells by exposure to increasing concentrations of MNNG. The 
strategy behind this was based on the ability of P ARP-l activation to cause cell death by 
depletion of NAD+ and ATP in response to high levels of DNA damage. Therefore the 
cells isolated from colonies surviving this treatment, called ADPRT 54 and ADPRT 
351, were deficient in P ARP-l and displayed between 5-11% P ARP-l activity 
compared to parental V79 cells. These cell lines were approximately 3-fold 
hypersensitive to exposure to camptothecin for 1 hour, the LCso values for ADPRT 54 
and 351 being 0.4 and 0.6 11M respectively, compared to 1.5 11M for the parental V79 
cells (ChatteIjee et al., 1989, ChatteIjee et aI., 1990). The process of selection that 
these cells underwent was harsh and may have caused other defects apart, from the 
PARP-l deficiency, particularly considering the doubling time for these cells is >72 
hours. Such a long doubling time may alter the response to S-phase acting drugs such 
as camptothecin although the cells would be more likely to be resistant to camptothecin. 
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However, despite the limitations of this model system, this is still one of the original 
demonstrations of hypersensitivity to camptothecin ofP ARP-l deficient cells. 
More recently three strains ofP ARP-1 knockout mice have been created by homologous 
recombination and cell lines have derived from them. P ARP-1 null mice with 
disruptions in exons 1, 2 or 4 of P ARP-1 have been created (Masutani et al., 1997, 
Wang et al., 1995 and Menissier de Murcia et al., 1997, respectively). Using the mice 
created by the de Murcia laboratory, it has been shown that a single i.p. dose of 140 
mg/kg irinotecan killed 64% of the P ARP-1 null mice after just 2 weeks. In 
comparison, none of the wild-type mice were affected, even 8 weeks after exposure to 
the drugs (de Murcia and Shall, 2000). As these mice were rendered P ARP-1 null by 
homologous recombination, it can be assumed that this is the only defect in the mice 
and therefore their hypersensitivity to camptothecin is linked to their lack of P ARP-1. 
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3.2 Aims. 
The aim of this chapter was to investigate the effects of P ARP-l inhibition by AG 14361 
on topo I poison-mediated growth inhibition and cytotoxicity in P ARP-l wild type, 
P ARP-l null and the K562 human leukaemic cell lines. The differential sensitivity of 
P ARP-l wild type and null cells in response to exposure to the topo I poison, topotecan, 
alone was investigated. This was to confirm previous studies with P ARP-l inhibitors 
showing that loss of P ARP-l activity results in increased sensitivity to topo I poisons. 
The differential effect of AG 14361 on topo I poison-induced cytotoxicity in P ARP-l 
wild type compared to null cells was also investigated. This was to confirm that the 
potentiation of topo I poisons is due to P ARP-l inhibition rather than some unrelated 
effect of the inhibitors; therefore showing the specificity of AG14361 for PARP-l. 
The effects of P ARP-l inhibition on camptothecin-induced growth inhibition and 
cytotoxicity were investigated in the K562 cell line. The K562 cells were used as a 
model system as these cells have been previously characterised for their response to 
camptothecin (Padget et al., 2000a). In order to conduct further studies presented in 
later chapters, the levels of sensitivity to camptothecin and the degree of potentiation 
induced by AG 14361 in these cells was determined. Camptothecin was used instead of 
topotecan as it has a near identical mode of action as topotecan, cost implications and its 
abundant use in cell culture based studies allowing direct comparison with the literature. 
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3.3 Results 
3.3.1 Characterisation of cell lines. 
A number of cell lines were obtained for this study. P ARP-1 wild type and P ARP-1 
null mouse embryo fibroblasts (MEFs) were established by E. Notriani (University of 
Newcastle upon Tyne) derived from PARP-1 -/- mice and their wild type counterparts 
provided by G de Murcia; CNRS Strasbourg (Menissier de Murcia et al., 1997 (for 
further details see section 2.3). Human chronic myelogenous leukaemia K562 cells 
(Lozzio and Lozzio 1975) were provided the ATCC (Manassas VA). Prior to 
conducting experiments using these cell lines a number of parameters needed to be 
established. 
3.3.1.1 Determination of cell doubling time. 
Determination of doubling times was carried out so that cells could be seeded at 
densities that did not become confluent during the course of the experiment and to 
ensure that cells were growing exponentially at the time of drug exposure. This was 
essential due to the strong S-phase specificity of camptothecin (D'Arpa et al., 1990). 
Doubling times for cells were determined as described in section 2.3.7. Briefly, 96-well 
plates were seeded with cells at a range of cell densities. Growth of monolayer cells 
was determined by fixing the cells with TCA and staining with SRB and measuring 
absorbance of SRB at 570 nM as described previously by Skehan et a/., (1990) (see 
section 2.4.1). Growth of suspension cells was measured using the XTT Cell 
Proliferation Kit by measurement of absorbance of XTT at 450 nM (see section 2.4.2). 
Doubling times were calculated from the exponential part of the growth curve using 
GraphPad prism (see section 2.3.7). Representative growth curves for PARP-1 wild 
type and null cells and K562 cells are shown in Figure 3.1 and Figure 3.2 respectively. 
These results showed that the optimal seeding densities for 5 day exposures were 1000 
and 2000 cells/ml for K562 and P ARP-1 MEF cells respectively, as wells seeded with 
5000 and 10000 became confluent and those seeded with 200 and 500 grew slowly. 
Doubling times for P ARP-l wild type, P ARP-1 null and K562 cells are shown in Table 
3.1. Previously published data on doubling times of the K562 cells suggest a 19.6 hour 
(NCI website http://dtp.nci.gov/docs/misc/common _files/cell_list.html) or 23 hour 
(Kanofsky and Sima 2000) doubling time for these cells, consistent with data presented 
here. PARP-l cells that ha\'e been isolated from the same strain of PARP-I wild type 
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and null mice as the cells used here have been shown to double every 24 hours and 36 
hours respectively (Trucco et al., 1998). The doubling times for P ARP-l wild type cells 
used in this study agree with these published data, however the P ARP-l null cells used 
here grew faster. It must be noted that these are not the same cell line just similar cells 
derived from the same mice. Therefore slight differences in doubling times could be 
due to non-identical cell lines. 
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Figure 3.1 Growth curves for PARP-l wild type and null cells. 
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Cells were seeded at 200, 500, 1000, 2000, 5000 and 10000 cells/ml in 96 well plates. 
Plates were fixed at 24 hour intervals and cell densities estimated using the SRB assay. 
Growth was measured by absorbance of SRB at 570 nM (See section 2.4.1). 
Representative growth curves for each cell line are shown. 
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Figure 3.2 Growth curve for the K562 cell line. 
Cells were seeded at 200, 500, 1000, 2000, 5000 and 10000 cells/ml in 96 well plates. 
XTT reagent was added at 24 hour intervals and left for 4 hours before measurement of 
absorbance of XTT at 450nm (see section 2.4.2). Representative growth curves are 
shown. 
Cell Line Doubling time (hours) 
P ARP-1 wild type 25.3 ± 1.9 
PARP-1 null 26.6 ± 1.0 
K562 20.2 ± 1.1 
Table 3.1 Doubling times of cell lines. 
Mean doubling times of cell lines determined from 3 independent growth curves per cell 
line ± SEM. Values were calculated as described in section 2.3.7 
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3.3.1.2 Drug Target Protein Levels. 
Western blotting was used to detennine the protein levels of the drug targets topo I and 
P ARP-1, in exponentially growing, asynchronous cultures of K562 and P ARP-I MEF 
cell lines. 
Topoisomerase I 
Topo I protein levels in the cells were measured because a decrease I in the expression 
of topo I protein has been described as a common mechanism of resistance to topo I 
poisons (Chang et al., 1992, Tanizawa, et al., 1993). Therefore, for the comparison of 
topo I poison-induced growth inhibition between cell lines was important to detennine 
the levels of topo I protein in these cell lines. Topo I levels were detennined in nuclear 
extracts prepared from P ARP-1 wild type and null cells, by Western blotting using 
human anti topo I antibody #2012 (as described in section 2.5). Figure 3.3 shows that 
there were similar levels of topo I protein in the P ARP-1 wild type and null cells. 
Multiple bands sometimes appeared and were due to protein degradation. The bands on 
the gel were quantified using a Fuji LAS-3000 camera and Aida version 3.28 as 
described in section 2.5.3. Using densitometry the topo I associated bands were shown 
to measure 10.0 x 105 and 9.5 x 105 arbitrary units for PARP-1 wild type and PARP-1 
null cell lines respectively. Therefore there was no notable difference in topo I levels 
between these cell lines. A loading control is absent as a suitable protein for use with 
nuclear extracts could not be optimised. Equal loading was confinned by Ponceau S 
staining of the membrane (data not shown). 
PARP-1. 
To detennine the levels of P ARP-l in the P ARP-1 wild type and null cells, whole cell 
extracts were prepared as described in section 2.5.1. Equal amounts of protein (30Ilg) 
from the extracts were run on SDS PAGE gels and blotted onto nitrocellulose prior to 
being probed with rabbit anti PARP-1 antibody (DAKO). Figure 3.4 shows the 
presence and absence of P ARP-l protein in P ARP-l wild type and null cells 
respectively, an actin loading control is also shown. 
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Figure 3.3 Topo I protein levels in PARP-l wild type (+/+) and null (-/-) cells. 
20 Jlg nuclear extract from each cell line was loaded/lane. Presence of topo I was 
determined by Western blotting (see section 2.5). Human polyclonal anti topo I primary 
(#2012, TopoGen) and HRP-linked anti-human secondary (Amersham) were used. 
Purified topo I is shown to enable identification of the protein band. Equal loading was 
confirmed using Ponceau S stain (not shown). All bands are topo I and its degradation 
products. A typical blot is shown. 
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Figure 3.4 PARP-l protein levels in PARP-l wild-type (+1+) and null (-1-) cells. 
30 J.lg protein from whole cell lysates was loaded per lane in duplicate. Western 
blotting was conducted according to section 2.5. Blots were probed with anti PARP-l 
(rabbit polyclonal anti-P ARP-l (H-250) antibody (Santa Cruz Biotechnology) and 
monoclonal anti actin (AC-40; Sigma) and the appropriate secondary antibody. 
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3.3.2 Investigation of growth inhibitory effects of AG14361 
The aim of these experiments was to ensure that an appropriate concentration of 
AG 14361 was selected for subsequent studies. For chemopotentiation experiments it 
was necessary to use AG14361 at a non-toxic concentration that had no intrinsic growth 
inhibition. This would ensure that any enhancement of topo I poison cytotoxicity by 
AG14361 could not be attributed to additive AGl4361-induced cytotoxicity or growth 
inhibition. 
In a previous study on the chemo and radio-potentiating effects of AG 14361, growth 
inhibition assays were conducted using a concentration of 0.4 ~M AG14361 inhibitor 
(Calabrese et al., JNCI in press). AG14361 was not growth inhibitory to PARP-l wild 
type or null cell lines at concentrations below 10 ~M AG14361 (Figure 3.5 Calabrese et 
a/., 2003, JNCI in press). 0.4 ~M AG14361 therefore potentially represents a 
concentration that has maximal P ARP-l inhibition with little or no growth inhibition. 
For the purposes of this study it was important to verify that 0.4 ~M was also a suitable 
concentration for use in K562 cells. 
In order to confirm that AG 14361 was not growth inhibitory at the concentrations used 
in chemopotentiation studies, exponentially growing K562 cells were exposed to 
increasing concentrations of AG14361. K562 cells were exposed to AG14361 for 16 
hours to correspond with exposure period used in chemopotentiation assays used later in 
this chapter. Growth inhibition was determined by cell counting (section 2.4.3). Figure 
3.6 shows that AG14361 did not significantly inhibit the growth of K562 cells at 0.4 
~M (p = 0.2 paired t-test compared to untreated cells) and indeed significant growth 
inhibition was not observed below 10 ~M AG14361. Thus 0.4 ~M was confirmed to 
lack growth inhibitory activity per se. However, it was also important to confirm that 
this concentration of AG14361 inhibited PARP-l activity in the cell lines under 
investigation. 
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Figure 3.5 Effect of AG14361 on growth ofPARP-l wild type and null cell lines. 
Cells were exposed to 0, I, 3, 10, 30 or 100 ~M AGI4361 for 5 days. Growth 
inhibition was measured by SRB assay, section 2.4.1. Data are the mean of 3 
independent experiments ± SEM, IC50 values are the mean of individual IC50 values 
from each experiment (Calabrese et aI., JNCI in press). 
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Figure 3.6 Effect of AG14361 on growth of K562 cells. 
K562 cells were exposed to 0, 0.4, 1, 10,40 or 100 J.lM AG14361 for 16 hours followed 
by 5 days growth in drug free medium. Cells were then fixed and growth inhibition was 
measured by cell counting as described in section 2.4.3. Data was expressed as a 
percentage of a DMSO-treated control. Data are the mean of 3 independent 
experiments ± SEM. 
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3.3.3 Investigation of PARP-1 inhibitory effects of AG14361. 
To ensure that PARP-l activity is sufficiently depleted by 0.4 ~M AG14361 in the cell 
lines used, P ARP-l activity was measured as described in section 2.6. Briefly, cells 
were pre-treated for 10 mins with a range of concentrations of AG 14361 before 
penneablisation and assaying for P ARP-l activity. This methodology ensures that any 
inhibition observed was caused by inhibitor that had been transported into the cells. 
The penneablised cells were incubated with e2p]-NAD and an oligonucleotide to 
stimulate P ARP-l. Incorporation of radiolabel into acid-insoluble ADP-ribose 
polymers was measured by scintillation counting. Figure 3.7 shows that 0.4 ~M 
AG14361 reduced PARP-l activity in K562 cells by 90 ± 0.070/0. A summary of 
P ARP-l activity data for P ARP-l wild type, null and K562 cell lines is given in Table 
3.2. In the PARP-l wild type cells 0.4 ~M AG14361 was sufficient to reduce PARP-l 
activity to less than 5% of nonnal activity. P ARP-l null cells were found to have -10% 
P ARP-l activity, possibly due to P ARP-2, and this could be fully inhibited by 0.4 ~M 
AG14361 
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Figure 3.7 Effect of AG14361 on PARP-l activity in K562 cells. 
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Exponentially growing K562 cells were exposed to 0, 1, 4, 10, 40, 100, 400 nM 
AG14361 for 10 mins. PARP-l activity was measured as described in section 2.6 and 
activity was expressed as a percentage of a DMSO-treated control. Data are the mean 
of3 independent experiments ± SEM. 
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Cell Line 
P ARP-l activity 0/0 inhibition by GIso AG14361 
(pmolfl06 cells) 0.4 J.lM AG14361 (nM) 
K562 233 ± 39 91 ± 0.1 30 ± 17 
PARP-l wild type 160 ± 40 96 ± 3 22 ± 3 
PARP-l null 10 ± 3 98 ± 3 15 ± 4 
Table 3.2 PARP-l activity and its inhibition by AG14361 in K562 and PARP-l 
wild type and P ARP-l null cells. 
Data are mean ± SEM for at least 3 independent experiments. P ARP-l wild type and 
null cell line data reproduced with permission (Veuger et al., manuscript in press 
Oncogene 2003). 
100 
i 
I 
3.3.4 Effect of AG14361 on Topo I poison-mediated growth inhibition. 
3.3.4.1 PARP-1 wild type and null cell lines. 
To confinn that P ARP-1 plays a role in the cellular response to topo I poisons and that 
AG14361 potentiates topo I poisons through its effect on PARP-1, the effect of 
AG14361 on topotecan-induced cell growth inhibition was investigated in PARP-l wild 
type and null cells. 
Exponentially growing P ARP-1 wild type and P ARP-1 null cell lines were exposed 
continuously for 5 days to increasing concentrations of topotecan in the presence or 
absence of 0.4 ~M AG 14361, and cell growth inhibition detennined by SRB assay 
(Figure 3.8). The data summarised in Table 3.3 show that the PARP-1 null cells were 
3-fold more sensitive to topotecan than wild-type cells, this differential sensitivity was 
statistically significant (p = 0.00045 unpaired t-test). It was also found that the growth 
inhibitory effect of topotecan in wild-type cells was enhanced 2 to 3-fold by co-
incubation with 0.4 ~M AG14361 and that this enhancement was statistically significant 
(p = 0.002 paired t-test). There was a modest potentiation of topotecan-induced growth 
inhibition by AG14361 in PARP-l null cells (p = 0.03 paired t-test) possibly due to 
inhibition of P ARP-2 by AG 14361. However this result was not reproduced in later 
experiments (see section 3.3.4.3). There was no significant difference in growth 
inhibition between P ARP-1 null cells treated with topotecan alone (G1so = 20.8) and 
PARP-l wild type cells treated with topotecan and AG14361 (G1so = 19.5; p = 0.9 
unpaired t-test), nor was there a statistically significant difference in growth inhibition 
between P ARP-1 wild type and P ARP-l null cells treated with both topotecan and 
AG14361 (G1so (wildtype) = 19.5 v (null) 15.6, p=0.25, unpaired t-test). This suggests 
that absence of P ARP-l and chemical inhibition of P ARP-1 have an approximately 
equivalent effect on cell growth following exposure to topotecan. 
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Figure 3.8 Effect of AG14361 on topotecan-induced growth inhibition in PARP-l 
wild-type (+1+) and null (-1-) cell lines. 
Cells were exposed to 0, 3, 10, 30, 100 and 300 nM topotecan in the presence or 
absence of 0.4 /-lM AG 14361 for 5 days continuously. Growth inhibition was measured 
using the SRB assay (see section 2.4.1) and growth was expressed as a percentage of the 
related DMSO or 0.4 /-lM AG 14361-treated control. Data are expressed as a percent of 
untreated control from 3 independent experiments ± SEM. 
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GIso Topotecan (nM) GIso Topotecan + 0.4 PFso 
JlM AG14361 (nM) 
PARP-l wild-type 65.0 ± 7.0 19.5 ± 4.3 ** (a) 3.4 ± 0..+ 
PARP-l null 20.8 ± 2.0 **(a), NS (c) 15.6 ± 0.6 *(b) 1.4 ± 0.1 
Sensitivity ratio 3 ± 0.2 1.3 ± 0.5 
Table 3.3 Effect of AG14361 on topotecan-mediated growth inhibition in PARP-l 
wild-type and null cells. 
i 
Mean IC50 values from 3 independent experiments are given ± SEM. PF 50 is the 
potentiation factor, the ratio of GI50 drug alone: GI50 drug plus P ARP-1 inhibitor 
calculated from GI50 values from individual experiments . 
.. p< 0.001 paired t-test. 
+ p <0.05 paired t-test. 
NS not significant 
a compared to P ARP-1 wild-type treated with topotecan alone. 
b compared to P ARP-1 null treated with topotecan. 
c not significantly different from P ARP-1 wild type treated with topotecan + AG 14361. 
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3.3.4.2 p53 status of PARP-1 cell lines. 
During the course of this study the P ARP-l wild type cell line used here was found to 
be expressing a mutant p53 (P. Jowsey, PhD thesis 2003). These cells contained a 
single base change from G to C in codon 278 conferring an Asp to Glu substitution 
GAC to GAG codon change). This mutation is located within a conserved region of the 
DNA binding domain, and rendered p53 unable to act as a transcriptional transactivator. 
The P ARP-l null cells expressed wild type p53. Loss of p53 is known to cause 
resistance to topo I poisons and this could be responsible for the relative resistance of 
the P ARP-l wild type cells compared to the P ARP-l null cells. It was therefore 
desirable to investigate the effect of P ARP-l on topo I poison sensitivity in cells with 
the same p53 status. 
3.3.4.3 Studies using PARP-1 nullTR and PARP-1 null cells. 
In an attempt to compare topo I poison mediated cytotoxicity in the presence, absence 
or inhibition of P ARP-l in cell lines that were p53 wild type, another set of cells were 
acquired. Previous studies within the NICR led to the stable transfection of P ARP-l 
into the P ARP-l null cell line. This retransfected cell line, called P ARP-l null TR had 
previously been shown to express wild type P ARP-l and wild type p53 (P.1owsey 
personal communication; for details see section 2.3.2). 
The P ARP-l nullTR cell line was used to determine whether the differences in p53 status 
of the cell lines had any impact on the differential response to topotecan. Exponentially 
growing P ARP-l nullTR and P ARP-l null cells were exposed to 0 - 300 nM topotecan in 
the presence or absence of 0.4 JlM AG 14361 for 5 days before measurement of growth 
inhibition by SRB assay (see section 2.4.1). The effect of P ARP-l inhibition on 
topotecan induced growth inhibition in these cells is shown in Figure 3.9. The results, 
summarised in Table 3.4, show that there was no significant difference between the 
P ARP-l nullTR and the P ARP-l null cells in their response to topotecan (p = 0.9 paired 
t-test). There was a modest potentiation of topotecan-induced growth inhibition by 
AG 14361 in the P ARP-l nullTR cells (p = 0.06 paired t-test), similar to that observed in 
the untransfected PARP-l null cells (Table 3.3 and Table 3.4). The PARP-l nullTR cells 
were approximately 3 times more sensitive to topotecan than the original PARP-l wild 
type cells shown in Table 3.3. These data indicate that retransfection of P ARP-l in to 
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P ARP-l null cells did not affect their hypersensitivity to topotecan. This unexpected 
result was investigated further by detennining the levels of P ARP-l protein in the 
PARP-l nullTR cells using Western blotting. The blot in Figure 3.l0 illustrates that the 
P ARP-l null TR cells did not express levels of P ARP-l comparable to those levels seen 
in the wild type cells. This blot is not ideal, however, other members of the NICR have 
observed a reduced level of P ARP in the retransfected P ARP null cells. It is therefore 
possible that the reason for the hypersensitivity of the P ARP-l null TR cells to topotecan 
is due to a reduced expression of the PARP-l gene compared to PARP-l wild type cells. 
This may be due to lack of selection pressure since the transfected pP ARP31 plasmid 
contains the neomycin resistance gene and the P ARP-l null genotype was created by 
homologous recombination and insertion of pGK-neo into the P ARP-l gene. Therefore 
G418 selection used on these cells could not ensure that only the transfected cells would 
survIVe. 
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Figure 3.9 Effect of AG14361 on topotecan-induced growth inhibition in PARP-l 
nullTR and PARP-l null cell lines. 
Exponentially growing cells were exposed to 0, 3 10, 30, 100, 300 nM topotecan in the 
presence or absence of 0.4 IlM AG 14361 for 5 days continuously. Growth inhibition 
was measured by SRB assay (see section 2.4.1) and growth was expressed as a 
percentage of the related DMSO or 0.4 IlM AGl4361-treated control. Data are the 
mean of 3 independent experiments ± SEM. 
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Figure 3.10 PARP-1 protein levels in PARP-1 nullTRcells (-/- TR) and PARP-l wild 
type cells (+/+). 
30~g of whole cell lysate was loaded per well. Proteins were separated and detected 
using Western blotting as in section 2.5. PARP-l was detected using rabbit anti-PARP-
1 antibody (Santa Cruz Biotechnology) and the appropriate secondary antibody. 
Cell Line GIso Topotecan GIso Topotecan PFso 
(nM) + AG14361 (nM) 
PARP-1 nullTR 22.2 ± 0.7 18.5 ± 0.5 • 1.20 ± 0.07 
PARP-1 null 22.0 ± 0.7 21.5 ± 1.3 1.03 ± 0.07 
P ARP-1 wild type 65.0 ± 7.0 19.5 ± 4.3 3.4 ± 0.4 
Table 3.4 Effect of AG14361 on topotecan -induced growth inhibition in PARP-1 
wild type, PARP-l nullTR and PARP-1 null cell lines. 
Growth inhibition was measured by SRB assay see section 2.4.1. Data are the mean of 
3 independent experiments ± SEM. 
* p = 0.06 paired t-test; compared to topotecan alone. 
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3.3.5 Effect of AG14361 on camptothecin-induced cytotoxicity in K562 
cells. 
The studies on P ARP-l wild type and null cells treated with topotecan in the presence 
or absence of AG14361 indicated both a role for PARP-l in the response to topo I 
poisons and that the chemopotentiating effect of AG14361 was due to PARP-l 
inhibition. Studies were then focussed on a human tumour cell line that has previously 
been characterised in response to another topo I poison, camptothecin (Padget et al., 
2000). Although camptothecin is not used clinically (due to unpredictable toxicity), its 
use in the subsequent experiments is justified on the grounds of its near identical mode 
of action to clinically used topo I poisons, and its abundant use in cell culture-based 
studies allowing direct comparisons with studies in the literature. 
The growth inhibitory effect of camptothecin on human chronic myelogenous 
leukaemia (CML) K562 cells in the presence or absence of 0.4 /-lM AG14361 was 
investigated. Two exposure times were used with the K562 cells. A 30 min exposure 
was used as this is a time corresponding to the peak in levels of camptothecin-stabilised 
cleavable complexes in K562 cells (Padget et al., 2000). A 16 hour exposure was also 
used as this had been used in previous studies by Mattern et al., (1987) and Bowman et 
al., (2001), and also allowed the majority of cells to have gone through one S-phase of 
the cell cycle. This is important because of the S-phase specific toxicity of 
camptothecin (D'Arpa et al., 1990). Cells were exposed to camptothecin in the presence 
or absence of 0.4 /-lM AG 14361 for 30 mins or 16 hours before removal of the drug and 
incubation in drug free medium or medium containing 0.4 /-lM AG14361 for a further 5 
days. In initial studies the XTT assay was used to determine growth inhibition but this 
assay, whilst suitable for determining growth of untreated cells gave very variable data 
with drug exposure, possibly due to the phenomenon of "unbalanced cell growth" of 
drug treated cells. Growth inhibition was therefore measured by direct counting 
measured aliquots of cell suspension using a Coulter counter (section 2.4.3). Figure 
3.11 and Figure 3.12 show the effect of AG 14361 on camptothecin-induced growth 
inhibition. The growth data summarised in Table 3.5 show that a significant 2-fold 
potentiation of camptothecin by AG 14361 was observed after a 16 hour exposure to 
camptothecin (PFso = 1.94~ p = 0.01005). However, after a 30 min exposure to 
camptothecin, AG 14361 failed to potentiate the anti-proliferative activity of 
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camptothecin, thus, there was no significant overall potentiation (PF 50 = 1.11 ± 0.02~ p 
= 0.7 paired t-test). Although following a 30 min exposure to 100 nM camptothecin cell 
growth inhibition was significantly enhanced by AG 14631 1.9 ± 0.04 fold (p = 0.005 
paired t-test). 
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Figure 3.11 Effect of AG14361 on camptothecin-induced growth inhibition in 
K562 cells. 
Exponentially growing cells were exposed to 0, 10, 50, 100, 500, 1000 and 10000 nM 
camptothecin ± 0.4 flM AG14361 for 30 mins and grown for 5 days in drug-free 
medium or medium containing AG14361. Cell growth was measured by cell counting 
(see section 2.4.3) and expressed as a percentage of the relevant DMSO or 0.4 JlM 
AG 14361 alone control. Graph shows the mean of 3 independent experiments ± SEM. 
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Figure 3.12 Effect of AG14361 on camptothecin induced growth inhibition in K562 
cells. 
Cells exposed to 0, 1,3, 6, 10,30, and 100 nM camptothecin ± 0.4 J.lM AGI4361for 16 
hours and grown for 5 days in drug free or medium containing 0.4 J.lM AGI4361. Cell 
growth was measured by cell counting (see section 2.4.3) and expressed as a percentage 
of the relevant DMSO or 0.4 J.lM AGI4361 alone control. Data are the mean of 4 
independent experiments ± SEM. 
III 
Time (bours) GIso Camptotbecin GIso Camptotbecin PFso 
(nM) + AG14361 (nM) 
0.5 40 ± 5.3 38 ± 6.5 a 1.11 ± 0.2 
16 * 4.7 ± 0.4 2.4 ± 0.1 1.9 ± 0.2 
Table 3.5 Effect of AG14361 on camptothecin-mediated growth inhibition in K562 
cells. 
I 
I 
Cells were exposed for 0.5 or 16 hours before removal of drug and growth in drug free 
medium or medium containing AG 14361 for a further 5 days. Growth inhibition was 
measured by SRB assay and ICso values calculated as described in section 2.4.1. Data 
are the mean of 4 independent experiments ± SEM. 
(*) significantly different from camptothecin alone p< 0.05 paired t-test. 
(a) not significantly different from camptothecin alone. 
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3.3.6 Effect of AG14361 on survival of K562 cells exposed to 
camptothecin for 16 hours. 
Growth inhibition assays cannot distinguish between a general retardation of growth in 
the entire cell population and killing of a proportion of the cells. To detennine if the 
effect of camptothecin and its potentiation by AG14361 was cytotoxic as well as 
cytostatic, the clonogenic survival of K562 cells in response to exposure to 
camptothecin in the presence or absence of AG14361 was also investigated. The 
clonogenic assay described in section 2.4.4, uses a different biological end-point to 
growth inhibition assays relying on the ability of the treated cells to be able to reproduce 
from a single cell to form a colony. K562 cells were exposed to camptothecin in the 
presence or absence of AG14361 for 16 hours before the cells were plated out at known 
cell numbers. The survival of these cells is shown in Figure 3.13. Camptothecin 
induced cytotoxicity was significantly increased 1.75-fold by 0.4 /-lM AG14361 
compared to treatment with camptothecin alone. These results are in good agreement 
with the results shown in the growth inhibition assay in Figure 3.12. The bi-phasic 
appearance of the survival curve is characteristic of curves produced in response to S-
phase specific agents, and suggests that not all of the cells have been through one cell 
cycle while exposed to camptothecin, as would be expected as K562 cells double every 
24 hours. This could be investigated further using different exposure times. 
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Figure 3.13 Effect of AG14361 on camptothecin induced cytotoxicity in K562 cells. 
Exponentially growing cells were exposed to 0, 1, 3, 6, 10, and 30 nM camptothecin for 
16 hours. Cytotoxicity was measured using the sloppy agar c1onogenic assay as 
described in section 2.4.5 and expressed as a percentage of the relevant DMSO or 0.4 
J..lM AG 14361 alone control. Data are pooled data from 4 independent experiments ± 
SEM. 
LCso camptothecin LCso camptothecin + PFso 
(nM) AG14361 (nM) 
K562 4.86 ± 0.37 2.77 ± 0.55 * 1.92 ± 0.34 
Table 3.6 Cell survival of K562 cells treated with camptothecin in the presence or 
absence of AG14361. 
LC 50 values are means ± SEM for 4 independent experiments. PF 50 was calculated from 
individual IC50 values for each experiment. 
* p = 0.05 paired t-test compared to camptothecin alone. 
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3.4 Discussion. 
The aim of this chapter was firstly to verify the role of P ARP-l in cellular survival and 
proliferation following exposure to topo I poisons using P ARP-l wild type and null 
cells. Secondly, to demonstrate that P ARP-l is the principle cellular target for the novel 
P ARP inhibitor AG 14361 and that the enhancement of the antiproliferative activity and 
cytotoxicity of topo I poisons by AG 14361 is due to its P ARP-inhibitory effect. The 
effect of AG 14361 on camptothecin-mediated cytotoxicity in K562 cells was also 
investigated to verify that this was a suitable model for further investigations, as 
described in subsequent chapters of this thesis. 
PARP-1 null cells were shown to be 2 to 3-fold more sensitive to topotecan than the 
wild type cells (Figure 3.8, Table 3.3). This suggests that there is a role for P ARP-l in 
the cellular response to topotecan. This was not due to differences in levels of topo I 
protein as Figure 3.3 shows that these cell lines have similar levels of topo I protein. 
During the course of these studies the P ARP-I wild type cell line were found to carry a 
p53 mutation in the P ARP-l wild type cell line that was not present in the P ARP-l null 
line. The difference in the p53 status in these cells could account for the differential 
sensitivity of the P ARP-l wild type and null cells to topo I poisons. It has also been 
shown previously that p53 status is not a good predictor of topo I poison cytotoxicity in 
a panel of cell lines, therefore it does not necessarily follow that a cell line expressing 
mutant p53 would be more or less sensitive than those expressing wild type p53 
(Goldwasser et aI., 1995). Furthermore, studies in the NICR have failed to show an 
effect of p53 status on growth inhibition by topotecan. Using the HCT116 (wt p53) and 
HCT116 N7 (p53 degraded by the human papilloma virus E6 protein) human colorectal 
carcinoma cell lines it was shown that there was no significant difference in topotecan-
induced cytotoxicity between these two cell lines (G1so topotecan HCTl16 = 4.8 ± 1.7; 
GIso topotecan HCT116 N7 = 5.1 ± 3.6) (G.Swaisland unpublished data). 
Whether p53 mutation or loss confers resistance to topo I poisons or not this does not 
appear to be by a pathway that involves P ARP-1. Delaney et al., (2000) demonstrated 
that that the potentiation of growth inhibition on topotecan by NU1025 in 12 human 
tumour cell lines was independent of the p53 status of the cell. There was also no 
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difference in the potentiation of growth inhibition of HCT116 and HCTl16 N7 cells 
exposed to topotecan and AG14361 compared to topotecan alone (PFso HCT116 = l.7 ± 
0.7 I-1M; HCTl16 N7 = 2.1 ± l.0 I-1M) (G. Swaisland unpublished data). The data 
presented in this chapter clearly show that AG14361 potentiates topotecan in p53 
mutant P ARP-1 wild type cells and also camptothecin in the p53 null K562 cells. 
Taken together these data suggest that the difference in p53 status of the P ARP-l wild 
type and P ARP-l null cells, although not ideal, should not alter the interpretation of the 
results presented in this study. 
In order to eliminate the added complication of differences in p53 status, an alternative 
P ARP-l wild type and null cell line was investigated. The alternative wild type line had 
been derived from the same P ARP-l wild type and null mice as the cells originally used 
here, but by Gilbert de Murcia's Laboratory, (Strasbourg). During the course of this 
study these cells were also found to have a p53 mutation that was different from the one 
found in the original cells. Following this, attempts were made to retransfect the P ARP-
1 null cells with P ARP-l to make a P ARP-l wild-type cell that expressed wild-type 
p53. These cells, called PARP-l nullTR in this study, had been fully validated and 
shown to express wild type p53 and P ARP-l protein by other workers in this lab prior 
to use (P Jowsey, PhD thesis 2003). However, these PARP-l nullTR cells behaved more 
like the P ARP-l null untransfected cells in that they were shown to be 2-3 fold more 
sensitive to topotecan compared to the original P ARP-l wild type cells and there was 
minimal potentiation of growth inhibition caused by topotecan in the presence of 
AG14361 compared to topotecan alone Figure 3.9. Further investigation revealed that 
the PARP-l nuUTR cells were not expressing PARP-l at levels comparable to the wild 
type cell line and this could be the reason for the lack of potentiation of growth 
inhibition by AG 14361 Figure 3.10. This apparent loss of expression of P ARP-l in the 
transfectants may have been due to the fact that the plasmid containing the P ARP-l 
gene expressed the neomycin resistance gene. The P ARP-l null mice were generated 
through recombination with a neomycin resistance gene. Thus selection in G418 
containing medium would not confer a selection advantage to cells retransfected with 
PARP-I. 
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In this chapter it has been shown that, at the concentrations used in this study (0.4 ~M), 
AG 14361 did not significantly inhibit growth in any of the cell lines used here (Figure 
3.5, Figure 3.6). 0.4 ~M AG14361 was sufficient to inhibit the actiyity of PARP-l in 
these cells by at least 90% ofnonnal activity (Figure 3.7, Table 3.2). Thus 0.4 ~M was 
a suitable concentration to use in this study. The observation that greater than 90% 
P ARP-l inhibition can be achieved at concentrations that cause less than 10 % growth 
inhibition is a strong indication that at 0.4 ~M AG 14361 P ARP-l is the principle target 
for AG14361. Previous studies have shown that, in A549 cells, exposure to 0.4 ~M 
AG 14361 for 17 hours did not change the expression of any of the 6800 genes studied. 
Exposure to the GIso concentration (14 ~M), the expression of 62 genes, including p21, 
were altered >2-fold (Calabrese et at., mCI in press). 
AG 14361 enhanced the growth inhibitory effects of topotecan 2 to 3-fold in P ARP-l 
wild-type cells (Figure 3.8, Table 3.3). This was a similar level of potentiation to that 
seen in other cell lines in response to AG14361 (Calabrese et at., mCI in press) and 
with the differential sensitivities of the P ARP-l wild type and null cells as described in 
this chapter. A similar degree of potentiation of camptothecin-induced growth inhibition 
has been seen using NUI025 and other P ARP-l inhibitors in the studies by Delaney et 
at., (2000) and Bowman et at., (2000). 
There was no significant increase in growth inhibition when P ARP-l null cells were 
exposed to topotecan and AG14361 compared to topotecan alone (Figure 3.5). This 
indicates that AG 14361-mediated potentiation of topotecan is primarily due to 
inhibition of P ARP-l, rather than non-specific effects, in agreement with a lack of effect 
on gene expression (Calabrese et at., mCI in press). 
The GIso for topotecan alone in P ARP-l null cells was not significantly different from 
that seen when PARP-l wild type cells treated with AG14361 (Table 3.3). Thus a 
concentration that inhibits P ARP-l by greater than 900/0 is equivalent to genetic ablation 
of P ARP-l activity in tenns of enhancing sensitivity to topo I poisons. 
The effect of AG 14361 on camptothecin in K562 (p53 null) cells was also investigated. 
Experiments showed that 0.4 ~M AG 1.+361 inhibits PARP-l activity by >90% in these 
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cells and that this concentration of AG 14361 does not affect proliferation of K562 cells. 
similar to observations in the other cell lines (Table 3.2). AG14361 was also shown to 
potentiate the effect of topo I poisons 2-fold in K562 cells after a 16 hour exposure 
which is comparable to the 2 to 3-fold potentiation in the P ARP-1 wild type cells (table 
3.5). However after a 30 min exposure growth inhibition was not potentiated by 
AG 14361 at the concentration of camptothecin corresponding to the GIso, although 
there was significant potentiation at 100 nM camptothecin (figure 3.11). There was 
approximately 10-fold difference in the concentration required to achieve the same level 
of cytotoxicity between the 30 min and 16 hour time point. A similar observation was 
made by Goldwasser et al., (1995) using a 1 and 24 hour exposure where there was a 
40-fold difference in the dose required to cause the same level of cytotoxicity. It has 
already been shown that PARP-1 is inhibited after a 10 min exposure to AG14361 
(Figure 3.7) and that the stabilised cleavable complexes are maximal after 30 mins 
exposure to camptothecin (Padget et al., 2000). Therefore this would suggest that the 
potentiation of topo I poisons is not a direct effect of P ARP-1 inhibition, i.e. a down 
stream effect of lack of P ARP-1. This would suggest that the effect that P ARP-1 exerts 
accumulates over time e.g. in regulating the formation and reversal of cleavable 
complexes via modulation of activity of topo I molecules by poly(ADP-ribosylation), or 
the creation or repair of the single strand breaks. Taken together this suggests that 
longer exposure to P ARP-1 inhibitors is required to achieve maximal potentiation of 
cytotoxicity and growth inhibition. This has been suggested previously by Mattern et 
al., (1987), using camptothecin and 3-AB. Here it was demonstrated that a 60 min 
exposure to 3-AB prior to treatment with camptothecin was not sufficient to potentiate 
cytotoxicity, however potentiation was seen after a 16 hour pre-treatment. 
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In summary the data presented in this chapter shows that: -
• P ARP-1 is involved in the response to topo I pOIsons as shown by the 
hypersensitivity of cells lacking P ARP-1 activity to topotecan. 
• AG14361 can be used to potentiate topo I poisons at a concentration that inhibits 
P ARP-1 activity by 90% without affecting cellular proliferation and survival per 
se. 
• AG 14361 is specific for P ARP-1 as potentiation of growth inhibition was seen 
in P ARP-1 wild type cells and not P ARP-l null cells. 
The data presented in this chapter and data from similar studies in the literature, shows 
that the lack or inhibition of P ARP-l activity increases sensitivity to topo I poisons 2 to 
3-fold in cell cultures and in human tumour xenografts. 
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Chapter 4 
Effect of PARP-1 on topoisomerase I activity. 
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4.1 Introduction. 
In the previous chapter inhibition or loss of P ARP-1 activity was shown to increase topo 
I poison-mediated cytotoxicity. Two hypotheses have been proposed to explain this 
phenomenon; (1) that P ARP-1 modulates topo I activity, and (2) that P ARP-1 is 
involved in the repair of topo I poison-mediated DNA damage. In this chapter the first 
hypothesis was tested, investigating whether P ARP-1 inhibition by AG 14361 could 
alter topo I activity. 
Poly(ADP-ribosylation) of topo I is thought to result in the repression of topo I by virtue 
of the negatively charged poly(ADP-ribose) polymers causing the topo I to be repelled 
from the negatively charged DNA. Inhibition of P ARP-l by preventing poly(ADP-
ribosylation) of topo I should therefore de-repress topo I. Increased topo I expression is 
associated with increased sensitivity to topo I poisons (Madden and Champoux, 1992, 
Husain et al., 1994). Presumably this is because of the greater potential for cleavable 
complex formation and hence stabilisation by topo I poisons. 
Inhibition of topo I activity by P ARP-1 activity was first shown in vitro by Ferro et aI., 
(1983). In this paper it was found that there was a modest DNA topoisomerase activity 
associated with a purified P ARP-1 preparation. This was demonstrated by the ability of 
this preparation to relax supercoiled plasmid DNA. This topo activity was equivalent to 
< 30 units/ml topoisomerase in the presence of NAD+ and DNA i.e. when P ARP-1 was 
active. However if NAD+ or DNA were omitted from the reaction, topo I was not 
inhibited and activity was 625-750 units/ml. The implication from this study was that 
poly(ADP-ribosylation) inhibited topo I activity. 
Poly(ADP-ribosylation) of topo I has also been described by Jongstra-Bilan et aI., 
(1983). Topoisomerase activity was detected in a preparation of poly(ADP-ribosylated) 
proteins. This was shown to be associated with topo I, as the activity was not dependent 
on the presence of ATP, which is required for topo II activity. As well as confirming 
the findings of Ferro et al., (that under conditions of poly(ADP-ribosylation) topo I is 
inhibited) it was shown that inhibition of relaxation activity of topo I by P ARP-l was 
reversed by nicotinamide and 3-AB, confinning that inhibition of topo I was dependent 
on PARP-I activity rather than a protein-protein interaction between topo I and PARP-
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1. This paper also showed a shift in the molecular weight of topo I protein to a higher 
weight in the presence of DNA-associated P ARP-l and radiolabelled NAD+. This shift 
corresponded to an increase in the amount of radiolabel associated with the topo I 
protein band on the gel and could be inhibited by nicotinamide, signifying that the topo 
I protein was being poly(ADP-ribosylated). These results confirmed that the topo I 
protein was an acceptor of poly(ADP-ribose) polymers from P ARP-I, and that this 
modification could inhibit topo I activity. 
In the studies by Ferro et al., (1983) and 10ngstra-Bilan et al., (1983), topo I that had co-
purified with ADP-ribosylated proteins had been used. This topo I activity 
corresponded to between 0.1 and 1 % of the total cellular topo I. Therefore it was 
important to show that this small fraction was characteristic of the total topo I in the 
cell. Ferro and Olivera, (1984) showed that the major topo I activity purified from calf 
thymus could be poly(ADP) ribosylated by purified P ARP-l and this inhibited topo I 
activity. This topo I was representative of the major topo I activity in the cells and 
therefore confirmed their previous results. The authors went on to postulate that the 
increase in the negative charge of topo I caused by the addition of the negative 
poly(ADP-ribose) polymers would eventually repel topo I from the DNA, thus 
inhibiting topo I activity (Ferro and Olivera, 1984). 
Poly(ADP-ribosylation) of topo I has also been demonstrated in intact cells. Krupitza 
and Cerutti (1988) showed that topo I was poly(ADP-ribosylated) in an extract of acid 
insoluble proteins from the 1B6 (clone 41) mouse epidermal cell line. Stimulation of 
P ARP-I by generation of DNA strand breaks following exposure of cells to active 
oxygen (produced by a xanthine-xanthine oxidase system) increased the amount of 
polymer associated with the topo I protein by 6-fold, and this could be inhibited by the 
P ARP-l inhibitor, benzamide (1 00 ~M). Therefore there is evidence that P ARP-
poly(ADP-ribosylates) to po I in intact cells. 
The poly(ADP-ribosylation) of topo I has been investigated by other authors by 
measuring the levels of topo I covalently bound to DNA in the cleavable complex but 
their findings are contradictory. Matten1 et al.. (1987) showed that the number of 
protein-linked DNA single strand breaks (PLDB) in LI210 treated with 1-10 ~M 
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camptothecin could be increased 1.6-fold in the presence of 5 mM 3-AB. These 
protein-linked DNA strand breaks were most likely to be camptothecin-stabilised topo I 
cleavable complexes. Given the earlier evidence that poly(ADP-ribosylation) down-
regulated topo I activity, Mattern et al., concluded that the increase in PLDBs was most 
likely to be due to loss of poly(ADP-ribose) from the topo I in the presence of 3-AB 
resulting in de-repression of topo I activity. Conversely, the levels of protein-linked 
DNA strand breaks fonned in camptothecin-sensitive or resistant KB cell lines treated 
with camptothecin were not altered by 3-AB even though camptothecin toxicity could 
be potentiated in the resistant cell lines (Beidler et al., 1996). The experimental 
conditions were not identical in these two studies. Mattern et ai., exposed cells for 16 
hours to 5 rnM 3-AB prior to a 1 hour pulse with 1-1 0 ~M camptothecin whereas, 
Biedler et al. exposed cells for 24 hours to 1 rnM 3-AB prior to a 30 min pulse with 5 
JlM camptothecin before estimating protein-linked DNA breaks. Moreover, different 
methods were used to detect the protein-linked strand breaks. Mattern et al., used a 
lysis buffer containing sarkosyl whereas Beidler used SDS. Topo I-DNA complexes 
can dissociate in the presence of sarkosyl, however complexes are stabilised when cells 
are lysed in SDS (Covey et al., 1987). The levels of protein-linked DNA breaks 
reported in the study by Mattern et al., may therefore underestimate cleavable complex 
levels. The increase in protein-linked DNA breaks in the presence of 3-AB could 
therefore reflect either an increased level of complex fonnation or a decrease in their 
dissociation in the presence of sarkosyl. Both scenarios would be consistent with 
poly(ADP-ribosylation) causing reduced affinity of topo I for DNA. 
Activation of P ARP-l by DNA damage may cause a reduction of cellular topo I 
activity. Topo I activity following treatment with IR was found to be reduced 2 to 4-
fold in nonnal cells and ~20-fold in tumour cells with elevated topo I activity. 
Exposure to IR did not change topo I protein or RNA levels (Boothman et al., 1994). 
This inhibition of topo I was thought to be associated with poly(ADP-ribosylation) of 
topo I protein because it was prevented by the PARP-l inhibitors 3-AB or PD128763. 
A small band shift of about 3 kDa was observed when topo I protein was separated on 
2D-gels following treatment with IR. This was thought to correspond to a mono(ADP-
ribosylation) of the topo I protein. Therefore, these data implicate a role for an ADP-
ribosylating protein in modulation of topo I activity in response to IR and provides 
further evidence to support the hypothesis that P ARP modifies topo I inhibiting topo I 
activity. 
A more recent study using TK6 human lymphoblastoid cells has shown that topo I and 
p53 form a complex that is poly(ADP-ribosylated) following 1 Gy of y-irradiation 
(Smith and Grosovsky, 1999). Immunoprecipitations of extracts of y-irradiated TK6 
cells were performed using topo I monoclonal antibody. Western blots of these 
immunoprecipitates were probed for poly(ADP-ribose) polymer, and these revealed a 
number of proteins that could be co-immunoprecipitated with topo I and also 
poly(ADP-ribosylated). One of the proteins identified was p53 and thus it was 
suggested that p53 and topo I form a complex and this complex could be poly(ADP-
ribosylated). ADP-ribosylation of topo I was not detectable in untreated cells, however 
in response to irradiation, poly(ADP-ribosylation) of topo I was complete within a 
minute of exposure. p53 is also poly(ADP)ribosylated in response to irradiation. 
Therefore it is possible that poly(ADP-ribosylation) of p53 in the complex as well as 
topo I itself may account for the inhibition of topo-l activity following y-irradiation. 
Topo I is a component of the multiprotein replication complex (MRC). Analysis of 
purified MRC complexes showed that P ARP-l co-purified with some of the core 
proteins of the 18-21 S multiprotein replication complexes from HeLa cells, as well as 
with the same proteins from a MRC from a different cell line. Immunoblot analysis of 
the MRC proteins for poly(ADP-ribosylated) proteins revealed that 15 proteins were 
poly(ADP-ribosylated). These proteins included topo I, DNA pol-a and PCNA. This 
provides further evidence for the poly(ADP-ribosylation) of to po I, in another biological 
setting (Simbulan-Rosenthal et al., 1996). 
Alternative pathways for the modulation of topo I activity by P ARP-l have been 
proposed. Topo I is phosphorylated by caesin kinase-2 (CK-2) or protein kinase C 
which results in an increase in the activity of topo I. Phosphorylation of topo I is 
associated with increased sensitivity to camptothecin (Pommier et al., 1990). A study 
was conducted using L Y -S camptothecin-resistant, X-ray-sensitive and the L Y-R 
camptothecin-sensitive, X-ray resistant murine lymphoma cells. Topo I was 
phosphorylated to a much lesser extent in the L '{ -S cells than the L Y -R cells (Staron cl 
12.+ 
al., 1994, 1995). Investigations into this revealed that the LY -S cells had impaired CK-2 
activity, approximately 1.7 -times lower than the L Y -R cells. The L Y -S cells also had 5-
times higher poly(ADP-ribose) activity than the LY-R cells. Treatment of these cells 
with benzamide inhibited P ARP-1, and increased the phosphorylation of topo I by CK-
2. There may be a number of reasons for this. PAR polymers, whose structures are 
different in the two cell lines (the L Y -S cells make significantly shorter polymers than 
the LY-R cells, Kleczkowska, et aI., (2002», may affect the formation of CK-2 
oligomers, or poly(ADP-ribosylation) of topo I may impede the phosphorylation of topo 
I by CK-2, or negatively charged proteins may inhibit CK-2 directly. These data 
suggest that as well as direct modulation of topo I by poly(ADP-ribosylation), P ARP-1 
may modulate topo I activity via phosphorylation (Staron et al., 1996). 
Taken together these studies indicate that P ARP-1 activity can repress topo I in cell-free 
and intact cell systems, with and without IR-mediated stimulation of P ARP-1 activity, 
and that the repression of topo I activity can be due to direct poly(ADP-ribosylation) of 
topo I, or mediated through an effect on p53 or CK-2. Therefore the potentiation of 
topo I poison-mediated cytotoxicity by AG 14361 could be due to topo I de-repression 
and an increase in the number of targets for topo I poisons. Thus, if there was an effect 
on topo I activity by the inhibition of P ARP-1 it could be determined through 
measurement of topo I enzyme activity and levels of cleavable complexes formed in 
response to topo I poisons in the presence or absence of AG14361. 
4.2 Aims 
The aim of the work described in this chapter was to determine whether inhibition of 
PARP-1 by AG14361 has any effect on topo I activity and if this is responsible for the 
potentiation of topo I poison induced cytotoxicity and growth inhibition by AG 14361. 
In this chapter topo I relaxation activity and cleavable complex formation were 
measured following exposure of K562 cells to AG 14361 for 30 mins or 16 hours to 
correspond to the time-points used in the growth inhibition and cytotoxicity assays in 
chapter 3. Levels of cleavable complexes haye been measured using the T ARDIS assay 
and K-SDS precipitation. 
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4.3 Results. 
4.3.1 Measurement of the effect of AG14361 on topoisomerase I 
relaxation activity. 
Topo I enzyme activity can be measured using a variety of different methods. In this 
section the relaxation activity of topo I has been measured. The relaxation assay 
measures the ability of topo to convert supercoiled purified plasmid DNA into the 
relaxed form, therefore measuring the breakage, unwinding and religation of the DNA. 
This assay can measure the relaxation activity of human topo II a and p as well as topo 
I. The assay is made specific for topo I relaxation activity by exclusion of ATP and 
Mg2+ from the assay. ATP is required for topo II activity. Omission of Mg2+ ensured 
that type 1-5' topoisomerase activity is not measured (for more detail see section 2.7). 
The effect of AG 14361 on topo I relaxation was investigated in the K562 cell line. 
K562 cells were exposed to 0.4 ~M AG14361 in medium for 30 mins or 16 hours at 
37°C before preparation of cell extracts according to section 2.7.1. A protein assay was 
conducted on the extracts to ensure that equal amounts of cellular protein were used i,n 
all samples (as section 2.5.1). Serial dilutions of cell extract were made such that the 
lowest concentration of cell extract corresponding to detectable relaxation activity and 
the highest concentration of extract corresponding to undetectable relaxation activity 
could be determined. 
30 min exposure 
Extracts of cells exposed to AG 14361 for 30 mins were incubated with purified plasmid 
DNA for 30 mins after which the reaction was terminated and the reaction products 
separated on an 0.80/0 agarose gel. Figure 4.1 shows that there was very little difference 
in relaxation activity between untreated cells and cells treated with 0.4 ~M AG 14361 
for 30 mins. This was shown by the presence of a band corresponding to supercoiled 
DNA in the 0.1 )lg protein sample for extracts from both control and AG 14361-treated 
cells. However, at 0.2 ~g protein both AG 14361-treated and control cell extracts had 
detectable topo I activity i.e. the band corresponding to supercoiled DNA was no longer 
visible and instead there were only bands cOITcsponding to relaxed DNA. This suggests 
that a 30 min exposure to 0,4 ~l\ 1 :\G 14361 did not affect topo I relaxation activity. 
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+- Relaxed DNA 
+- Supercoiled DNA 
Figure 4.1 Topo I relaxation activity in K562 cells treated with AG14361 for 30 
mins. 
Nuclear extracts were prepared from K562 cells treated with or without 0.4 ).!M 
AG1436 for 30 mins. These were incubated with 1 ~g supercoiled plasmid DNA for 30 
mins. The reaction products were separated on an agarose gel as described in section 
2.7.2, (-ve) is a negative control containing water and corresponds to supercoiled DNA, 
(+ve) is a positive control containing 4 units of purified topoisomerase I corresponding 
to relaxed DNA. Numbers correspond to cellular protein in each reaction, i.e. 0.8, 0.4, 
0.2 and 0.1 ~g cellular protein. Gel shown is one representative of 3 independent 
experiments. 
To further measure the effect of the P ARP-l inhibitor on topo I activity a longer 
exposure to AG14361 was also investigated. It has been shown in section 3.3.3 that 
P ARP-l activity was reduced within 10 minutes of exposure to AG 14361 in these cells. 
Therefore any effects of P ARP-l inhibition should be seen soon after exposure to 
AG14361. Poly(ADP-ribose) glycohydrolase is reported to degrade polymer rapidly; 
the half life of polymers being less than a minute in cells treated with alkylating agents 
(Alvarez-Gonzalez and Althaus, 1989). However, in the cytotoxicity assays (section 
3.3.5) a 30 min exposure to AG14361 was insufficient to significantly potentiate 
camptothecin, but a 16 hour exposure increased camptothecin cytotoxicity 2 to 3-fold. 
This suggests that a prolonged P ARP-l inhibition may be required to reduce poly(ADP-
ribosylation) levels sufficiently to modulate topo I activity. To allow direct comparison 
with cytotoxicity assays in K562 cells the effect of a 16 hour exposure to AG 14361 on 
topo I relaxation activity was investigated. 
16 hour exposure 
K562 cells were exposed to 0.4 J.1M AG14361 for 16 hours before preparation of 
extracts and measurement of topo I relaxation activity as before. The relaxation of 
plasmid DNA by these extracts is shown in Figure 4.2. This figure shows that topo I 
activity was undetectable at 0.1 J.1g cellular protein and detectable at 0.2 J.1g cellular 
protein, in both the control and treated samples. This therefore shows that there was no 
detectable difference in topo I relaxation activity in the presence or absence of 
AG14361. It should be noted that activity was undetectable at the same level of protein 
in this experiment and the one shown in Figure 4.1 confirming that there was no 
difference in activity following short of long term PARP-l inhibition. 
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Figure 4.2 Topo I relaxation activity in K562 cells treated with AG14361 for 16 
hours. 
Nuclear extracts were prepared from K562 cells treated with 0.4 J.!M AG1436 (A) or a 
DMSO treated control (B) for 16 hours and with supercoiled plasmid DNA for 30 mins 
and the reaction products run out on an agarose gel as described in section 2.7.2 (-ve) is 
a negative control containing water, (+ve) is a positive control containing 4 units of 
purified topoisomerase 1. Numbers correspond to cellular protein in the reaction, ie 0.4, 
0.2, 0.1, 0.05, 0.025, 0.0125 J.!g protein. Figure is of one gel that is representative of at 
least 3 experiments. 
4.3.2 Measurement of topoisomerase 
complexes. 
poison-stabilised cleavable 
Transient cleavable complexes are formed as a part of the catalytic cycle of topo I, and 
topo I poisons stabilise these complexes. The number of stabilised cleavable complexes 
is therefore related to the amount of active topo I present in the cell. Therefore to 
investigate the effect ofPARP-l on topo I activity the effect of AG14361 on the levels 
of complexes as well as the reversal of these stabilised complexes was measured. If 
DNA-bound topo I was a target for poly(ADP-ribosylation) then this may promote its 
dissociation from DNA, providing the cell with the means to remove stabilised topo 1-
DNA complexes. 
Cleavable complex levels were measured using the T ARDIS (Trapped in agarose DNA 
immunostaining) assay. This assay has been developed at the University of Newcastle 
upon Tyne for the detection of topo I, IIa and II~-associated cleavable complexes. It 
has been used to detect complexes stabilised by a variety of topo I, II and dual poisons, 
in human and murine cell lines (Willmore et aI., 1998, 2002, Errington et aI., 1999, 
Padget et aI., 2000b). This assay had been used previously to measure the levels of 
stabilised cleavable complexes formed in response to camptothecin in K562 cells 
(Padget at al 2000a), and was therefore selected for use in the present study with K562 
cells. 
T ARDIS is an immunofluorescent assay that measures the levels of topo I covalently 
bound to DNA in individual cells. Briefly, cells were treated with camptothecin ± 
AG 14361 for varying times and then mixed with agarose and spread onto microscope 
slides. The cells were then lysed leaving just the DNA, and proteins covalently bound 
to DNA including any drug-stabilised topo I cleavable complexes trapped in the agarose 
matrix. The presence of DNA-bound topo I was quantified using microscopy to 
measure fluorescence associated with the FITe-conjugated secondary antibody bound 
to the topo I-specific primary antibody (for more details see section 2.8). Fluorescence 
of DNA in the cell was measured by staining \vith Hoechst 33258 and this was used to 
define the areas occupied by the DNA for each cell. Thus the fluorescence associated 
with topo I bound to DNA for each cell could be calculated. 
l~O 
4.3.2.1 Effect of 30 min exposure to camptothecin on levels of cleavable 
complexes. 
Experiments were conducted to validate the assay compared to previous data. A 30 min 
exposure to camptothecin had previously been shown to be optimal for measuring the 
maximum levels of cleavable complexes in K562 cells treated with camptothecin. 
Reproducible high levels of cleavable complexes had been measured previously using 
the T ARDIS assay at 10 /J.M camptothecin (Padget et at., 2000a). Therefore K562 cells 
were exposed to a range of concentrations up to 10 /J.M camptothecin for 30 mins. 
Representative images of camptothecin-treated K562 cells are shown in Figure 4.3. 
This figure shows that the blue Hoechst associated staining and therefore DNA content 
of the cell was unchanged by camptothecin exposure. FITC-associated fluorescent 
(green) labelling of topo I-DNA complexes was undetectable in the control cells and it 
was barely detectable at the lowest concentration (0.01 /J.M) of camptothecin. However, 
a progressive increase in fluorescence was seen following exposure to 0.1 to 10 /J.M 
camptothecin. Figure 4.4 shows a scatter plot of the FITC-fluorescence associated with 
individual cells treated with camptothecin, and a plot of the mean values for triplicate 
experiments. These data show that there was a camptothecin concentration-related 
increase in the number of cleavable complexes formed after 30 mins exposure. Figure 
4.5 shows the scatter and mean plot for Hoechst-associated fluorescence for the same 
data sets as shown in Figure 4.4 confirming that DNA staining was unaffected by 
camptothecin. These data are consistent with other data produced using the same drug 
and cell line (Padget et at., 2000a, and A. Jobson personal communication). These data 
also showed that a reproducible signal could be achieved using 10 /J.M camptothecin, 
therefore this was the concentration chosen for use in all of the subsequent experiments. 
1 J 1 
Control 
O.01,uM CPT 
O.1,uM CPT 
1,uM CPT 
10,uM CPT 
Figure 4.3 Fluorescence of camptothecin-treated K562 cells. 
ells were exposed to 0, 0.1, 1 and 10 /-lM camptothecin for 30 mins. Fluorescence was 
measured by the TARDIS assay (section 2.8). Blue images represent Hoechst-stained 
DNA and green images represent the corresponding FITC-stained immunofluorescence 
whi h dir ctly reflects topo I-cleavable complex levels. Images are typical of those 
n in 3 ind pendent e periments. 
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Figure 4.4 Effect of camptothecin on levels of cleavable complexes in K562 cells. 
Cells were treated with camptothecin for 30 mins before measurement of cleavable 
complex levels using the T ARDIS assay (section 2.8). A is a representative scatter 
showing FITC-associated fluorescence in each cell from one experiment. B is a plot of 
mean FITC associated integrated fluorescence for J independent experiments ± SE~1. 
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Figure 4.5 Effect of camptothecin on levels of Hoechst-stained DNA in K562 cells. 
Cells were treated with camptothecin for 30 mins before measurement of the amount of 
DNA per cell by Hoechst staining using the T ARDIS assay. A is a representative 
scatter plot showing Hoechst fluorescence in indi\'idual cells. B is a plot of mean 
Hoechst fluorescence for ~ independent experiments ± SEM. 
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4.3.2.2 Effect of AG14361 on camptothecin-stabilised cleavable 
complex formation. 
Measurement of topo I relaxation activity in cell extracts that had been treated with 
AG 14361 showed that there was no significant difference in activity compared to 
untreated cells. However this only means that total nuclear topo I relaxation activity is 
apparently not inhibited by poly(ADP-ribosylation) and that exposure to AG 14361 does 
not increase topo I relaxation activity in this artificial system. A real effect of 
poly(ADP-ribosylation) status on topo I activity may not be detected in this system if 
ADP-ribose polymers are lost during the preparation of the nuclear extract. However, 
this assay may not be sensitive enough to detect small changes in activity. Therefore 
the more specific T ARDIS assay was used to detect changes in levels of camptothecin-
stabilised cleavable complexes in the presence or absence of AG 14361. 
30 min exposure to camptothecin :t AG14361 
To investigate whether PARP-1 inhibition by AG14361 had any effect levels of 
cleavable complexes formed as a result of exposure to camptothecin, K562 cells were 
exposed to 10 J.lM camptothecin for 30 mins in the presence or absence of 0.4 J.lM 
AG14361. Cleavable complex levels were measured using the TARDIS assay (section 
2.8). Figure 4.6 shows mean levels of cleavable complex-associated fluorescence in 
these cells from 7 independent experiments. Means were calculated from each 
experiment and averaged. This shows that there was no significant difference between 
cells treated with camptothecin in the presence of AG14361 compared to cells treated 
with camptothecin alone (p = 0.74 paired t-test). There was no increase in levels of 
cleavable complexes in cells treated with AG 1 .. +361 alone compared to untreated cells 
(data not shown). These data show that P ARP-1 inhibition had no effect on levels of 
camptothecin-induced cleavable complexes which is inconsistent with the original 
hypothesis. 
In these experiments a 30 minute exposure to camptothecin was used because it was 
shown previously that thc le\'els of cle~l\'able complexes measured in K562 cells using 
the T ARDIS assay are only maintained for 90 mins, and after this time levels of 
complexes decrease C\'CIl in the presence of drug (Padget et at., 2000a). 
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Figure 4.6 Effect of AG14361 on camptothecin-stabilised cleavable complexes. 
K562 cells were treated with 10 )J.M camptothecin in the presence or absence of 0.4 )J.M 
AG14361 for 30 mins. Levels of cleavable complexes were measured using the 
T ARDIS assay as described in section 2.8. Data are the mean of FITC-associated 
fluorescence values obtained from 7 independent experiments ± SEM. 
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4.3.2.3 Effect of AG14361 on persistence of cleavable complexes. 
P ARP-l inhibition may not alter the levels of cleavable complexes, but it may have a 
role in the reversal of the complexes. It has recently been reported that the tyrosyl 
phosphodiesterase (TDP-1) that is responsible for the removal of cleavable complexes 
co-purifies with XRCC1 and PNK activities (Plo et al., 2003). This may provide a 
functional link between the removal of the cleavable complex and the BER pathway. 
Thus, as P ARP-1 is involved in the BER pathway, it is possible that P ARP-1 could be 
involved in the reversal of cleavable complexes. 
The reversal and persistence of camptothecin-induced cleavable complexes in the 
presence or absence of 0.4 ~M AG 14361 was studied. K562 cells were treated with 
camptothecin in the presence or absence of AG 14361 for 30 mins, after which the drug 
was removed and replaced with fresh medium or fresh medium containing 0.4 ~M 
AG 14361 for a further 30 mins. A representative scatter plot is shown in Figure 4.7 and 
mean data from all experiments is shown in Table 4.1. These data demonstrate that 
there was a significant increase in the level camptothecin-stabilised cleavable 
complexes in those cells treated with camptothecin + AG14361 followed by a reversal 
period of 30 mins in medium containing AG 14361, compared to those treated with 
camptothecin + AG 14361 followed by a reversal period of 30 mins in fresh medium (p 
= 0.028, paired t-test). This may suggest that P ARP-1 plays a role in the reversal of 
topo I poison stabilised cleavable complexes. However, there was no significant 
increase in the persistence of cleavable complexes in those cells treated with 
camptothecin alone followed by reversal in AG14361 compared to reversal in fresh 
medium. Therefore it is difficult to draw a definitive conclusion from these results. 
Reversal of the complexes was - 70% complete after 30 mins in fresh medium in the 
presence or absence of AG 14361, consistent with the findings of Padget et al., (2000a) 
using camptothecin treated K562 cells. Data were expressed as % camptothecin control 
to correct for inter-assay yariability, data could not be expressed as % untreated control, 
as these values were negatiyc in some of the experiments. Negative fluorescence values 
is a phenomenon often observed in untreated cells and lower doses and reflects the way 
that the image analysis procedure \\'as can'ied out. It is related to the use of a mean 
background fluorescence Yalue, \\'hich is subtracted from the sample fluorescence. This 
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background takes into account the variability in the field of view. Thus the subtraction 
of the mean value from untreated controls may result in negative values. 
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Figure 4.7 Effect of AG14361 on persistence and reversal of camptothecin-
stabilised cleavable complexes. 
K562 cells were exposed to 10 JlM camptothecin in the presence or absence of 0.4 JlM 
AG14361 (CPT, and CPT + 361) for 30 mins before removal of the drug and 
replacement with fresh medium (IFM) or medium containing AG14361 (/361) for a 
further 30 mins. An untreated control is also shown. Cleavable complexes were 
measured using the T ARDIS assay. Data are the FITC-associated fluorescence for 
individual cells from one representative experiment. 
1.)9 
Conditions 
Untreated control 
Camptothecin followed by incubation in fresh 
medium 
Camptothecin followed by 30 min incubation 
in medium containing AG 14361 
Camptothecin + AG 14361 
Camptothecin + AG14361 followed by 30 
min incubation in fresh medium 
Camptothecin + AG14361 followed by 30 
mm incubation m medium containing 
AG14361 
Cleavable complexes 
Mean % Camptothecin alone 
control ± SEM 
25 ± 21 
38 ± 25 
34 ± 11 
108 ± 40 
24 ± 14 
42 ± 16* 
Table 4.1 Effect of AG14361 on persistence and reversal of camptothecin-induced 
cleavable complexes. 
K562 cells were treated with 10 MM camptothecin in the presence or absence of 0.4 MM 
AG14361 for 30 mins followed by drug removal and a post incubation in the presence 
or absence of AGl4361 for a further 30 mins. Table shows mean integrated 
fluorescence values expressed as a percentage of the camptothecin alone control for 
each experiment. Data are the mean of..+ independent experiments ± SEM. 
* significantly different from cleayable complex lc\'els in cells incubated with fresh 
medium after a 30 min incubation in camptothecin + AG 1..+361 (p = 0.028 paired t-test) 
1..+0 
4.3.2.4 Effect of PARP-1 stimulation by ionising radiation (IR) on 
cleavable complex formation. 
It was possible that reason that there was no effect of AG 14361 on camptothecin-
induced complexes was because P ARP-1 was not maximally stimulated. If P ARP-1 
activity is at a basal level in the cells, AG 14361 may not have a detectable effect. 
However, stimulation of P ARP-1 activity by IR-induced DNA breaks, should mean that 
there is a marked difference in poly(ADP-ribosylation) levels between irradiated cells 
(high PARP-1 activity) and AG14361-treated irradiated cells (less PARP-1 activity). 
Therefore, the effect of IR-stimulation of P ARP-1 on levels of cleavable complexes in 
response to treatment with camptothecin in the presence or absence of AG 14361 was 
investigated. 
K562 cells were irradiated with 6 Gy, this dose was chosen as it corresponds to the LC90 
for L1210 cells and causes significant PARP-1 activation in whole cells as measured by 
NAD+ depletion (Bowman et al., 2001). Immediately after irradiation cells were treated 
with 10 /-!M camptothecin in the presence or absence of 0.4 /-!M AG 14361 for a further 
30 mins and cleavable complexes were measured using the TARDIS assay. The results 
in Figure 4.8 demonstrate that there was no significant difference between the levels of 
cleavable complexes in cells treated with camptothecin and IR, camptothecin and 
AG14361, and camptothecin, AG14361 and IR compared to camptothecin alone (p = 
0.2 paired t-test). Therefore stimulation of P ARP-1 did not significantly reduce levels 
of camptothecin-stabilised cleavable complexes and AG 14361 did not increase the 
levels of camptothecin-stabilised cleavable complexes relative to irradiated cells. 
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Figure 4.8 Effect of PARP-l stimulation on levels of cleavable complexes in cells 
treated with camptothecin in the presence or absence of AG14361. 
K562 cells were irradiated with 6 Gy IR before exposure to 10 I-lM camptothecin in the 
presence or absence of 0.4 I-lM AG14361 for 30 mins. Cleavable complexes were 
measured using the T ARDIS assay. Integrated fluorescence values for individual 
experiments were expressed as a percentage of the camptothecin alone control for each 
experiment. Mean data fron1 3 independent experiments ± SEM are shown. 
4.3.3 Effect of PARP-1 on levels of camptothecin-stabilised cleavable 
complexes measured using potassium-SOS precipitation (K-SOS). 
To verify the data obtained using the T ARDIS assay, a second assay, was used to 
measure cleavable complexes. The K-SDS precipitation assay is not as specific as the 
T ARDIS assay in detecting topo I-DNA cleavable complexes, as it does not use topo 1-
specific antibodies but instead detects any covalent protein-DNA complex. However, 
increases in cleavable complex levels seen in cells treated with camptothecin is 
generally assumed to be due to an increase in camptothecin-stabilised topo I-DNA 
cleavable complexes. This assay is more widely used and has been shown to detect 
cleavable complexes following longer exposures to camptothecin (A. Jobson personal 
communication). In this section, K562 cells were exposed to 1 or 10 11M camptothecin 
as these concentrations were shown to give good reproducible signals in the presence or 
absence of 0.4 11M AG14361 for 30 mins or 16 hours using the K-SDS assay in 
preliminary experiments. A 30 min exposure was used to allow comparison with data 
obtained using the T ARDIS assay, a 16 hour exposure was used to investigate the effect 
of longer exposures and allow comparison with the cytotoxicity studies presented in 
section 3.3.5. 
To conduct the K-SDS assay K562 cells were labelled with 14C-thymidine to allow 
quantification of the results. These cells were then treated with camptothecin and 
AG 14361 as appropriate. The cells were then lysed with SDS to dissociate non-covalent 
protein-DNA complexes. Addition of potassium chloride leads to the formation of 
insoluble potassium dodecyl sulfate crystals, which precipitate the protein-DNA 
covalent complexes, leaving protein-free DNA in solution. This allows purification of 
the complexes through a series of wash steps and quantification by scintillation counting 
(see section 2.9). 
4.3.3.1 Effect of AG14361 on levels of camptothecin-stabilised cleavable 
complexes. 
The effect of AG 14361 on k\'cls of covalent protein-DNA complexes formed after a 30 
min exposure to camptothccin measured by K-SDS is sho\\"n in Figure 4.9 and Table 
4.2. These figures show that there was an increase in complex k\'els corresponding to 
the increasing concentration of camptothecin but the levels of complexes were not 
significantly increased or decreased in the presence of AG14361. There was no 
significant change in complex levels when cells were exposed to AG 14361 alone 
compared to untreated cells. 
To determine whether it was necessary to expose cells for a longer in order to detect any 
changes in cleavable complexes the effect of a 16 hour exposure to camptothecin was 
investigated. The levels of cleavable complexes in K562 cells exposed to camptothecin 
in the presence or absence of AG14361 for 16 hours are shown in 
Figure 4.10 and Table 4.3. These data also show an increase in the level of cleavable 
complexes with increasing concentration of camptothecin and again the levels of 
camptothecin-stabilised complexes were not affected by the presence of AG14361. 
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Figure 4.9 Effect of 30 min exposure to AG14361 on cleavable complex formation. 
K562 cells were exposed to 0, 1 or 10 flM camptothecin for 30 mins in the presence or 
absence of 0.4 JlM AG 14361 before measurement of protein-DNA complexes using the 
K-SDS assay (see section 2.9). Bar chart shows mean [14C]-associated radioactivity 
data from 3 samples from one representative experiment. 
[Camptothecin] Protein-DNA complexes 
JlM 
Camptothecin alone Camptothecin + Fold increase 
AG14361 
1 798 ± 351 934 ± 463 1.17±0.77 
10 1202 ± 620 1311±621 1.09 ± 0.75 
Table 4.2 Effect of PARP-l inhibition on cleavable complex formation. 
K562 cells were exposed to camptothecin in the presence or absence of 0.4 flM 
AG 14361 for 30 mins. L Is of cl a able complexes \ ere expressed as a percent of 
th DMSO or 0.4 flM G 14361-tr ted control a appropriate. Mean data from 3 
ind pend nt cxp rim nt ar giv n ± EM. 
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Figure 4.10 Effect of 16 hour exposure to AG14361 on cleavable complex 
formation. 
K562 cells were exposed to 0, 1 or 10 ).lM camptothecin for 16 hours in the presence or 
absence of 0.4 ).lM AG14361 before measurement of cleavable complex levels using the 
K-SDS assay (see section 2.9). Bar chart shows mean C4C]-associated radioactivity 
data from 3 samples from one representative experiment 
[C amptoth ecin] Protein-DNA complexes 
JlM 
Camptothecin alone Camptothecin + Fold increase 
AG14361 
1 206 ± 46 194 ± 29 0.94 ± 0.25 
10 457 ± 94 516 ± 62 1.13 ± 0.27 
Table 4.3 Effect of AG14361 on cleavable complex formation. 
K562 cells were exposed to can1ptothecin in the presence or absence of 0.4 ).lM 
AG 14361 for 30 mins. Levels of clea able complexes \ ere eJ pressed as a percent of 
the DMSO or 0.4 ).lM AG 14361-treated control as appropriate. Mean data from 3 
indep ndent experiments ar giv n ± EM 
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4.3.3.2 Effect of AG14361 on reversal of topo I poison-stabilised 
cleavable complexes measured by K-SDS. 
In the previous sections it was shown that AG14361 had no effect on the levels or 
persistence of to po I-DNA cleavable complexes measured using the TARDIS assay. To 
confirm these results a more widely used method, the potassium-SDS assay was used. 
Previous work by Beidler and Cheng (1995) had shown that < 20% complexes formed 
by exposure to 5 J.lM camptothecin for 60 mins remained 30 mins after camptothecin 
was removed as measured by the K-SDS assay. To ensure that protein-DNA complexes 
were still present after drug removal, a shorter reversal time of 10 mins was used 
compared to 30 mins used with the TARDIS assay. Initial studies had also shown that 
~50% of complexes had reversed 10 mins after camptothecin removal in the K562 cells 
therefore this was deemed a suitable time point for these experiments. K562 cells were 
treated with 10 J.lM camptothecin for 30 mins and allowed to reverse for 10 mins in 
fresh medium or medium containing AG14361. The results in Figure 4.11 show that 
there was no significant difference in the levels of cleavable complexes remaining after 
10 minutes in drug free medium (56.0 ± 9.6% remaining) or medium containing 
AG14361 (56.7 ± 8.4 % remaining). 
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Figure 4.11 Effect of AG14361 on reversal of topo I poison-mediated cleavable 
complexes. 
K562 cells were treated with 10 /-lM camptothecin in the presence or absence of 0.4 /-lM 
AG14361 for 30 mins and then allowed to reverse for 10 mins in drug free medium or 
medium containing 0.4 /-lM AG14361. A control sample treated with camptothecin and 
not allowed to repair (CPT) and a DMSO control were included for comparison. Cells 
treated with camptothecin + AG14361 and not allowed to repair are not shown but were 
not significantly different to those cells treated with camptothecin alone. Cleavable 
complexes were measured by K-SDS as described in section 2.9. Graph shows mean 
[14C]-associated radioactivity (DPM) from three independent experiments ± SEM. 
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4.3.3.3 Effect of camptothecin on cleavable complex formation in PARP-
1 wild type and null cells. 
To investigate the effects of camptothecin on cleavable complexes in the absence of 
P ARP-l rather than in the presence of inhibited P ARP-l, the P ARP-l wild type and null 
cells were used. This allowed investigation of the role of P ARP-l in protein-protein 
interactions with topo I, which might modulate its activity, distinct from the effect of 
P ARP-l activity on topo I activity. These cells were exposed to camptothecin for 30 
mins and then cleavable complexes were measured using the K-SDS assay. Initial 
experiments showed a lack of reproducibility between replicate samples, and large 
variability in the untreated controls. This was thought to be due to washing steps 
between radiolabelling and resuspension of these adherent cells, which were different 
from the previous experiments using the K562 suspension cells. Many alterations in 
methodology were tried but unfortunately due to time limitations a conclusive result 
could not be obtained. Given more time alternative methods for the measurement of 
cleavable complexes in these cells would have been investigated. 
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4.4 Discussion. 
The purpose of this chapter aimed to investigate the effects of AG 14361 on topo I 
activity. Previous authors have demonstrated that topo I activity can be inhibited by 
poly(ADP-ribosylation) and it is thought that this is due to the increase in negative 
charge conferred on the topo I by ADP-ribose units, causing the repulsion of topo I 
away from the DNA (reviewed in section 4.1). 
The effect of AG 14361 on topo I activity has been explored using three different 
techniques. Topo I activity was determined using an assay to measure the DNA 
relaxation activity of to po I. The DNA relaxation assay measures the ability of to po I in 
cell extracts, to nick, unwind and religate plasmid DNA, converting DNA from the 
supercoiled to relaxed fonll. Topo I activity was also measured indirectly through the 
measurement of the cleavable complexes formed in response to treatment with topo I 
poisons using two different methods. The number of cleavable complexes formed 
during the catalytic cycle of topo I are proportional to the activity of the topo I in the 
cell. The transient topo I-DNA cleavable complex can be stabilised by topo I poisons, 
and are rapidly reversed on the removal of the drug (Covey et ai, 1989, Padget et al., 
2000a). Therefore the quantification of the levels of cleavable complexes following 
drug treatment is a good measure of the activity of the topo I in the cell. 
The first method used to detect cleavable complexes was the T ARDIS assay, a specific 
immunofluorescent assay that measures the levels of topo I covalently bound to DNA in 
individual cells, using topo I-specific antibodies (Padget et al., 2000a). The second 
method was the K-SDS precipitation assay which measures the level of covalent 
protein-DNA complexes (Rowe, 2000). This method has been more widely used but is 
not necessarily specific for the topo I-DNA complexes above any other covalent 
protein-DNA complex as antibodies are not used. This method precipitates any protein 
that is covalently bound to DNA. However, it can be assumed that any increase in 
complex levels observed in response to treatment with topo I poisons will be due to an 
increase in topo I-DNA cleavable complexes. 
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The effect of AG 14361 following two different drug exposures of 30 mins and 16 hours 
were investigated using the relaxation assay and K-SDS. These time points correspond 
to those used in the cytotoxicity assays in chapter 3. Only the 30 min time point was 
investigated using the T ARDIS assay as it had previously been shown that the levels of 
complexes decreased in these cells following 1.5 hours exposure to camptothecin 
without drug removal, (Padget et al., 2000a). It had previously been shown that there 
was a more than 50% decrease in levels of cleavable complexes in the presence of 
camptothecin following a 5 hour exposure, compared to a 30 mins exposure. The 
results presented in this thesis also show that there was a massive reduction in cleavable 
complexes detected by K-SDS following a 16 hour exposure to camptothecin compared 
to those detectable after just 30 mins. Therefore it was assumed that after 16 hours the 
cleavable complex levels would barely be detectable using this assay. 
In this chapter it has been shown that topo I relaxation activity was not altered in K562 
cells following 30 mins exposure to AG14361 compared to an untreated control. 
AG14361 did not increase the levels of cleavable complexes formed following a 30 min 
exposure to camptothecin as measured by both the T ARDIS and K -SDS assays. This 
was not entirely unexpected as a 30 min exposure to AG 14361 failed to potentiate 
camptothecin cytotoxicity (section 3.3.5). However, topo I relaxation activity and 
levels of cleavable complexes were not affected following exposure to AG14361 for 16 
hours either. Therefore it would seem that the potentiation of camptothecin-induced 
cytotoxicity by AG 14361 is not related to changes in relaxation activity of topo I or the 
level of cleavable complexes formed in response to treatment with camptothecin. 
These results are not consistent with the early published data on the effect of P ARP-l 
on topo I activity. Jongstra-Bilan et al., (1983) and Ferro and Olivera (1984) found that 
P ARP-l inhibits topo I relaxation activity and that this inhibition could be reversed by 
nicotinamide and 3-AB. However, these early studies were conducted using highly 
purified topo I and PARP-1 proteins in the presence ofNAD+ and small double stranded 
DNA to stimulate PARP-I activity. As these assays were conducted with purified 
elllymes, and do not take into account the role of other cellular factors that might affect 
topo I-DNA interactions, such as histones, these experiments may not be representative 
of the situation in the cell. Thc data presented in this thesis is consistent the findings of 
Boothman et al., (1994) who investigating the effect of P ARP-l inhibition by PD-
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128763 in VI-Mel radio-resistant melanoma cells. In this study it was shown that there 
was no change in topo I relaxation activity in these cells following a 5 hour exposure to 
concentrations up to 3 mi\l PD-128763. 
Similarly, studies conducted Beidler et aI., (1996) agree with the data presented in this 
chapter. Biedler and co-workers showed that in KB cells an incubation of up to 2.+ 
hours with 1 mM 3-AB had no effect on topo I cleavable complexes as measured by K-
SDS precipitation. Nor did the presence of 3-AB for up to 24 hours increase the level of 
cleavable complexes formed by a 30 min pulse with 5 ~M camptothecin in parental KB 
cells or their camptothecin-resistant derivatives. Therefore they concluded that P ARP-l 
inhibition did not alter the levels of topo I protein available for complex formation 
following camptothecin exposure. 
The possibility that the difference between basal (unstimulated) P ARP-l activity and 
PARP-l activity in the presence of AG14361 in K562 cells was too small to detect an 
effect of P ARP-l on topo I activity was investigated as had been previously by 
Boothman et at., (1994). These authors showed that 3-AB did not alter the activity of 
topo I unless the cells had been treated with IR prior to treatment with camptothecin. In 
theory, treatment with IR would create DNA strand breaks that would stimulate P ARP-
1 activity. This might result in maximal stimulation of P ARP-l and higher levels of 
poly(ADP-ribosylation) on topo I resulting in its inhibition. Therefore treatment with 
IR and camptothecin should result in lower levels of cleavable complexes than 
treatment with camptothecin alone. Use of AG1.+361 could therefore prevent this 
inhibition and result in the f01111ation of higher levels of cleavable complexes when used 
in combination with camptothecin and IR. Following the observation that there was no 
change in levels of topo I acti\'ity in response to treatment with AG 14361 in this thesis, 
it was thought that PARP-l may not be maximally stimulated under the conditions used. 
Therefore cells were exposed to camptothecin following treatment with IR. However, 
the results shown in Figure 4.8 demonstrate that this was not the case and that 
stimulation of P ARP-l had no significant effect on levels of cleavable complexes 
compared to treatment \\ith c<.lmptothecin alone. The discrepancy between these studies 
may be related to the us\.' of confluence arrested cells in the study by Boothman and 
exponentially growing cells in this study causing the cells to respond differently. Topo 
1 - ') ).:.. 
I poisons and IR cause synergistic cell killing in various human tumour cells and this is 
associated with an increase in the level of protein-DNA complexes formed (Boothman 
et al., 1992). This is in conflict with the experimental data suggesting that P ARP-1 
activation by IR results in a reduction in topo I cleavable complex formation. However 
the data presented in this chapter does not support the proposals that topo I cleavable 
complexes are increased or decreased by IR nor that P ARP-1 inhibition has an effect on 
complex formation in irradiated or non-irradiated cells. 
In the study reported here the levels of protein-DNA complexes were significantly 
reduced following a 16 hour exposure to camptothecin compared to that seen at 30 
mins. A decrease in the level of cleavable complexes over time despite the continued 
presence of a topo I poison has been observed by a number of other authors (Beidler et 
al., 1995, Danks et al., 1996, Padget et al., 2000a). Beidler et al., (1995) showed a 
time-dependent decrease in the level of protein-linked DNA strand breaks (PLDB) 
when KB cells were exposed to 5 JlM camptothecin and that the most rapid loss of 
PLDB was seen in the first 6 hours of exposure. Reversal of topotecan-stabilised 
complexes in human SJ-G5 anaplastic astrocytoma cells in the presence of drug has also 
been observed by Danks ct al., (1996). This was shown to be related to redistribution of 
the topo I from the nucleoli within 60 mins of exposure to topotecan and was 
accompanied by a small but significant decrease in the amount of topo I in the nucleus 
coupled with a simultaneous 50-100% increase in the levels of the 67 kDa topo I 
fragment in the cytoplasm. Subsequent authors have reported that this nuclear 
delocalisation is related to sumoylation of the protein. SUMO's are small ubiquitin-like 
modifiers that conjugate to target proteins and may act as a tag for delocalisation (Mo et 
al., 2001, Rhallabandi et al., 2002, Desai et al., 2001 and 1997). Therefore it is possible 
that the decrease in complexcs seen here at 16 hours compared to 30 mins is due to 
redistribution of topo I in response to drug treatment. 
Interestingly, PARP-1 has also been shown to delocalise following treatment with the 
RNA synthesis inhibitor 
(Desnoyers et a/., 1996). 
5,6,-dichloro-1-p-ribofuranosyl-benzimidazole (DRB) 
P ARP-1 is distributed throughout the nuclei but is 
concentrated in the nue leoh. On treatment with conccntrations of DRB that inhibited 
uridine incorporation by 75°;;), P.\RP-I was found to be distributed e\'enly throughout 
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the nucleus. Similar results \\'ere found using actinomycin D. Topo I has been shown 
to translocate in response to the same inhibitors as those causing delocalisation of 
P ARP-l. However the translocation of P ARP-l was seen to precede that of topo I, and 
P ARP-l was not degraded as has been seen for topo I in some cell types. This may 
have implications when detennining the exact role of P ARP-l in the response to topo I 
poisons and will be important when considering the scheduling of administration of 
topo I poisons and P ARP-l inhibitors. 
The reversal of cleavable complexes was studied at two time points. 30 mins after drug 
removal in the TARDIS assay and 10 mins after drug removal using K-SDS 
precipitation. Cleavable complexes are known to reverse rapidly following removal of 
drug, therefore these time-points were chosen based on previous data and initial 
experiments (Beidler et aI., 1995, Padget et aI., 2000a). Using the T ARDIS assay a 
variety of combinations of AG14361 and camptothecin exposures were used to 
determine whether AG 14361 increased the persistence of the cleavable complex after 
camptothecin removal. Inclusion of AG 14361 after camptothecin removal did not 
increase the induction of complexes, nor did the inclusion of AG14361 in the 
camptothecin exposure and reversal incubation increase persistence compared to 
samples treated with camptothecin alone. However, there was a significant increase in 
the persistence of the clem'able complexes fonned when cells were treated with 
AG14361 and camptothecin followed by incubation in AG14361 alone compared to 
those treated with AG 14361 and camptothecin followed by incubation in fresh medium. 
This may suggest that AG 14361 is involved in the persistence of camptothecin-
stabilised cleavable complexes, however it must be noted that there was no significant 
difference between either of these samples and those cells treated with camptothecin 
and allowed to repair in fresh medium. Therefore care must be taken in the 
interpretation of these results. Results obtained using the K-SDS assay showed that 
AG 14361 did not increase the persistence of camptothecin-stabilised cleavable 
complexes. These results suggest that P ARP-l is not involved in the reversal of topo 1-
cleavable complexes, apart from the one anomalous result showing significant 
persistence, obtained with the TARDIS assay. To be confident of this result other 
experiments need to he conducted. The K-SDS is probably not specific enough to 
detect such small diffcrences, therefore other assays such as the ICE bioassay or non-de-
proteinising alkalinc elution l'lHlld be used. 
15.+ 
Evidence to support the role of P ARP-1 in the persistence of cleavable complexes has 
been published recently by Plo et at., (2003). In this study it was shown that the tyrosyl 
DNA phosphodiesterase that is primarily responsible for the remoyal of the cleayable 
complex, co-immunoprecipitates with XRCCl. Such a functional association suggests 
that the BER pathway may repair the damage caused by processing of the cleavable 
complex. As P ARP-1 is involved in BER it is possible that P ARP -1 is involved in the 
removal of to po I poison-stabilised cleavable complexes. 
Although all of the methods here have looked at topo I, it is possible that poly(ADP-
ribosylation) of other proteins could affect topo I actiyity. Histones, for example are 
poly(ADP-ribosylated), and this results in loosening of chromatin that may increase the 
access of topo I to DNA, increasing activity. Therefore inhibition of P ARP-1 could 
reduce topo I acti \ ity. Of course these two actions could also offset each other. 
However the data presented in this chapter suggests that topo I may not be poly(ADP-
ribosylated) or if it is, it does not affect activity, and that if histones are modified by 
poly(ADP-ribose) then this does not effect topo I access to DNA. 
The data presented in this chapter show that P ARP-1 inhibition seems to have little 
effect on topo I activity, in contradiction to the early publications on this area of 
research. Much of the early published data was produced using purified systems which 
are not representati \'c of the cellular environment. Therefore, after using one of the 
most potent P ARP-1 inhibitors available and three different methods of measuring topo 
I activity under a variety of conditions in whole cells and extracts, it can be concluded 
that AG 14361 has no c lTect on topo I activity or levels of cleavable complexes. There 
was a suggestion th~l~ :\G 14361 did lead to the persistence of cleavable complexes using 
the T ARDIS. Howcyer, thcsc data should be treated with caution until further work can 
be carried out. Th-.:rcfore based on these data it can be concluded that potentiation of 
topo I poison mediatcd gro\\th inhibition or cytotoxicity by AG 14361 is not due to an 
increase in topo I activity by AG 14361. 
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Summary. 
• 30 min or 16 hour exposure to AG14361 does not effect the relaxation activity of 
topo I. 
• AG 14361 does not increase the level of camptothecin-stabilised cleavable 
complexes measured by the T ARDIS and K-SDS assays. 
• Stimulation of cellular P ARP-l activity by irradiation does not modulate topo I 
activity. 
• AG 14361 may Increase the persistence of camptothecin-stabilised DNA strand 
breaks after removal of camptothecin however further investigation is required. 
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Chapter 5 
Effect of PARP-1 on inhibition of topo I poison-
induced DNA single strand breaks. 
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5.1 Introduction. 
In this chapter the role of P ARP-1 in the repair of topo I poison-mediated DNA damage 
was investigated. In the previous chapters a role for P ARP-l in topo I poison mediated 
cytotoxicity and growth inhibition has been demonstrated. Two hypotheses were 
proposed to explain this, (i) modulation of topo I activity by poly(ADP-ribosylation) of 
topo I or (ii) repair of topo I poison-mediated DNA damage by P ARP-1. The effect of 
P ARP-1 inhibition on topo I activity was investigated in chapter 4 and it was shown that 
AG14361 had little effect on topo I activity under the conditions studied. Therefore in 
this chapter the second hypothesis was investigated; that P ARP-l was involved in the 
repair of topo I poison induced DNA damage. 
Topo I poisons cause a number of different DNA damage lesions, as shown in Figure 
5.1, and this may implicate a number of pathways in the repair of topo I poison-
mediated DNA damage. The evidence for the involvement of P ARP-1 in the repair of 
DNA single strand breaks via the BER pathway is overwhelming (see section l.6.7). 
There is also very good evidence showing the importance of BER in topo I poison-
mediated cytotoxicity (described in this chapter and chapter 6). To investigate ifP ARP-
1 is involved in the repair of to po I poison-induced DNA single-strand breaks, the effect 
of AG 14361 on camptothecin-induced single-strand breaks was determined. 
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Figure 5.1 Types of DNA damage caused by topo I poisons. 
5' 
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Topo I binds to DNA to form a protein-linked DNA strand break that can be stabilised 
by topo I poisons such as CPT, and a single strand break. Collision with the 
progressing replication fork converts the single strand break into a double strand break 
and leaves a single strand break on the lagging strand. 
The role ofPARP-l in BER has been reviewed in section 1.6.7. PARP-1 inhibition 
results in potentiation of cytotoxicity caused by alkylating agents and IR, whose damage 
is repaired by the BER pathway. The potentiation of cytotoxicity by P ARP-1 inhibitors 
is related to a decrease in strand break rejoining (Durkacz et al., 1980, Bowman et al., 
1998). Similarly, P ARP-l deficient cells are hypersensitive to alkylating agents and IR, 
and are defective in repair of damage caused by these agents (Menissier de Murcia et 
al., 1997, Masutani et al., 1999, and reviewed in Shall and de Murcia, 2000). It has also 
been demonstrated in vitro that in the absence of P ARP-l long patch BER is ineffective 
and short patch repair is impaired by 50% (Dantzer et al., 2000). In addition to this, 
PARP-l co-immunoprecipitates with XRCCl, DNA ligase VI, FEN-l and DNA pol-~, 
proteins known to be involved in BER (Dantzer et al., 2000, Masson et al., 1998, Lavrik 
et al., 2001). Thus, there is good evidence for a role for PARP-l in BER. The exact 
nature of this role is still in dispute due to many conflicting reports, some suggesting 
that BER is efficient in the absence of PARP-l (Vodenicharov et al.,2000). However 
evidence for the role of P ARP-l in BER does not implicate P ARP-l in the repair of 
tapa I poison-mediated DNA damage. 
Direct evidence for the role of P ARP-l in repair of DNA single strand breaks induced 
by top a I poisons was pro ided by work conducted in the NICR (Bowman PhD thesis, 
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1999, and Bowman et al., 2001). The level of DNA single strand breaks induced by a 
16 hour exposure ofL1210 cells to camptothecin was increased 2.5-fold in the presence 
of 200 JlM NU 1 025. Exposure of L 1210 cells to 60 nM camptothecin for 6 hours 
resulted in NAD+ depletion, which could be reduced by 200 JlM NU1025, showing that 
this effect was P ARP-I-mediated. P ARP-1 activity assays (measuring e2PJ-NAD 
incorporation) showed that treatment with 120 nM camptothecin for 6 hours caused 
statistically significant 4-fold activation of P ARP-1. These data provide evidence that 
P ARP-1 is activated following camptothecin-induced DNA damage and inhibition of 
P ARP-1 increases strand breaks, implicating P ARP-1 in the repair of these breaks. 
Similar results were obtained by Mattern et al., (1987) who demonstrated that 
potentiation of camptothecin cytotoxicity by 3-AB was associated with an increase in 
the yield of DNA strand breaks. Exposure of LI2IO cells to 1 or 5 mM 3-AB for 16 
hours and subsequently to camptothecin for a further 60 mins in the presence of 3-AB 
resulted in a 2 to 3-fold increase in DNA single strand breaks. However, these workers 
proposed that the increase in DNA strand breaks and cytotoxicity was due to the 
prevention ofPARP-I-mediated repression of to po I activity. 
Evidence for the role of P ARP-I in the repair of topo I poison-mediated DNA damage 
is scarce. However there is evidence connecting BER to the repair of camptothecin-
induced damage therefore indirectly implicating P ARP-l via its role in BER. Most of 
this evidence has come from the use of cells deficient in the BER scaffold protein 
XRCC 1. The EM9 Chinese hamster ovary cell line isolated on the basis of its increased 
sensitivity to EMS is a cell line deficient in XRCCI that has been studied in relation to 
topo I poison-induced DNA damage. These cells have a reduced rate of DNA strand 
break rejoining following treatment with X-rays, EMS or MMS and a high baseline 
frequency of sister chromatid exchange (Thompson et al., 1982). These cells are 
hypersensitive to many alkylating agents (Caldecott and Jeggo, 1991). The defect in 
XRCC 1 results in a reduction in DNA ligase III activity (Ikejima et al., 1984, Barrows 
('I al., 1998). Most interestingly, although these cells have normal levels of both topo I, 
and PARP-l, they are 2 to 5-fold hypersensitive to camptothecin, following long and 
short-term exposures and this sensitivity is independent of replication (Caldecott and 
Jeggo, 1991, Palitti et al., 1993, Barrows et al., 1998). This shows that BER is involved 
in the response to camptothecin-induced DNA damage. 
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Further evidence has been provided in support of the role of XRCC I in the repair of 
topo I poison-mediated DNA damage. Plo et ai., (2003) established a connection 
between XRCCI and tyrosyl DNA phosphodiesterase (TdpI) a protein responsible for 
the removal of the topo I peptide linked to 3'-DNA terminus by hydrolysing the 
covalent bond between the topo I tyrosyl residue and the 3'-DNA phosphate. They 
showed that XRCC I-complemented EM9 cells were able to repair topo I poison-
induced DNA damage faster than the XRCCI deficient EM9 cells. Following a 1 hour 
exposure to camptothecin and 30 mins repair in drug-free medium, levels of single 
strand breaks were approximately 3-fold higher in EM9 cells compared to XRCCI 
complemented EM9 cells. This corresponded to enhanced TdpI activity In the 
complemented cells. Polynucleotide kinase (PNK) activity was enhanced In the 
XRCC I-complemented cells compared to the deficient line. PNK is a protein 
associated with the long patch BER pathway that is used to remove a 3'-phosphate 
produced as a result of removal of the topo I, or by other means, and replace it with a 3'-
hydroxyl terminus that can be extended by DNA polP and ligated. It was also shown 
that XRCCI immunoprecipitates contained both TdpI and PNK peptides and activity, 
suggesting a functional link between the XRCC 1 strand break pathway and the repair of 
topo I covalent complexes. 
Further evidence for the role of XRCC 1 and thus the BER pathway has been provided 
by Park et a/., (2002). These authors made cell lines resistant to camptothecin by 
exposure to increasing concentrations of camptothecin, revertant cell lines were also 
derived from the resistant cells by removing them from camptothecin-containing growth 
medium. These revertant cell lines were still 2-fold resistant compared to the parental 
KB cell line (Biedler et ai., 1995). The resistant cell line was shown to be over-
expressing XRCCI greater than 5-fold compared to the revertant cell line. The degree 
of resistance was related to the amount of XRCCI present in the cell. Interestingly, 
resistance to camptothecin was reduced by -20% when these cells were exposed to 1 
mM 3-AB, therefore suggesting that the effect of XRCCI on camptothecin resistance 
was modulated by P ARP-I. This study therefore provides evidence for the role of 
P ARP-l in the response to canlptothecin via the BER pathway, and its interaction with 
XRCCI. 
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5.2 Aims 
In this chapter the aim was to investigate the second hypothesis for the role of P ARP-l 
in the response to topo I poisons; that P ARP-l is involved in the repair of topo I poison-
mediated DNA damage. To investigate this hypothesis, the levels of DNA single strand 
breaks formed in response to treatment with camptothecin and AG 14361 were 
determined. Single strand breaks were measured as these are the primary DNA lesions 
caused by treatment. Exposure times of 30 mins and 16 hours were used to correspond 
with the exposures used in the cytotoxicity assays in section 3 in order to see if the 
potentiation of cytotoxicity was related to increases in DNA strand breaks. 
The effect of scheduling of AG 14361 on levels of strand breaks formed in response to 
treatment with camptothecin was also investigated. This aimed to determine whether 
maximal strand breaks could be achieved when P ARP-l was inhibited for 16 hours 
before or after exposure to camptothecin for 30 mins as described by Mattern et at., 
(1997). Results presented in chapter 3 showed that 30 mins exposure to camptothecin 
was sufficient to cause growth inhibition in K562 cells, but a 16 hour exposure to 
AG 14361 was required for significant potentiation of camptothecin-induced 
cytotoxicity and growth inhibition. Therefore the studies described in this chapter were 
aimed to determine whether cytotoxicity was related to the levels of DNA strand breaks 
present following these exposures. These studies were also predicted to give an insight 
into the mechanism of enhancement of cytotoxicity by P ARP-l. If enhancement of 
strand break levels was observed with exposure to AG 14361 prior to camptothecin, this 
would suggest that a modification of topo 1 activity by poly(ADP-ribosylation) and/or 
poly(ADP-ribosylation) of other acceptor proteins may be required. Whereas increases 
in DNA strand breaks following a exposure to AG 14361 after camptothecin would 
indicate that P ARP-l might playa role in the repair of topo I associated damage. The 
repair of camptothecin-induced DNA damaged after shorter repair times was also 
studied in the presence or absence of AG 14361. 
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5.3 Results. 
5.3.1 Effect of AG14361 on camptothecin-induced DNA single strand 
breaks. 
P ARP-l inhibitors have been shown to increase the number of DNA strand breaks 
produced by exposure to camptothecin (Mattern et al., 1987, Bowman et al., 1998). 
The inhibitors used in these previous studies (3-AB, NUI025) were less potent than 
AG 14361, but were able to increase the levels of DNA strand breaks induced by 
camptothecin by 2 to 3 fold. However these studies did not address the question as to 
whether the increased strand breaks was due to increased break formation or decreased 
repair. Therefore these experiments were designed to confirm the previous results and 
investigate in more detail the effects of a more potent P ARP-l inhibitor in levels of 
DNA single strand breaks. The effect of drug scheduling on strand breaks and the 
repair of the lesions was also investigated. 
5.3.1.1 Effect of AG14361 on DNA single strand break levels in K562 cells 
exposed to camptothecin for 16 hours. 
The initial conditions for this experiment were based on the work by Bowman et al., 
(1998). In this paper the effect of 200 f.1M NUI025 on levels of DNA single strand 
breaks formed in L1210 cells following treatment with camptothecin for 16 hours was 
investigated by alkaline elution. Potentiation of camptothecin-induced DNA strand 
breaks by NU 1 025 was observed using 15 and 40 nM camptothecin corresponding to 
the LC50, and LC90 for cytotoxicity of camptothecin following 16 hours exposure in 
L 1210 cells. These studies demonstrated a good correlation between the enhancement 
of camptothecin-induced DNA strand breaks and cytotoxicity so the initial studies in 
this thesis aimed to reproduce these conditions except for substitution of AG 14361 for 
NUI025 and the K562 cell line for the L1210 cell line. 
In this study, K562 cells were exposed to camptothecin in the presence or absence of 
0.4 f.1M AG 14361 for 16 hours. Concentrations of 15, 40 and 100 nM camptothecin 
were used initially to correspond with the concentrations used by Bowman et ai,. 
(2001). DNA single strand breaks levels were measured using alkaline elution. The 
alkaline elution method separates DNA fragments on the basis of size using 
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polycarbonate filters. Radiolabelled cells were treated, applied to the filters and lysed. 
The DNA was then eluted through the filter into fractions using a buffer at pH 12. DNA 
strand breaks were quantified by liquid scintillation counting (for further details see 
section 2.10). The elution profile of K562 cells exposed to 15, 40 and 100 nM 
camptothecin in the presence or absence of AG 14361 for 16 hours is shown in Figure 
5.2A. Unfortunately at both 40 and 100 nM camptothecin the levels of DNA strand 
breaks were at the maximal level that can be measured using this assay as indicated by 
the steep gradient of the elution profile at these concentrations. Therefore, any increase 
in strand breaks caused by P ARP-1 inhibition could not be detected and was not 
significantly different from camptothecin alone. A small increase in the levels of strand 
breaks in the presence of AG 14361 compared to camptothecin alone was seen using 15 
nM camptothecin but this was not significant (p = 0.1 paired t-test). 
As the concentration range used in Figure 5.2A produced strand breaks at the upper 
limits of detection of the assay, the effect of P ARP-1 inhibition on camptothecin-
induced DNA strand breaks at lower doses of camptothecin was investigated. 
Concentrations of camptothecin corresponding to 50, 90 and 950/0 survival (3, 10, and 
30 nM, respectively) as measured in chapter 3, were used. The elution profile in Figure 
5.2B shows that levels of DNA strand breaks below the uppermost limits of detection 
were achieved. DNA strand breaks were expressed as relative elution i.e. the proportion 
of [14C]-associated activity eluted when half of the [3H]-activity has eluted, compared to 
an untreated control as this accounts for variation in elution rate between assays (see 
section 2.10.5). Mean relative elution values from both of the concentration ranges used 
are summarised in Table 5.1. This shows that there was an increase in single strand 
breaks corresponding to increasing concentrations of camptothecin as has been shown 
previously by Mattern et al., (1989) and Bowman et al., (2000). 0.4 J.lM AG 14361 
increased the number of single strand breaks induced by camptothecin by a factor of 1.2 
to 2.4 at all concentrations of camptothecin, with greatest increases at lower 
concentrations of camptothecin. However, due to the inherent variability of the assay 
this was only significant at 30 nM camptothecin (p = 0.004, paired t-test). There was no 
significant DNA strand breakage following exposure to 0.4 J.lM AG 14361 alone. 
Although the possibility that some of the DNA breaks observed were due to apoptosis 
cannot be ignored. it has been shown previously that L 121 0 cells exposed to 120nM 
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camptothecin for 16 hours only resulted in 80/0 of cells showing morphology typical of 
apoptosis. Therefore the number of strand breaks observed here should be 
representative of breaks produced by campothecin and not skewed by breaks caused by 
apoptosis. 
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Figure 5.2 Effect of AG14361 on camptotbecin-induced DNA single strand breaks. 
K562 cells were exposed to (A) 15, 40, 100 nM or (B) 3, 10, 30 nM camptothecin in the presence or absence of 0.4 11M AG 14361 for 16 hours. 
DNA single strand breaks were measured by alkaline elution (see section 2.10). Representative elution profiles from each set of experiments are 
shown. 
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16 hour exposure DNA single strand breaks 
(Relative Elution) 
Camptothecin (nM) Camptothecin Camptothecin + Fold increase in 
alone 0.4 J1M AG14361 strand breaks 
3 0.021 ± 0.02 0.08 ± 0.05 2.4 ± 0.7 
10 0.12 ± 0.05 0.15 ± 0.04 1.6 ± 0.5 
15 0.17 ± 0.06 0.23 ± 0.02 1.6 ± 0.4 
30 0.20 ± 0.04 0.26 ± 0.04* 1.3 ± 0.09 
40 0.32 ± 0.06 0.37 ± 0.02 1.2 ± 0.17 
100 0.32 ± 0.08 0.35 ± 0.04 1.2 ± 0.14 
Table 5.1 Effect of AG14361 on levels of DNA single strand breaks induced by 
camptothecin. 
K562 cells were exposed to camptothecin in the presence or absence of 0.4 ~M 
AG 14361 for 16 hours prior to determination of DNA single strand breaks by alkaline 
elution (see section 2.10). Relative elution calculated by comparison with DMSO 
treated or 0.4 ~M AG 14361 alone control as appropriate. Data are the mean ± SEM for 
3 independent experiments. Fold increase was calculated from mean RE values for 
individual experiments ± SEM. 
* p = 0.004 paired t-test. 
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5.3.1.2 Effect of AG14361 on DNA strand breaks formed by exposure to 
camptothecin for 30 min. 
The 1.2 to 2.4-fold increase in camptothecin-induced DNA strand breaks by AG 14361 
following a 16 hour exposure corresponds reasonably well to the 2 to 3-fold potentiation 
of camptothecin-induced growth inhibition and cytotoxicity studies by AG 14361 after 
16 hours exposure described in chapter 3. In growth inhibition assays significant 
potentiation by AG14361 of a 30 min exposure to camptothecin was only seen at 100 
nM camptothecin, even though 30 mins exposure to 0.4 ~M AG14361 was shown to be 
enough to reduce PARP-1 activity to less than 10% of normal (section 3.3.3). 30 mins 
was also the time taken to generate maximal levels of camptothecin-induced cleavable 
complexes (Padget et a/., 2000a), and camptothecin-induced DNA single strand breaks 
(Covey et a/., 1989). To determine whether the reduced level of potentiation observed 
following 30 mins exposure was related to levels of DNA strand breaks it was necessary 
to measure DNA strand breaks after a 30 min exposure to camptothecin in the presence 
or absence of AG14361. 
To investigate this, K562 cells were exposed to a range of concentrations of 
camptothecin in the presence or absence of 0.4 JlM AG14361 for 30 mins. Following 
this DNA single strand breaks were measured by alkaline elution. A representative bar 
chart of relative elution values is shown in Figure 5.3 and pooled relative elution values 
from 3 independent experiments are shown in Table 5.2. These data show that there 
was no significant difference between those cells treated with camptothecin and 
AG 14361 compared to those treated with camptothecin alone at any of the 
concentrations used. 
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Figure 5.3 Effect of AG14361 on DNA strand breaks formed following 30 min 
exposure to camptothecin 
K562 cells were exposed to 3, 10, and 30 nM camptothecin in the presence or absence 
of 0.4 J.!M AG14361 for 30 mins. DNA strand breaks were measured by alkaline 
elution (see section 2.10). Relative elution was calculated by comparison with DMSO 
or AG14361 alone control as appropriate. A bar chart of relative elution values from 
one representative experiment is shown. 
30 min DNA single strand breaks (Relative Elution) 
Camptothecin Camptothecin Camptothecin + 0.4 J.1M Fold increase 
(nM) alone AG14361 
3 0.091± 0.04 0.082 ± 0.09 0.9 ± 0.9 
10 0.18 ± 0.05 0.21 ± 0.06 1.2 ± 0.5 
30 0.36 ± 0.08 0.35 ± 0.06 1.0 ± 0.3 
Table 5.2 Effect of AG14361 on DNA strand breaks formed following 30 min 
exposure to camptothecin. 
K562 cells were exposed to 3, 10 and 30 nM camptothecin in the presence or absence of 
0.4 J.!M AG14361 for 30 mins before measurement of DNA single strand breaks by 
alkaline elution. Relative elution was calculated by conlparison with DMSO or 0.4 J.!M 
AG 14361 alone control as appropriate. Data are mean RE values from 3 independent 
perim nts ± SEM. 
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5.3.2 Effect of drug scheduling on camptothecin-mediated DNA strand 
breaks. 
Although a 30 min exposure to camptothecin was sufficient to cause DNA strand breaks 
and cytotoxicity, a 16 hour incubation with AG 14361 was required to detect an increase 
in camptothecin-induced strand breaks and cytotoxicity. Therefore it seems that 
although 30 mins exposure to camptothecin is sufficient to cause cytotoxicity a longer 
exposure to AG 14361 may be required to maximally potentiate camptothecin. The aim 
of this section was to optimise the scheduling of camptothecin and AG 14361 in order to 
achieve maximal potentiation. This could have implications for administration of this 
class of drug in a clinical setting. The results produced in this section may also give an 
indication of the possible mechanism behind the potentiation of growth inhibition and 
cytotoxicity of topo I poisons by P ARP-l inhibition. 
Firstly, cells were exposed to AG 14361 for 16 hours, and exposed to camptothecin for 
only the final 30 mins (pre-exposure, see Figure 5.4A). Although it was shown in 
section 3 that P ARP-l is inhibited in cells within 10 mins of drug exposure, it may take 
longer for the effects of P ARP-l inhibition to be measurable in the cell. Therefore 
treatment with AG 14361 for 16 hours prior to administration of camptothecin, ensured 
that P ARP-l was fully inhibited for long enough to exert any down-stream effects by 
loss ofpoly(ADP-ribosylation) of target proteins, including topo I. 
The effect of a 16 hour exposure to AG 14361 following exposure to camptothecin for 
the first 30 mins was also investigated (post-exposure; see Figure 5.4B). 30 mins was 
sufficient to cause high levels of DNA strand breaks (Figure 5.2). Using a post 
exposure to AG 14361 for 16 hours allows investigation into the effects of AG 14361 on 
repair or reversal of these breaks. Any significant result under these conditions would 
provide implication of a role for P ARP-l in repair of topo I poison-induced DNA strand 
breaks. 
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Figure 5.4 Dosing schedule for pre (A) and post (B) exposure to AG14361. 
5.3.2.1 Effect of a 16 hour pre-exposure to AG14361 on camptothecin-
induced DNA strand breaks. 
K562 cells were exposed to 0.4 /lM AG 14361 for 16 hours before the addition of a 
range of concentrations of camptothecin in the presence or absence of AG 14361 for a 
further 30 mins. Figure 5.5 shows a representative bar chart of relative elution values, 
pooled data for 3 experiments are shown in Table 5.3 . Increases in DNA strand break 
levels were observed, particularly at low concentrations of camptothecin, but overall 
there was no significant effect of P ARP-1 inhibition on DNA single strand break levels 
when P ARP-1 was inhibited prior to topo I poisoning by camptothecin. 
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Figure 5.5 Effect of pre-exposure to AG14361 on camptothecin-induced DNA 
strand break levels. 
K562 cells were exposed to 0.4 f.lM AG14361 for 16 hours before the addition of3, 10, 
or 30 nM camptothecin for a further 30 mins. DNA strand breaks were measured by 
alkaline elution. Relative elution was calculated by comparison with DMSO or 0.4 f.lM 
AG 14361 alone control as appropriate. A bar chart of relative elution values from one 
representative experiment is shown. 
DNA single strand breaks (Relative Elution) 
Camptothecin Camptothecin Camptothecin + 0.4 J.1M Fold increase 
(nM) alone AG14361 
3 0.046 ± 0.02 0.072 ± 0.03 1.6 ± 0.8 
10 0.16±0.01 0.19 ± 0.001 1.2 ± 0.08 
30 0.28 ± 0.02 0.32 ± 0.02 1.1±0.1 
. Table 5.3 DNA strand break levels in K562 cells treated with AG14361 for 16 
hours followed by camptothecin for a further 30 mins. 
Mean relative elution values ± SEM from 3 independent experiments are shown. 
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5.3.2.2 Effect of a 16 hour post exposure to AG14361 on strand breaks 
induced by 30 mins exposure to camptothecin. 
Since a 16 hour pre exposure to AG 14316 had no significant effect on levels of 
camptothecin-induced DNA strand breaks the effect of a 16 hour exposure to AG 14361 
immediately following exposure to camptothecin for 30 mins was investigated 
(Schedule B, Figure 5.4). Any significant potentiation seen with AG14361 under these 
conditions would show that P ARP-1 might be involved in the repair of the 
camptothecin-induced strand breaks. 
The effect of post exposure to 0.4 JlM AG14361 on camptothecin treated K562 cells 
was investigated. K562 cells were exposed to camptothecin or camptothecin with 
AG 14361 for 30 mins; the drug was then removed and replaced with fresh medium 
containing AG 14361, for a further 16 hours. The levels of single strand breaks were 
then determined using alkaline elution (see section 2.10). Initially concentrations of3, 
10, and 30 nM camptothecin were used to correspond with the data shown in section 
5.3.l.1, but it was found that there was very little detectable DNA damage remaining 
after 16 hours (data not shown). This is probably because of the rapid reversal of the 
cleavable complexes and the repair of any DNA strand breaks. Following this, the dose 
was escalated up to a maximum of 300 nM camptothecin. The results in Figure 5.6 
show that there was a small increase in levels of DNA single strand breaks in those cells 
treated with AG 14361 compared to those treated with camptothecin alone. The greatest 
increase was observed at 300 nM; giving relative elution values of 0.04 for 
camptothecin alone compared to 0.1 with camptothecin and AG 14361. This was not 
quite statistically significant (p = 0.06 paired t-test). 
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Figure 5.6 Effect of post exposure to AG14361 on 30 mins exposure to 
camptothecin. 
K562 cells were exposed to 30, 100 and 300 nM camptothecin in the presence or 
absence of 0.4 JlM AG 14361 before the drug was removed and the cells were returned 
to fresh medium or medium containing 0.4 JlM AG14361. DNA strand breaks were 
measured by alkaline elution. Relative elution was calculated by comparison with 
DMSO or AG 14361 alone control as appropriate. A bar chart of one representative 
experiment with duplicate samples is shown. 
DNA single strand breaks (Relative Elution) 
Camptothecin Camptothecin Camptothecin + 0.4 Fold increase 
(nM) alone J.1M AG14361 
30 0.013 ± 0.01 0.041 ± 0.008 3.2 ± 2.5 
100 0.027 ± 0.0037 0.079 ± 0.029 2.9 ± 1.1 
300 0.040 ± 0.034 0.10 ± 0.04 + 2.5 ±2.3 
Table 5.4 DNA strand breaks in K562 cells treated with camptothecin for 30 mins 
followed by AG14361 for a further 16 hours. 
Mean relative elution values ± SEM are given. 
+ p = 0.06 paired t-test compared to camptothecin alone. 
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An increase in DNA strand breaks was observed as a result of a 30 min exposure to 300 
nM camptothecin followed by 16 hour incubation with AG 14361 compared to 
camptothecin alone. Although the fold increase in DNA strand breaks was 2.5 to 3.2-
fold compared to 1.1 to 1.6-fold in the pre-exposure experiments, this was not 
significant at the 95% confidence level. However, the relative elution values obtained 
in this experiment were almost at the lower limits of detection for the assay presumably 
because at 16 hours repair was largely complete. To verify the putative proposal that 
repair was retarded by P ARP-l inhibition levels of DNA strand breaks were measured 
at shorter time points where the level of strand breaks remaining would be greater and 
thus increase the accuracy of the results obtained. 
K562 cells were exposed to 300 nM camptothecin for 30 mins followed by 1 and 16 
hour incubation in the presence or absence of AG 14361. The results in Figure 5.7 show 
a representative bar chart of relative elution values. The mean RE values given in Table 
5.5 show that the majority of the DNA strand breaks were repaired within the first hour 
of drug removal. There was a significant increase in strand breaks at both 1 and 16 
hours after removal of camptothecin in the presence of AG 14361 indicating that 
inhibition of P ARP-l retards repair. 
Since the majority of strand breaks were reversed within the first hour of drug removal, 
consistent with previous published data (Covey et al.,1989), in order to detect strand 
breaks at physiologically relevant camptothecin concentrations a shorter time of 
exposure to AG 14361 after the camptothecin was investigated. The time course of 
reversal of camptothecin-induced DNA strand breaks was studied to find out the 
optimum time to measure the effect of AG14361 on the level of camptothecin-induced 
reversal of DNA strand breaks, preferably at a time when half of the breaks are 
remaining. K562 cells were exposed to 30 nM camptothecin (which corresponds to -50 
and >5% survival after 0.5 and 16 hours exposure respectively and as used in the DNA 
strand break assays in section 5.3.1), for 30 mins and allowed to reverse in drug free 
medium before determination of the levels of DNA strand breaks. The results in Figure 
5.8 show that DNA strand breaks were totally reversed following a 30 min incubation in 
drug-free meduium with no further detectable change for up to 4 hours. Given that most 
of the DNA strand breaks had been reversed within 30 mins of drug removal, it was 
practical to look at earlier time points to examine the effects of PARP-l inhibition. 
175 
0.4 
CI) 
~ 
nJ Q) 0 .3 l- e 
.0 0 
'0 .-
e -nJ.2 
I- Q) 
-
Q) CI) 0.2 Q) .~ 
- -C)nJ 
c-
.- Q) Cl)D:: 
ct 
z 0.1 
c 
0.0 
Figure 5.7 Effect of AG14361 on repair of camptothecin-induced DNA strand 
breaks. K562 cells were exposed to 300 nM camptothecin ± 0.4 IJ.M AG14361 for 30 
mins, after this time the drug was removed and replaced with fresh medium or medium 
containing 0.4 IJ.M AG 14361 for a further 1 or 16 hours. Bar chart shows results from 
one representative experiment. 
DNA single strand breaks (Relative Elution) 
Repair time Camptothecin / control Camptothecin + 0.4 J.1M 
(hours) medium AG14361 / AG14361 
0 0.28 ± 0.08 0.29 ± 0.05 
1 0.062 ± 0.024 0.12 ± 0.018 * 
16 0.04 ± 0.034 0.10 ± 0.04 + 
. Table 5.5 Effect of 1, and 16 hour post-exposure to AG14361 following 30 mans 
exposure to 300 nM camptothecin. 
Mean relative elution values calculated from 3 independent experiments ± SEM are 
glVen. 
* p = 0.023 paired t-test compared to camptothecin alone. 
+ p = 0.06 paired t-test compared to camptothecin alone. 
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Figure 5.8 Time course of reversal of DNA strand breaks induced by 30 mins 
exposure to 30 nM camptothecin. 
K562 cells were exposed to 30 nM camptothecin for 30 mins before removal into drug 
free medium for 10 min, 30 min, 1, 2, and 4 hours. DNA strand breaks were measured 
by alkaline elution. Relative elution was calculated by comparison with untreated 
control. A representative repair profile is shown. 
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5.3.2.3 Effect of AG14361 on repair of camptothecin-induced DNA strand 
breaks. 
The time course of repair of damage induced by 30 mms exposure to 30 nM 
camptothecin indicated that the majority of strand breaks had been repaired within 30 
min of removal of camptothecin (Figure 5.8). Therefore, the effect of AG14361 on 
DNA strand breaks at a 10 and 20 min time point after camptothecin removal was 
investigated. 
K562 cells were exposed to 30 nM camptothecin for 30 mins in the presence or absence 
of 0.4 JlM AG14361. This was followed by removal of camptothecin and incubation 
for a further 10 or 20 mins in fresh medium or medium containing AG14361. DNA 
strand breaks were measured by alkaline elution. The bar chart in Figure 5.9 shows that 
there was no difference in the level of strand breaks present following 30 mins exposure 
to camptothecin alone or camptothecin plus AG14361, as shown previously. Following 
drug removal, the level of breaks decreased, such that at 10 mins, 20% of breaks 
remained. The repair was significantly retarded by AG 14361, such that at 10 mins 500/0 
of breaks remained. Thus, P ARP-l inhibition retards the repair of camptothecin 
induced single strand -2.5- fold following a 10 min repair period. A similar, but non-
significant, trend was followed at 20 mins after drug removal. 780/0 of DNA strand 
breaks were repaired 20 mins after drug removal in the presence of AG 14361, whereas 
84% were repaired in drug free medium (see Table 5.6). 
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Figure 5.9 Effect of AG14361 on the repair of camptothecin-induced strand 
breaks. 
K562 cells were exposed for 30 mins to 30 nM camptothecin followed by repair in drug 
free medium or medium containing 0.4 ~M AG14361 for 0, 10 or 20 mins. Relative 
elution was calculated by comparison with DMSO or 0.4 ~M AG14361 alone control as 
appropriate. Data are the mean of 3 independent experiments ± SEM. 
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Time after camptothecin removal (mins) 
0 10 20 
RE RE % unrepaired RE 0/0 unrepaired 
DNA DNA 
Camptothecin 0.29 ± 0.05 0.063 ± 0.03 20 ± 5.4 0.046 ±0.007 16 ± 2.8 
Camptothecin + AG14361 0.32 ± 0.05 0.16 ± 0.03* 50 ± 1.7 0.073 ± 0.02 22 ± 4.9 
Fold increase in strand 
2.5 ± 0.2 1.4 ± 0.4 
breaks remaining 
- - - - --- ------ -- - -- -- --- ---- - ---------- -- - - --
Table 5.6. Effect of AG14361 on repair of DNA single strand breaks formed following a 30 min exposure to 30 nM camptothecin. 
K562 cells were exposed to 30 nM camptothecin in the presence or absence of 0.4 JlM AG14361 for 30 mins. Following this the drug was 
removed and replaced with fresh medium or medium containing 0.4 JlM AG14361 for a further 10 or 20 mins. DNA single strand breaks were 
measured by alkaline elution. Data shown are mean relative elution values ± SEM. % unrepaired DNA was calculated from RE values for 
strand breaks remaining after 10 or 20 mins, expressed as a percentage of the relevant unrepaired control (with or without 0.4 JlM AG14361). 
*p = 0.001 paired t-test; compared to camptothecin alone. 
0/0 breaks remaining was calculated by the equation RE at time (t) x 100 
RE at time (0) 
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5.3.3 Effect of AG14361 on repair of camptothecin-induced DNA damage 
in PARP-1 wild-type and null cells. 
In K562 cells AG 14361 increased both the cytotoxicity and the level and persistence of 
DNA strand breaks induced by camptothecin by 2 to 3-fold. This suggested that the 
increase in camptothecin-induced growth inhibition by AG 14361 was due to the 
AG 14361-induced increase in persistence of camptothecin-induced single strand breaks. 
P ARP-l wild type and null cells were used to measure whether there were differential 
levels of strand breaks formed in response to treatment with camptothecin, to confinn a 
role for PARP-l in the response to camptothecin. AG14361 was used with these cell 
lines to demonstrate whether there was a differential effect of AG 14361 on the P ARP-l 
wild type and null cells. Therefore this would show that any effect observed was 
mediated by the inhibition of P ARP-l by AG 14361 rather than an effect of AG 14361 on 
some other factor associated with the repair of camptothecin-induced DNA damage. 
5.3.3.1 Effect of camptothecin on DNA strand breaks in PARP-1 wild type 
and null cells. 
As in the previous studies on DNA strand breaks, a concentration of camptothecin and 
incubation period had to be determined that was suitable for the measurement of strand 
breaks. This had to be a concentration that produced measurable strand breaks and 
whose damage was not repaired in less than 10 mins after drug removal (the minimum 
time that was practical for measurement of strand breaks). Initial experiments indicated 
that the concentration and/or time points used for the K562 cells (30 mins 30 nM 
camptothecin followed by 30 mins repair in drug free medium) were not sufficient as 
DNA strand breaks were barely detectable after a 30 min repair of damage caused by 
exposure to 30 nM camptothecin (data not shown). P ARP-l wild-type and null cells 
were exposed to increasing concentrations of camptothecin for 30 mins, to determine an 
appropriate concentration to produce the required levels of DNA strand breaks to study 
repair. Figure 5.10 shows that in the P ARP-l null cell line there was an increase in 
strand breaks that begins to plateau at 111M, but levels of breaks still increase to 10 11M, 
the maximum concentration used in these experiments. Similar results were obtained 
for the PARP-l wild type cells (data not shown). 
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Figure 5.10 DNA single strand breaks induced by increasing concentrations of 
camptothecin in PARP-l null cells. 
Cells were exposed to 0, 30, 100, 300, 600, 1,000, 3,000 and 10,000 nM camptothecin 
for 30 mins before measurement of DNA strand breaks by alkaline elution. Data are 
from one representative experiment. 
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5.3.3.2 Effect of PARP-1 status of cell lines on levels of camptothecin-
induced DNA single strand breaks. 
The P ARP-I wild-type and null cells were exposed to 10 IlM camptothecin for 30 min 
before measurement of DNA strand breaks by alkaline elution. Mean relative elution 
values show that after a 30 min exposure, there were significantly higher levels of DNA 
strand breaks in the P ARP-l null cells (RE = 0.44 ± 0.04) compared to the P ARP-l wild 
type cells (RE = 0.36 ± 0.03, p = 0.002 paired t-test). This suggests that the observed 
hypersensitivity to topo I poisons seen in the P ARP-l null cell line seen in section 3.3.4 
could indeed be due to an increase in the number of DNA strand breaks. 
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5.3.3.3 Effect of AG14361 on repair of camptothecin-induced DNA single 
strand breaks in PARp"1 wild type and null cells. 
To confirm that the increase in strand breaks seen in the presence of AG14361 was due 
to PARP-1 inhibition rather than an effect of AG14361 on other cellular processes the 
effect of AG 14361 on the P ARP-1 wild type and null cells was studied. Initial 
experiments were conducted to determine the optimum repair time following a 1 0 ~M 
camptothecin for 30 mins. It was shown that repair for 60 mins resulted in easily 
detectable and reproducible levels of strand breaks in both cell lines as 20-50 % of the 
DNA damage was still detectable, and that repair seemed to be faster in the wild-type 
compared to the null cells (Figure 5.11). Therefore, PARP-l wild type and null cells 
were exposed to 1 0 ~M camptothecin in the presence or absence of AG 14361 for 30 
mins followed by a 60 min repair incubation in the absence of camptothecin. The 
results are shown in Figure 5.12 for PARP-l wild type cells and Figure 5.13 for PARP-
1 null cells. In the P ARP-1 wild type cells 48.2 ± 4.3 % of the DNA strand breaks 
induced by a 30 in exposure to 1 0 ~M remained following 60 mins repair in drug free 
medium, compared to 57.3 ± 5.80/0 that remained in these cells treated with AG14361. 
In the P ARP-1 null cells, 21.1 ± 2.5 % of the strand breaks induced by the 30 min 
incubation with camptothecin remained after 60 mins incubation in fresh medium 
compared to 21.0 ± 3.40/0 in those PARP-l null cells treated with AG14361. These data 
show that AG 14361 caused a small but significant inhibition of repair at 60 mins in 
PARP-l wild type cells (p = 0.03, paired t-test), but not in the P ARP-1 null cells (p = 
0.8 paired t-test). From these data it appeared that the P ARP-1 wild type cells repaired 
more slowly than the null cells. The P ARP-1 wild type cells achieved -50 % repair 
compared to -80% for the P ARP-l null cells after 60 mins repair in drug free medium. 
This is not consistent with the initial time course experiments shown in Figure 5.11 
where it would seem that the wild type cells repaired the damage much faster than the 
P ARP-l null cells. However, in neither of these studies were both of cell lines 
investigated simultaneously and the contradictory nature of these data may reflect inter-
assay variation. This was investigated in the next section. 
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Figure SolI Repair of PARP-1 wild type and null cells following treatment with 
camptothecino 
P ARP-l wild type and null cells were treated with 1 ° JlM camptothecin for 30 mins. 
The drug was removed and replaced with fresh medium for a further, 10, 30 60, 120, 
240 mins, before measurement of DNA strand breaks by alkaline elution. The repair of 
each cell line was studied in independent experiments and the data presented are 
representative of two independent experiments. 
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Figure 5.12 Effect of AG14361 on camptothecin-induced single strand breaks in 
P ARP-l wild type cells. 
P ARP-l wild type cells were exposed to 10 J-lM camptothecin for 30 mins in the 
presence or absence of 0.4 J-lM AG14361. Following this the drug was removed and the 
cells washed once in Dul A. Fresh medium or medium containing 0.4 J-lM AG14361 
was then added to the cells for a further 60 mins. DNA single strand breaks were 
measured by alkaline elution. Relative elution values for each condition were 
calculated by comparison with the appropriate untreated or 0.4 J-lM AG14361 alone 
control. Data are the mean of 3 independent experiments ± SEM. 
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Figure 5.13 Effect of AG14361 on camptothecin-induced single strand breaks in 
PARP-1 null cells. 
P ARP-l null cells were exposed to 10 J..lM camptothecin for 30 mins in the presence or 
absence of 0.4 J..lM AG14361. Following this the drug was removed and the cells 
washed once in Dul A. Fresh medium or medium containing 0.4 J..lM AG14361 was 
then added to the cells for a further 60 mins. DNA single strand breaks were measured 
by alkaline elution. Relative elution values for each condition were calculated by 
comparison with the appropriate untreated or 0.4 J..lM AG14361 treated control. Data 
are the mean of 3 independent experiments ± SEM. 
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5.3.4 Repair of camptothecin-induced DNA strand breaks in PARP·1 wild 
type and null cells. 
In the prevIOUS section it was shown that AG 14361 increases the persistence of 
camptothecin-induced strand breaks present at 60 mins after drug removal. It also 
appeared that there might be a difference in the rate of repair between the two cell lines. 
As the previous experiments did not compare the cell lines simultaneously it was 
necessary to look at the repair in the same experiment to eliminate inter-assay 
variability. To investigate the repair of camptothecin-induced DNA strand breaks in 
P ARP-1 wild-type and null cells in parallel, cells were exposed to 1 0 ~M camptothecin 
for 30 mins and then allowed to repair in drug-free medium for 1 or 4 hours. A 
representative bar chart of relative elutions and summary of percent damage remaining 
after drug removal relative to an unrepaired control are shown in Figure 5.14 and Table 
5.7, respectively. These data show that there was no significant difference between the 
ability of the P ARP-I wild type or null cells to repair camptothecin-induced DNA 
strand breaks. The difference in levels of strand breaks remaining between this 
experiment and the previous one (Figure 5.12 and Figure 5.13) may be due to the use of 
different passage numbers of the cell lines and different batches of media, as these 
experiments were carried out several months apart. 
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Figure 5.14 Repair of camptothecin-induced DNA strand breaks in PARP-l wild 
type and null cells. 
P ARP-1 wild-type and null cells were exposed to 10 JlM camptothecin for 30 mins, 
camptothecin was then removed and replaced with fresh medium for 0, 1 or 4 hours 
before determination of DNA strand breaks be alkaline elution (see section 2.10). 
Relative elution values are given from one representative experiment. 
1 9 
PARP-l wild type PARP-l null 
o repair 
0.36 ± 0.03 0.44 ± 0.04* (RE) 
1 hour repair 
0.114 ± 0.023 0.109 ± 0.039 (RE) 
% repair 67.8 ± 5.8 72.9 ± 9.5 
4 hour repair 
0.111 ± 0.007 0.101 ± 0.016 
(RE) 
0/0 repair 72.9 ± 2.9 75.2 ± 3.2 
Table 5.7 Repair of camptothecin-induced DNA strand breaks in PARP-l wild 
type and null cells. 
Values are RE and % repair following the indicated period of repair relative to an 
unrepaired control from 3 independent experiments ± SEM. 
(*) p = 0.002 paired t-test compared to PARP-1 wild type cells. 
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5.4 Discussion. 
The studies in this chapter were conducted to determine whether P ARP-1 was involved 
in the repair of topo I poison-mediated DNA damage. If P ARP-1 inhibition could 
inhibit the repair of DNA strand breaks caused by camptothecin this could provide an 
explanation for the potentiation of growth inhibition seen in chapter 3 and data 
previously reported in the literature. To address this, the effect of AG 14361 on the level 
and persistence of camptothecin-induced DNA single strand breaks was investigated in 
the human leukaemia K562 cell line and murine P ARP-1 wild type and null cells. 
In K562 cells AG14361 significantly increased the levels DNA single strand breaks 
caused by a 16 hour exposure to camptothecin by -300/0 (table 5.1), suggesting that the 
increase in DNA strand breaks was a major factor in the potentiation of growth 
inhibition and cytotoxicity observed in these cells as described in chapter 3. The 
increase in DNA strand breaks and cytotoxicity were remarkably similar following a 16 
hours exposure to 3, 10, and 30 nM camptothecin. AG14361 caused a 2.5, l.6 and l.3-
fold increase in DNA strand breaks 1.8, 1.9 and 1.5 fold increase in cytotoxicity 
respectively. Moreover, exposure to AG 14361 for only 30 mins failed to significantly 
increase DNA damage induced by a 30 min exposure to camptothecin, this 
corresponding to the lack of potentiation of camptothecin-induced growth inhibition 
(section 3.3.5). Potentiation of camptothecin-induced cytotoxicity by AG14361 was 
however seen at higher concentrations of camptothecin but unfortunately these could 
not be used in strand break assays as the levels of breaks induced by concentrations 
higher than 30 nM camptothecin were at the upper limit of detection of the assay. 
Previous authors have shown a similar time-dependent effect on strand breaks. 
Increases in DNA single strand breaks by inhibition of P ARP-1 have been reported by 
Mattern et al., (1987), using 3-AB where it was shown that there was no increase in the 
level of strand breaks formed after a 60 min exposure to camptothecin in the presence or 
absence of 3-AB, however an increase in strand breaks could be detected after 16 hours. 
It is interesting that strand breaks were only increased after a 16 hour exposure to 
AG 14361 because AG 14361 is able to inhibit PARP-1 within 10 mins of exposure 
(figure 3.7), and 30 mins has been shown to be sufficient for the formation of maximum 
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levels of topo I-DNA complexes in response to camptothecin (Padget et ai., 2000a). 
Therefore this may suggest that the increase in the level of strand breaks is related to 
down-stream effects of P ARP-l or the cumulative effect of the inhibition of poly(ADP-
ribosylation) of topo I or other proteins, or on the repair of topo I damage. 
Alternatively, the increase in total DNA strand breaks could be a reflection of a 
gradually accumulating increase in break formation or a decrease in reversal/repair. 
Further experiments were designed to investigate this. 
To investigate if a cumulative loss of poly(ADP-ribosylation) from target proteins was 
required to permit a greater induction of DNA breaks by camptothecin, or if prolonged 
P ARP-l inhibition was required for the inhibition of downstream processing of 
camptothecin-induced breaks, the effect of scheduling of AG14361 on a 30 min 
exposure to camptothecin was studied. These experiments demonstrated that a 16 hour 
pre-exposure to AG 14361 had no significant effect on the level of camptothecin-
induced strand breaks produced by a 30 min exposure to camptothecin (table 5.3). 
However a 16 hour post exposure to AG 14361, did increase the level of strand breaks 
remaining after exposure to camptothecin (table 5.4). This would suggest that P ARP-l 
plays a role in the reversal or repair of camptothecin-induced strand breaks, rather than 
their generation. Furthermore, as a pre-exposure had little effect, this suggests that 
increased DNA breaks are not due to modulation of topo I activity by poly(ADP-
ribosylation) in agreement with the data presented in chapter 4, rather, they reflect an 
effect down stream of the DNA damage i.e. in repair. 
As a 16 hour post exposure to AG14361 caused a significant increase in the persistence 
of camptothecin-induced strand breaks detected but the breaks remaining at that time 
were near the lower limits of detection, shorter post-exposure times were investigated. 
This aimed to increase the amount of detectable breaks and therefore provide more 
accurate results. As was previously shown, co-exposure to AG 14361 did not affect 
camptothecin-induced DNA strand breaks following a 30 min exposure. However, 
AG 14361 significantly increased the level of strand breaks remaining after a 10 min 
incubation in drug free medium following drug exposure by 2 to 3-fold (table 5.6). This 
shows that AG 14361 retards the repair of camptothecin-induced DNA strand breaks, 
implicating a role for PARP-l in the repair of such damage. After 20 mins, there were 
still more strand breaks present in those cells treated with AG 14361, although these 
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were not significantly different from those without AG 14361. The reduced 
enhancement of damage seen 20 mins after drug removal may be due to the fact that any 
differences in strand break levels were undetectable as most of the DNA damage had 
been repaired by this point. 
The P ARP-l wild-type and null cells were used to verify that the increased sensitivity of 
P ARP-l null cells to topo I poisons was due to P ARP-l-mediated repair of topo I 
poison-induced DNA damage, and furthermore, that the increased level of strand breaks 
seen in the presence of AG14361 was indeed due to PARP-l inhibition. The results 
presented here show that there were significantly more single strand breaks detectable 
following exposure to camptothecin in the P ARP-l null cells than the wild-type cells. 
This differential sensitivity demonstrates that P ARP-l is involved in the response to 
camptothecin-induced DNA strand breaks and the increased level of breakage most 
probably leads to the hypersensitivity of the null cells to TP as shown in chapter 3. 
Furthermore, AG 14361 increased the level of camptothecin-induced single strand 
breaks in the P ARP-l wild type but not in the P ARP-l null cells. This differential 
effect between the cell lines seen in response to AG14361 shows that the effect of 
AG14361 on the repair of camptothecin-induced DNA single strand breaks is due to 
inhibition of P ARP-l rather than on some other factor involved in the processing of 
topo I poison-induced DNA damage. 
Further studies presented here have shown the P ARP-l null cells were not deficient in 
the repair of camptothecin-induced DNA single strand breaks. This may be a reflection 
of the time points studied as there may be a rapid, P ARP-l-dependent repair phase 
followed by a slower P ARP-l independent phase. It is also possible that P ARP-l-
independent pathways can function to repair this damage in the absence of P ARP-l and 
these could possibly be upregulated to compensate for the lack ofPARP-l in these cells. 
It has been shown by some authors that BER is active in the absence of NAD+ or 
P ARP-l in in vitro and whole cell studies, which could suggest that the hypersensitivity 
of PARP-l null cells was related to the lack of poly(ADP-ribosylation) of other cellular 
targets and not related to BER (Allinson et al .. 2003, Vodenicharov et aI., 2000). 
Allinson et al., also showed that that PARP-l null cell extracts repaired DNA damage at 
a faster rate than the P ARP-l wild type cell extracts, consistent with data presented in 
this thesis. However it is widely accepted that PARP-I is involved in BER (see chapter 
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1), and has been shown that the long patch BER pathway cannot function in the absence 
of P ARP-l. However, the short patch mechanism is still partly functional in the 
absence of P ARP-l (Dantzer et aI., 2000) and therefore could serve to repair the 
camptothecin-induced damage seen in this study. Therefore, in the absence of P ARP-l 
it is possible that the camptothecin-induced damage could still be repaired by a P ARP-l 
independent mechanism that is not normally the primary mechanism of repair. This 
may be an adaptive response to the removal of P ARP-l. It is known that P ARP-2 can 
participate in the BER pathway performing a similar role as P ARP-l (Schreiber et aI., 
2002). It may be that there is redundancy in the BER pathway and that BER can 
operate in the absence of P ARP-l by using P ARP-2. However, AG 14361 is known to 
inhibit P ARP-2 (Karen Maegely (Pfizer), personal communication) as well as P ARP-l, 
thus this cannot account for the repair seen in the presence of AG 14361. 
It should be noted that single strand breaks are not the only lesion produced following 
exposure to camptothecin. Had more time been available, it would be useful to 
investigate levels of double strand breaks that are produced following collision with 
replication forks, as P ARP-l is able to bind double as well as single strand breaks. As 
camptothecin induced damage can occur independently of replication, most likely due 
to collision with the transcription machinery, it would also be interesting to study the 
effect of P ARP-l inhibition on replication-independent camptothecin-induced DNA 
damage. 
The studies in this chapter demonstrate that exposure to AG 14361 not only increases the 
level of camptothecin-induced single strand breaks, but also slows the repair of these 
breaks upon drug removal, confirming that P ARP-l is involved in the repair of topo I 
poison-mediated DNA damage. This finding could have implications if a combination 
of topo I poison and P ARP-l inhibitor should ever be used in the clinic. It would be 
important to ensure that P ARP-l inhibition was maintained for a period of time after 
topo I poison exposure for the effect of P ARP-I inhibition on cellular cytotoxicity to be 
maximised. 
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Summary 
• AG14361 Increases the levels of camptothecin-induced DNA strand breaks VIa 
inhibition ofP ARP-l in K562 and P ARP-l wild-type cells under certain conditions. 
• Reversal of camptothecin-induced strand breaks is delayed by AG 14361 in K562 
cells. 
• Camptothecin-induced single strand breaks can be repaired in the absence of P ARP-
1, demonstrating that there are P ARP-l-independent mechanisms to repair this 
damage. 
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Chapter 6 
Effect of PARP-1 inhibition on topoisomerase I 
poison induced cytotoxicity in cell lines deficient 
in DNA repair. 
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6.1 Introduction. 
In the previous chapters it was shown that AG 14361 could potentiate the growth 
inhibitory and cytotoxic effects of topo I poisons, and that this was most likely to be via 
modulation of DNA repair. The aim of this chapter was to determine how inhibition of 
PARP-l was affecting the repair of to po I poison-mediated DNA damage. For example, 
whether the inhibition of P ARP-1 prevented the repair of the lesion via the BER 
pathway or some other repair pathway such as non-homologous end-joining or 
homologous recombination. 
Many DNA repair pathways have been implicated in the repair of topo I poison-
mediated DNA damage. The major cytotoxic lesion created following exposure to topo 
I poisons occurs upon collision of the stabilised cleavable complex with the replication 
fork (Hsaing et aI., 1989). Such a collision results in three different types of DNA 
damage as shown in Figure 6.1. Firstly, there is an irreversible protein-DNA covalent 
complex with topo I covalently linked to the 3'-terminus of the break. This covalent 
complex has been shown to be removed by a 3'-tyrosyl DNA phosphodiesterase (TDP-
1, Yang et a/., 1996). This protein can cleave the phosphotyrosyl bond between the 
enzyme and the DNA. Although genetic inactivation of TDP-1 sensitised yeast to topo 
I poisons, the degree of sensitisation was less than expected suggesting that there are 
other ways to remove the cleavable complex (Pouliot et aI., 1999, Liu et aI., 2002). 
Secondly, there is a DNA double strand break consisting of the 5'-end of the cleaved 
strand annealed to the newly synthesised strand. The double strand breaks may be 
repaired by either of the double strand break repair pathways, HR or NHEJ. Finally, 
there is a single stranded region of the partially replicated lagging DNA strand. The 
single strand section may be repaired by BER (reviewed by Pourquier and Pommier 
2001). 
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Figure 6.1 DNA damage caused in response to topo I poisons. Arrows indicate types 
of DNA damage, and the pathways and enzymes used to repair them are shown in 
boxes. 
The most likely mechanism of interaction between P ARP-1 and the repair of topo I 
poison-mediated DNA damage is via the BER pathway. As has been reviewed 
previously in this thesis, the role of P ARP-1 in BER has been demonstrated although 
not yet fully understood. BER is the pathway that is responsible for the repair of DNA 
single strand breaks caused by excision of damaged bases e.g. following exposure to 
alkylating agents or IR (see section 1.6.7). BER has been implicated in the repair of 
topo I poison-induced DNA damage, as cells deficient in BER through a mutation in the 
BER scaffold protein, XRCC1 (EM9 cells) are hypersensiti e to topo I poisons 
independently of replication (Caldecott and Jeggo, 1991, Barrows et al., 1998). In 
addition to this KB cells that have been made resistant to camptothecin, through 
exposure to increasing concentrations of camptothecin, have been shown to over-
express XRCCl. The degree of resistance of these cells was directly related to the level 
ofXRCC1 in the cell line (park et al., 2002). 
It is possible that P ARP-1 is involved in the repair of the oth r forms of damage. 
Recently a link has been suggested between the repair of the cleavable complex and the 
BER pathway. TDP-1 is the enzyme that sp cifically clea s th chemical bond that 
joins the active site tyrosine of topo 1 to the 3'-end of D A all v ing removal of the 
cleavable complex (Yang et al.,19 6). This enzyrne is \ id ly conserved between 
eukaryotes which sugg sts that it plays an important rol . Ho\ e er this enzyme does 
not have the 3'-pho phatas activit that i r quir d to pradu a 3'-hydroxyl D A end 
for the extension f D b .111 nl r paIr ome of 
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the lesions. Polynucleotide kinase phosphatase (PNK) can remove the phosphate and 
produce a 3'-hydroxyl terminus that can be extended by DNA pol p and ligated by 
ligases. Yeast deficient in PNK exhibit hypersensitivity to camptothecin demonstrating 
the importance of PNK in the response to camptothecin (Meijer et al., 2002). Recently 
a link has been made between PNK, TDP-1 and the scaffold protein XRCCl. Plo et al., 
(2003) compared the EM9, XRCC1 deficient cell line and XRCC1-complemented EM9 
cells and showed that the camptothecin-sensitivity observed in the EM9 cells was 
related to reduced single strand break repair. The XRCC 1-transfected EM9 cell line 
also exhibited and enhanced TDP and PNK activities. XRCC 1 was also shown to 
immunoprecipitate with TDP and PNK. An interaction between XRCC 1 and PNK has 
previously been shown using yeast-2-hybrid technology and further investigation 
revealed that XRCC1 stimulated PNK activity (Whitehouse et al., 2001). These 
findings indicated that there might be a functional link between the BER repair pathway 
and the repair of topo I cleavable complexes. It was hypothesised that XRCC 1 may act 
as a scaffold protein to recruit TDP-1, to sites of breakage, as it does with other repair 
enzymes. Once the topo I had been excised by TDP-1 and the DNA ends prepared by 
PNK, then the BER pathway could religate the break (see figure 6.2). XRCC1 is known 
to associate with P ARP-1 via BRCT domains present in both proteins, and possibly the 
zinc-finger domain of P ARP-l. (Masson et al., 1998). Therefore it is possible that 
P ARP-1 could be involved in the repair following the removal of the cleavable complex 
by TDP-l. 
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Figure 6.2 Proposed mechanism for the repair of topo I cleavable complexes by an 
XRCCI-dependent pathway. The repair complex is shown at the top and is co-
ordinated by the scaffold protein, XRCC1, to repair the DNA strand break. Tdpl 
hydrolyses the 3'-phosphotyrosyl bond, then PNK hydrolyses the 3'-phosphate and 
phosphorylates the 5'-hydroxyl. The gap is sealed by ligase III. Adapted from Plo et 
al., (2003). 
There is evidence that the homologous recombination repair pathway (HR) is involved 
in the repair of camptothecin-induced DNA double strand breaks. HR is described in 
section 1.5.3.1. Briefly, HR is an error-free mechanism of DSB repair that uses the 
sister chromatid as a template. This process involves the Rad50IMREIIINBS-1 
complex and Rad52. The involvement of HR in the response to camptothecin has been 
demonstrated using cells deficient in a number of components of the HR pathway. 
Yeast deficient in homologous recombination through a mutation in Rad52 are 
hypersensitive to camptothecin (Nitiss and Wang, 1988). Cells deficicnt in NBS-I, part 
of the Rad50IMrel1INBS 1 complcx, are three-fold hypersensitive to camptothecin 
(Kraakman-van der Zwet et al.. 1999). The CHO cell line irslSF, del~.:ient in the HR 
protein XRCC3, has been shown to be 5-fold sensitive to camptothecin. Amaudeau et 
al.. (2001) and Hinz et al.. (2003) have made a comparison ofsensitiviL",s ofNHEJ and 
HR-deficient cells to camptothccin. The HR deficicnt irs 1 SF cells \\ d':: shown to be 
more sensitive to a 24 hour exposure to camptothccin than NHEJ-J~licient V3 cells, 
2()0 
with LC90 values of 10 nM and 50 IL\1 respectively, compared to 100 n!-.1 in the parental 
AA8 cell line. In these papers it was suggested that HR played a more important role in 
the response to camptothecin than NHEJ due to to reletive sensitiyities of the cell lines. 
Recently, a role for P ARP-l in the HR pathway has been described. P ARP-l deficient 
cells have an increased level of sister chromatid exchange suggesting a hyper 
recombination phenotype. Therefore a role for P ARP-l in HR was inY\..stigated. Rad51 
foci fonn at sites ofHR, and are an indicator of an efficient HR patl1\vay; cells deficient 
in HR do not fonn foci. Rad51 foci form in PARP-l deficient celL and in general 
P ARP-l does not co-localise with Rad51 foci. Repair of DSB by HR was not affected 
in the P ARP-l deficient cells. However, the P ARP-I null cells l: . i)layed a 30% 
increase in spontaneous Rad51 foci and inhibition of P ARP-l by 3-AB, ISQ or 
NUI025, increased the number of cells with Rad51 foci in the PArvT)-l proficient cell 
line but not the P ARP-I deficient line. Therefore this shows tha~ Rad51 foci are 
induced in the absence of PARP-I or as a consequence of PARP-l j,l1iibition. These 
data suggest that P ARP-l does not participate in HR directly but may have a role in 
controlling the DNA damage recognised by HR (Schultz et al., 2003). -l .~fefore as HR 
is involved in the repair of camptothecin-induced damage and P ARP-l 11l..ty be involved 
in HR, it is possible that P ARP-I exerts some effect on topo I cytotoA,,:ity via the HR 
pathway. 
Camptothecin-induced DNA double strand breaks can be repair(~ via the NHEJ 
pathway. NHEJ is reviewed in section 1.5.3.2. This process is mOf( l.l.Or-prone and 
involves the rejoining of the DNA double strand breaks by DNA-PK, X~~C4 and DNA 
ligase IV, without the synthesis of new DNA. Much of the eyidcll __ ': [Of the role of 
NHEJ in the response to camptothecin involves the nuclear serine-threonine kinase 
DNA-PK, which is activated by DNA double strand breaks, and is the end-binding 
complex of the NHEJ pathway. DNA-PK activity was increased 5-fo:J ill HT-29 cells 
in response to I hour treatment with camptothecin. Also, human glioL:" :,oma MO-59J 
cells, deficient in the catalytic subunit of DNA-PK are hypersensiti \'(' tv camptothecin 
(Shao ct aI., 1999 yalues not quoted). The V3 cell line also defici':I,l in DNA-PK has 
been shown to be ~2-fold more sensiti\-e to camptothecin than thc p"rcl1lal AA8 cell 
line (Amaudeau ct aI., 2003). This demonstrates that NHEJ is invol\(d in the response 
to camptothecin. 
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P ARP-1 and DNA-PK have been shown to interact by a number of 811:hors (reviewed 
by de Murcia and Shall, 2000). Both of these enzymes have similar properties in the 
single and double strand break repair pathways. Both bind DNA strand interruptions 
and are activated by strand breaks, however DNA-PK is only activated by double strand 
breaks (Blier et aI., 1993), where as PARP-1 is activated by a variety <"'[breaks, both 
double and single strand (Benjamin and Gill, 1980). P ARP-1 poly(ADP-ribosylates) 
DNA-PK, leading to activation of the protein. DNA-PK phosphoryL.l.'!s PARP-l in 
vitro without any consequence (Ruscetti et aI., 1998). PARP-l, Di\i\-PLcs and the Ku 
proteins have also been shown to co-immunoprecipitate (Morrisson et aI., 1997). Since 
there is definitely a functional interaction between these proteins, such an interaction 
may regulate a pathway that is involved in the repair of camptothecin-induced DNA 
damage, and it is therefore possible that P ARP-l may mediate its c I ,(:ct on topo I 
activity via the NHEJ pathway. 
Topo I poison-mediated DNA damage may also be repaired by the 1111kotide excision 
repair pathway (NER) pathway. NER is described in detail in section 1.5.2. NER is 
responsible for the repair of damage that distorts DNA such as thymiJinl' Jimers caused 
by UV light and other bulky adducts. This process involves many pL -.:ins including 
XPC, XPG, CSA, CSB and RP A. Cells deficient in either of the 1\\ \) transcription 
coupled-NER proteins associated with Cockayne syndrome (CSA tilld CSB), are 
sensitive to camptothecin (Squires et aI., 1993). Camptothecin-resistanl MCF/C4 cells 
have also been shown have enhanced nucleotide excision repair acti\'ity (Fujimori et aI., 
1996). However, cells deficient in other NER factors such as the XP factors are not 
hypersensitive to camptothecin (Squires et aI., 1993). P ARP-l is not t1> ,ught to have a 
role in the NER pathway as 3-AB was unable to potentiate UV damagl ~ Cleaver et aI., 
1983). Since it has been reported that P ARP-l does not exert its effect 011 topo I poison-
mediated cytotoxicity via the NER pathway, this pathway was not ill\'l..stigated in this 
study. 
PARP-I is primarily thought to be involvcd in BER, although the cvi I.'!nce presented 
above may implicate a role for PARP-I in the HR and NHEJ pathways as well. As 
multiple DNA lesions are fomlcd in response to damage with camptothccin which may 
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be repaired by any of these pathways, it is therefore possible that the modulation of 
repair of DNA strand breaks by P ARP-l may be mediated by one or all of these 
pathways. Therefore the aim of this chapter is to elucidate which pathway or pathways 
are involved in the response of P ARP-l to camptothecin-mediated DNA damage. 
6.2 Aims. 
In the previous chapters it has been shown that AG 14361 increases the cytotoxic and 
growth inhibitory effects of topo I poisons. Investigations into the mechanisms 
underlying this have shown that P ARP-l is most likely to effect topo I poison-induced 
cytotoxicity via modulation of DNA repair. The aim of the experiments described in 
this chapter was to try to identify the repair pathways that P ARP-l was involved in, to 
cause the modulation of camptothecin-induced cytotoxicity. In this chapter the effect of 
AG 14361 on camptothecin-mediated cytotoxicity in BER, HR and NHEJ deficient cell 
lined was investigated as P ARP-l has been implicated in these pathways as described 
above. Also the effect of AG 14361 on the repair of camptothccin-induced DNA 
damage in BER deficient cells was investigated. The theory behind these studies was 
that if a cell line was already deficient in a repair pathway then fwiher in inhibition of 
this pathway should not result in potentiation of cytotoxicity. 
Cell lines used in this chapter. 
The cell lines used in this chapter were the parental AA8 Chinese hamster ovary cell 
line, the base excision repair deficient EM9 cell line, non-homologous end joining 
deficient V3 cell line and the homologous recombination deficient irs 1 SF cell line. 
The CHO EM9 cell line is deficient in base excision repair. This cell line was isolated 
on the basis of their hypersensitivity to killing by ethyl methanesulfonate (EMS) 
(Thompson et aI., 1980). These cells have ~ 1 O-fold sensitivity to EMS and MMS, 
moderate sensitivity to H202 and camptothecin (2 to 5-fold), and weak sensitivity to IR, 
ENU, MNNG, mitomycin C, UYe, UVA, near \"isible and blue light and heavy metals. 
They also have a reduced rate of DNA-strand break rejoining following treatment with 
X-rays, EMS or MMS, as well as a high baseline frequency or sister chromatid 
exchange compared to the parental AAS cell line (Thompson ef aI., 1982). It had been 
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demonstrated that hypersensitivity is mediated via a mutation in the XRCCI gene. 
resulting in a deficiency in base excision repair. (Thompson et aI., 1990). The gene 
coding for XRCC 1 in the EM9 cells has been shown to contain a C to T base change in 
codon 221, which introduces a termination codon one third of the way into the 
sequence. This results in the expression of a truncated XRCC 1, which does not contain 
either of the BRCT domains (Shen et ai., 1998). 
The V3 CHO cell line is deficient in NHEJ via a deficiency in DNA-PK. The V3 cell 
line does not express DNA-PKcs due to an inactivating mutation in the C-terminal 
region of one allele of the DNA-PKcs gene (XRCC7) (Blunt et aI., 1995). These cells 
have been shown to be 2-fold more sensitive to camptothecin than the parental AA8 cell 
line (Arnaudeau et ai., 2003). 
The irslSF cell line was isolated because of their 2-fold sensitivity to x-rays. These 
cells have been shown to have cross-sensitivity to UV (2.5-fold), EMS (2.3-fold), 
camptothecin (5-fold), and also the cross-linking agent mitomycin C, cisplatin, nitrogen 
mustard, and melphalan (between 20 to 60-fold). The irs 1 SF cells have also been 
reported to have a ~50% reduced efficiency of repair of single strand breaks, and an 
increased levels of spontaneous chromosome aberrations (10-24% abnormal cells). 
(Caldecott and Jeggo, 1991, Fuller and Painter, 1988). The irs1SF cells have been 
shown to be deficient in the HR protein, XRCC3 (Tebbs et ai., 1995). These cells show 
an altered death and cell cycle checkpoint responses following treatment with 
camptothecin (Hinz et al., 2003). 
6.3 Results 
6.3.1 Effect of AG14361 on camptothecin-induced cytotoxicity in AA8, 
EM9 and V3 cell lines. 
To investigate the repair pathways involved in the effect of AG 14361 on topo I poison 
induced damage, cells deficient in DNA repair were obtained. The cell lines were 
deficient in BER, HR, and NHEJ pathways, the three pathways for which there is 
evidence of interaction with P ARP-1 (Table 6.1). The cell lines were selected on the 
basis of their common parental cell line to allow comparison between cell lines. Since a 
human model set of cell lines were not available, Chinese hamster ovary cell lines were 
used as these cells have a well defined genotype and phenotype as described in section 
6.2. The repair deficient cells were used to define which pathway or pathways involve 
PARP-l. 
Cell Line Repair Deficiency Genotype 
AA8 Parental CHO cell line 
EM9 BER Deficient in XRCC 1 
V3 NHEJ Deficient in DNA-PKcs 
irs1SF HR Deficient in XRCC3 
Table 6.1 Cell lines used in this chapter and their characteristics 
To investigate the effect of AG14361 on camptothecin-induced cytotoxicity in AA8, 
EM9 and V3 cell lines, c1onogenic survival assays were used (see section 2.4.4). Initial 
studies with a range concentrations of camptothecin defined the appropriate 
concentration range for investigation of the impact of 0.4 ~M AG14361 on 
camptothecin-induced cytotoxicity. Cells were exposed to camptothecin for 16 hours 
before harvesting, counting and re-plating a defined number of cells for colony 
formation in drug-free medium (Figure 6.3). Cell survival was expressed as a percent of 
untreated control. 
Figure 6.3 shows that the irs 1 SF cells \\'ere the most sensitive to camptothecin, being 
9.3 ± 2.8-fold more sensitive to camptothecin than the AA8 cells (p = 0.003 unpaired t-
test). The EM9 cells \\'cre 4.5 ± 1.2-fold more sensitivc to camptothecin than the AA8 
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cells (p = 0.0007, unpaired t-test). The V3 cells were 1.6 ± O.4-fold more sensitive to 
camptothecin than the AA8 cells (p = 0.03, unpaired t-test). The EM9 cells were 2.9 ± 
0.9-fold more sensitive to camptothecin than the V3 cells (p = 0.03, unpaired t-test). 
These sensitivities are consistent with previous reports (Arnaudeau et al., 2001, 
Caldecott and Jeggo, 1991). The significant sensitivities of all three repair-deficient cell 
lines to camptothecin relative to the repair-proficient parental cells implicate all three of 
the rapair pathways in the cellular response to topo I poisons, with HR being the most 
important and NHEJ the least. In order to determine which pathways involve P ARP-1, 
the effect of AG14361 on camptothecin induced cytotoxicity was investigated in these 
cells. Initial revealed that the irs 1 SF cells were hypersensitive to AG 14361 alone and 
combination experiments with these cells are described in section 6.3.2. The following 
section describes studies with V3 and EM9 cells in comparison with AA8 cells. 
The effect of co-incubation with 0.4 J.lM AG14361 on the cytotoxicity of a 16 hour 
exposure to an appropriate range of camptothecin concentrations was investigated. 
Survival curves of mean data from AA8, V3 and EM9 cell lines exposed to 
camptothecin ± AG 14361 for 16 hours are shown in Figure 6.4, Figure 6.4, and Figure 
6.5, respectively. Pooled data from all cell lines are shown in Table 6.2. AG14361 
significantly potentiates the cytotoxicity of camptothecin by 2.25-fold in AA8 cells, and 
2.0-fold in V3 cell lines (p = 0.005 and 0.04 respectively paired t-test). This was 
comparable with the 2 to 3-fold potentiation seen in the K562 and PARP-I wild type 
cell lines in chapter 3 and potentiation of other cell lines by P ARP-1 inhibitors as 
reported in the literature. Potentiation of camptothecin-induced cytotoxicity by 
AG 14361 in the V3 cells suggests that there are other camptothecin-induced damage 
repair pathways besides NHEJ that involves PARP-1. AG14361 did increase the 
sensitivity of EM9 cells to camptothecin 1.8-fold, however, this increase was not 
significant (p = 0.18, paired t-test). Examination of the individual experiments shows 
that there was no potentiation in of camptothecin-induced cytotoxicity by AG 14361 in 3 
of the 5 experiments. This would suggest that BER was the major P ARP-l dependent 
pathway for repair of camptothecin-induced DNA damage. However as potentiation 
was seen in some experiments there is still a possibility that there are other P ARP-l-
dependent pathways that lead to survival follo\ving exposure to camptothecin, besides 
BER. 
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Figure 6.3 Relative sensitivities of AA8, V3, EM9 and irslSF cells to camptothecin. 
Cells were exposed to a range of concentrations of camptothecin for 16 hours. Cell 
survival was detennined by the clonogenic assay (see section 2.4.4). The number of 
colonies fonned was expressed as a percentage of the untreated control. Data are 
representative curves from one individual experiment using triplicate samples, they are 
not from the same experiment and not all examined at the same time. 
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Figure 6.4 Effect of AG14361 on camptothecin-induced cytotoxicity in AA8 cells. 
AA8 cells were exposed to 0, L 3, 10, 30, 50 and 80 nM camptothecin in the presence 
or absence of 0.4 j.lM AG14361 for 16 hours. Cell survival was detennined using the 
clonogenic assay (see section 2.4.4). The number of colonies fonned was expressed as 
a percentage of the untreated or 0.4 j.lM AG14361 alone control. Data are from one 
representative experiment. 
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Figure 6.5 Effect of AG14361 on camptothecin-induced cytotoxicity in V3 cells, 
V3 cells were exposed to 0, 1, 3, 10, 30, and 50 nM camptothecin in the presence or 
absence of 0.4 J.lM AG14361 for 16 hours. Cell survival was detennined by the 
clonogenic assay. The number of colonies fonned was expressed as a percentage of the 
relevant untreated or 0.4 J.lM AG 14361 alone control. Data are from one representative 
experiment. 
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Figure 6.6 Effect of AG14361 on camptothecin-induced cytotoxicity in EM9 cells. 
EM9 cells were exposed to 0, 1, 3, 10, and 30 nM camptothecin in the presence or 
absence of 0.4 JlM AG 14361 for 16 hours. Cell survival was determined by c1onogenic 
assay. The number of colonies formed was expressed as a percentage of the untreated 
or 0.4 JlM AG 14361 alone control. Data are from one representative experiment. 
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Cell Line LCso (oM) PFso(nM) 
Camptothecin 25.0 ± 3.5 
AA8 2.25 ± 0.31 Camptothecin + 
12.2 ± 2.4 ** 
AG14361 
Camptothecin 5.6 ± 1.2 
EM9 I.S5 ± 0.63 
Camptothecin + 
4.0±1.1 NS 
AG14361 
Camptothecin 16.1±4.0 
V3 2.0 ± 0.50 Camptothecin + 
10.2 ± 3.6* 
AG14361 
Table 6.2 Survival of AAS, EM9 and V3 cell lines following a 16 hour exposure to 
camptothecin in the presence or absence of AG14361. 
Mean LC 50 values from at least 4 independent experiments are given ± SEM. Mean 
PF 50 ± SEM values calculated using LCso values from individual experiments. 
NS = not significantly different from camptothecin alone, * p < 0.05, ** p< 0.01 
compared to camptothecin alone, paired t-test. 
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6.3.2 Effect of AG14361 on camptothecin-induced cytotoxicity In the 
irs1 SF (homologous recombination-deficient) cell line. 
The effect of AG14361 on homologous recombination deficient cells was also 
investigated. The irs 1 SF cell line was used, which has a deficiency in homologous 
recombination that can be corrected by transfection of XRCC3 into the cell. This cell 
line has previously been shown to be hypersensitive to camptothecin and are unable to 
rejoin single strand breaks (Caldecott and J eggo, 1991, Fuller and Painter, 1988). It has 
also been shown that these cells are hypersensitive AG14361 alone (S Kyle, NICR 
personal communication). Therefore it was necessary to identify a concentration of 
AG14361 that would not cause significant cytotoxicity compared to untreated control in 
a cell survival assay, but still inhibited P ARP-1 activity. 
The cytotoxic effects of AG 14361 on the irs 1 SF cell line were detennined by 
clonogenic survival assay (section 2.4.4). The survival of irs 1 SF cells following a 16 
hour exposure to increasing concentrations of AG14361 is shown in Figure 6.7. 
Survival ofirs1SF cells was reduced by < 50% by 0.4 11M AG14361. At concentrations 
below 100 nM there was >90% survival. In order to detennine if this hypersensitivity 
was due to altered P ARP-1 activity and to ensure that an adequate concentration of 
AG 14361 to inhibit P ARP-1 activity was used in subsequent clonogenic survival 
assays, PARP-1 activity was detemlined in the presence and absence of AG14361 by 
e2PJ-NAD incorporation as described in section 2.6. The effect of a 10 min exposure to 
a range of concentrations of AG14361 on PARP-1 activity is shown in Figure 6.8. 
Based on these data, P ARP-1 actiyity in these cells was 70 pmoV106 cells. 
Concentrations of AG14361 (15 and 70 nM) that inhibited PARP-l by 50 and 90% 
respectively, were chosen for the determining the impact of P ARP-1 inhibition on 
camptothecin-induced cytotoxicity in irs 1 SF cells. These concentrations of AG 14361 
had minimal effect on cell sUr\'i\'al and corresponded to a 26 and 6-fold lower 
concentration of AG 1-+361 than used in the other cell lines. 
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Figure 6.7 Effect of AG14361 on cell survival in the irslSF cell line. 
irslSF cells were exposed to 0.01, 0.1 and 0.-+ /-lM AG14361 for 16 hours. Cytotoxicity 
was determined by clonogenic assay (section 2'-+.4). The number of colonies formed 
was expressed as a percentage of the untreated control. Data from one experiment is 
shown. 
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Figure 6.8 Inhibition of PARP-l activity by AG14361 in the irslSF cell line. 
irslSF cells were exposed to 0, 10,20,30, 50,70, and 100 nM AGI4361 for 10 mins. 
P ARP-I activity was detennined by C2PJ-NAD incorporation assay (see section 2.6). 
Data are the mean of three independent experiments ± SEM. 
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6.3.3 Effect of AG14361 on survival of irs1 SF cells treated with 
camptothecin. 
The clonogenic survival of irs 1 SF cells in response to 16 hours treatment with 
camptothecin in the presence or absence of 15 or 70 nM AG14361 was determined. 
The survival of irslSF cells is shown in Figure 6.9 and mean LC50 values are given in 
Table 6.3. These data show that there was no significant potentiation of camptothecin 
induced cytotoxicity in the presence of either of the concentrations of AG14361 used (p 
> 0.2 paired t-test). The combination of acute hypersensitivity to both camptothecin and 
AG14361 in these cells has made it difficult to determine if there was any additive 
effect of AG14361 on camptothecin cytotoxicity. Since much lower AG14361 
concentrations had to be used in these experiments it is difficult to compare these data 
with those in the other cell lines. Nevertheless, looking at figure 6.9, 70 nM AG14361 
did cause a similar degree of potentiation to that seen in the AA8 and V3 cell lines, 
suggesting that HR-independent mechanisms are involved in AG 14361-mediated 
potentiation of camptothecin. 
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Figure 6.9 Effect of AG14361 00 camptothecio-ioduced cytotoxicity io irslSF cells. 
irslSF cells were exposed to 0, 1, 3, 10, and 30 nM camptothecin in the presence or 
absence of 15 or 70 nM AG14361 for 16 hours. Cell survival was measured using the 
clonogenic assay (see section 2.4.4). The number of colonies formed was expressed as 
a percentage of the untreated, 15 or 70 nM AG 14361 alone control. Data are from a 
single representative experiment. 
LCso Camptothecio LCso Camptothecio + LCso Camptothecio + 
(oM) 15 oM AG14361 (oM) 70 oM AG14361 (oM) 
2.69 ± 0.69 1.66 ± 0.43 1.43 ± 0.42 
PFso l.97 ± 0.72 2.29 ± 0.79 
. 
Table 6.3 Effect of AG14361 on camptothecin induced cytotoxicity io irsl~F cells. 
Mean IC50 values from 4 independent experiments ± SEM are shown. PF50 values 
calculated from Ie so \'alues from individual c:-;pcriments ± SEM. 
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6.3.4 DNA damage repair in AA8 and EM9 cell lines. 
In the previous section it was found that AG14361 significantly enhanced 
camptothecin-induced cytotoxicity in repair competent, NHEJ and HR-deficient cells 
but in the camptothecin-sensitive, BER-deficient, EM9 cells, potentiation by AG 14361 
was not significant. This suggested that (a) BER was implicated in the repair of 
camptothecin-induced DNA damage and (b) that P ARP-1 dependent repair/survival was 
conducted via BER. To investigate this further at the level of DNA repair, the effect of 
AG14361 on repair of camptothecin-induced DNA strand breaks in AA8 and EM9 cells 
was determined by alkaline elution. 
EM9 cells had been reported to be slow at rejoining single strand breaks (Thompson et 
al., 1982). Therefore an appropriate time point to measure the repair in these cells was 
determined. Initial experiments revealed that the EM9 cells had completed -70% repair 
of single strand breaks induced by 1 0 ~M camptothecin after 60 mins repair in drug free 
medium. This was comparable to the results obtained using the P ARP-1 wild-type and 
null cells where 48 and 57% repair was achieved after 60 mins in drug free medium. 
Therefore, 60 mins was thought to be a suitable time point to measure rqJ.lir in these 
cells in comparison with the AA8 cells. AA8 and EM9 cells were treated with 10 ~M 
camptothecin for 30 mins in parallel, the drug was removed and the cells were allowed 
to repair in drug free medium or medium containing AG 14361 for a furth~r 60 mins. 
Representative elution profiles and table summarising data for triplicate experiments is 
shown in Figure 6.10 and Table 6.4, respectively. The EM9 cells had significantly more 
DNA strand brca;~s than the AA8 cells after a 30 min exposure to camptotL'-';~,l without 
repair; relativc elution in EM9 cells = 0.63 ± 0.0-+ compared to 0.44 ± 0.04 ill AA8 cells 
(p = 0.05 paired t-test), in agreement \\'ith the retarded repairing in these cc;;s reported 
previously (Thompson et aI., 1982). These data show that AG 14361 significantly 
retarded DNA strand break ligation in the AA8 cell line at 60 mins (p = O.td, paired t-
test). In the [:\ 19 cells, despite the initial higher k\d of DNA breaks cOl11 tJclred to the 
AA8 cells, tlw IdlC of repair in the presence and absencc of AG 14361 wa" \\..: y similar 
to that obsen'L'" in the AA8 cells (Table 6.-+), i.e. in both cdl lines --) ~~ breaks 
remained aftcr a 60 min in control medium and --+0 % in ;\G 1-+361-containl.lg ll1edium. 
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However the effect of AG14361 on breaks rejoining was not significant in the EM9 
cells (p = 0.09 paired t test). 
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Figu re 6.10 Effect of AG 14361 on repair of camptothecin-induced DNA strand breaks in AA8 and EM9 cells. 
~'("I ~~!, 1 r:\:') ; .. ~1s \\'::':_ \.\1' ;::l~ ~o ~ f\ p' ll~\: '; ~. t:I'::::: in t:l'~ 1 1"""l:1CC (lr "l'::-C:LC 0: \~11~rl fCllluwcd by n.:'lC\':11 ofthc drug and a f'lIrthn 
GO . iii 11;) rq,,,:i ill 11",->11 medium or 11l",J;lI1l1 containing 0.4 ~ltyl AG14361. Elution profiles from one representative expcrimcnt arc shown. 
219 
AA8 E~I~)-
No repair (Relative Elution) 0.49 ± 0.04 0.63 ± ( 0..+ I 
60 min repair (Relative elution) 0.12 ± 0.011 0.16 ± ('.1)1"+ 
0/0 DNA strand breaks .. 25.8 ± 2.9 remaImng I 25.1±2.9 I 
I 
I 
60 mm repaIr + AG14361 
0.19 ± 0.003 * 0.25 ± OJ 123+ (Relative elution) 
% DNA strand breaks .. 39.7 ± 1.7 38.4 ± 1.9 remammg 
Table 6.4 Effect of AG14361 on repair of camptothecin-induced D:~A strand 
breaks in AA8 and EM9 cells. 
Cells were exposed to 10 /-lM camptothecin in the presence or absence of AG 14361 
followed by removal of the drug and a further 60 mins repair in medium ± 0.4 /-lM 
AG 14361. Data are mean relative elution values from 3 independent experiments ± 
SEM. % DN:\ strand breaks was calculated using relative elution values r 1!" smlples 
and expressin:: these as a percentage of a camptothecin treated control tl' !t was not 
allowed to repai r. 
Significant differences from RE value in absence of AG14361 are given by: + p < 0.01, 
* P < 0.05. 
220 
6.4 Discussion 
Topo I poison-mediated DNA damage has been reported to be repaired by a number of 
different pathways including BER, HR, and NHEJ (reviewed in Pourquier and 
Pommier, 2001, Caldecott and Jeggo, 1991, Arnaudeau et al., 2001). The aim of this 
chapter was to try to determine by which repair pathways P ARP-1 was acting to 
increase the amount of DNA damage caused by topo I poisons thus enhancing 
cytotoxicity. P ARP-l may play a role in all of these pathways as described in the 
introduction to this chapter and therefore the effect of AG 14361 on cells deficient in 
BER, NHEJ and HR was investigated. 
The data presented in this chapter showed that cells deficient in BER, NHEJ and HR 
were hypersensitive to topo I poisons compared to the parental AA8 cell line. The 
irslSF cells were 9-fold more sensitive, EM9 cells were 4.5-fold more sensitive, and the 
V3 cells were 1.5-fold more sensitive to camptothecin than the parental AA8 cell line 
(table 6.2). This is consistent with previous data showing hypersensitivity of these cell 
lines to topo I poisons. Caldecott and J eggo (1991) showed that the EM9 cells were 4-5 
fold more sensitive to camptothecin than the parental AA8 cell line following a 24 hour 
exposure and the irslSF cells were more sensitive than the EM9 cells (figures not 
available). Arnaudeau et at., (2001) compared the V3 and irslSF cells to the AA8 line, 
and showed that they were ~2 and 10-fold more sensitive to camptothecin, respectively. 
This would suggest that all of these DNA repair pathways are involved in the repair of 
topo I-mediated DNA damage. These data also suggest that HR was the predominant 
repair pathway for the repair of camptothecin-induced DNA damage followed by BER 
and NHEJ. 
AG14361 was used to investigate in which pathway of topo I poison-induced DNA 
damage repair PARP-l was involved. In theory, ifPARP-1 was involved in only one of 
these pathways then in a cell line already deficient in this particular pathway AG 14361 
should not potentiate the cytotoxicity of camptothecin. In other words, if a cell had 
already lost a particular repair pathway that involved P ARP-l then inhibiting PARP-l 
should not have any effect. The effect of AG 14361 on camptothecin-mediated 
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cytotoxicity was investigated in all of the DNA repair deficient cell lines mentioned 
above 
AG 14361 caused a significant -2-fold potentiation of camptothecin-mediated 
cytotoxicity in the AA8 cells (table 6.2) consistent with the levels seen in other repair 
competent cells, e.g. the K562 (1.9-fold), P ARP wild type cells (3.4-fold) (chapter 3) 
SW620 (1.7-fold) and LoVo (1.6-fold) (Calabrese et al JNCl in press). AG1.+361 also 
caused 2-fold potentiation of camptothecin cytotoxicity in the V3 cell line. This would 
suggest that P ARP-l may mediate its effect on camptothecin-induced cytotoxicity via 
NHEJ -independent pathways 
AG14361 caused a 0.7 to 4.3-fold increase in camptothecin-induced cytotoxicity in 
EM9 cells however (table 6.2), the cytotoxicity of camptothecin and AG 14361 was not 
significantly different from the cytotoxicity of camptothecin alone in EM9 cells (4 out 
of 5 PF 50 values fell in the range of 0.7 -1. 7). This may suggest that the involvement of 
P ARP-l in BER is at least in part responsible for the potentiation of camptothecin-
induced cytotoxicity by AG14361. Nevertheless, since potentiation was occasionally 
observed, albeit not significantly (due to experimental variation), it is possible that 
P ARP-l may be involved in other pathways as well. Interestingly, the level of 
potentiation caused by AG 14361 in AA8 cells treated with camptothecin was not 
equivalent to a loss of BER (by comparison of LC50 for AA8 + 361 12.0 nM, and EM9 
camptothecin alone 5.6 nM). This indicates that inhibition of P ARP-l does not have 
such a marked effect on survival after exposure to camptothecin as loss of XRCC 1, and 
suggests that the BER pathway may function to a limited extent in the absence of 
P ARP-l activity. P ARP-l has been shown to be more or less essential for long patch 
BER but only about 50%) of short patch repair (Dantzer et al.,2000). Indeed, some 
authors have shown that P ARP-l is not essential for BER. Vodenicharov et al., (2000) 
showed that extracts prepared from wild-type and P ARP-l null cells were able to repair 
plasmid DNA damaged by either X-rays or MNNG. Similarly P ARP-l null cells were 
also able to repair MNNG-induced plasmid DNA damage as efficiently as the wild-type 
cells. Therefore it is possible that BER can function in the absence of P ARP-l 
explaining why the effect of loss of XRCCI and hence BER was more detrimental than 
lack of PARP-l. Alternatively, XRCCI could be involved in other repair pathways in 
which PARP-l does not participate. Thus, the relative sensitivities of E\19 and AAS 
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cells to camptothecin and potentiation of camptothecin by AG 14361 suggests that (a) 
PARP-l activity facilitates, but is not essential (b) P ARP-l may be involyed in XRCC 1-
independent repair pathways. 
The irslSF cells were intrinsically sensitive to AG14361 alone (figure 6.7). This 
suggests that PARP-l can compensate for HR in resolution of spontaneous DNA 
damage or that in the absence of HR, DNA lesions are resolved by pathways dependent 
on P ARP-l activity. The possibility that the sensitivity of these cells to AG 14361 was 
because they had upregulated P ARP-l activity, in response to loss of HR, was 
investigated. However, total stimulatable P ARP activity in these cells is -70 
pmol/million cells was comparable to that in K562 (113 pmoVmillion cells) and PARP 
wild-type cells (78 pmoVmillion cells, data not shown) 
As the irslSF cells were hypersensitive to AG14361, concentrations of AG14361 were 
determined that were P ARP-l inhibitory but not growth inhibitory for use in the 
cytotoxicity assay. These concentrations of AG 14361 were not able to significantly 
potentiate the cytotoxicity of camptothecin following a 16 hour exposure (table 6.4). 
This may suggest that P ARP-l is involved in the repair of camptothecin-induced DNA 
strand breaks via the HR pathway. Schultz et al., (2003) has shown that P ARP-l may 
playa role in the recognition of the DNA damage repaired by the HR machinery as a 
deficiency in P ARP-l leads to an increase in the spontaneous generation of Rad 51 foci. 
These foci are central to the HR process. Therefore this evidence suggests that P ARP-l 
may playa role in the recognition of camptothecin induced double strand breaks and 
target them for repair by the HR pathway. 
The lack of potentiation of camptothecin cytotoxicity by AG 14361 in irs 1 SF cells may 
simply be due to the fact that lower concentrations of AG14361 had to be used because 
of its intrinsic cytotoxic effect in these cells. The concentrations of AG 14361 used with 
these cells were between 6 and 26 times lower than that used in the other cell lines in 
this study. It may be that the concentration of AG 14361 being used in these cells is not 
enough to cause potentiation of cytotoxicity. P ARP-l inhibition was shown to be 50 
and 900/0 for 15 and 70 nM AG 14361 respectively. The inhibition seen at 70 nM 
AG 14361 is comparable to the -950/0 inhibition seen in response to 0.4 ~M AG 14361 in 
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the other cell lines studied. If more time had been available, it would have been useful 
to investigate the potentiation of camptothecin by 70 nM AG14361 in AA8, EM9 and 
V3 cells. to aid in the interpretation of the results obtained with the irs 1 SF cells. 
The lower (and not statistically significant) levels of potentiation of camptothecin 
cytotoxicity in the EM9 cells, compared the other cell lines suggested that P ARP-l \\'as 
primarily involved in BER-mediated repair of camptothecin-induced DNA lesions. 
Therefore the effect of AG14361 on repair of camptothecin- induced DNA damage was 
investigated in the EM9 cells compared to the wild type AA8 cells. If more time had 
been available the other cell lines would also have been investigated. 
The EM9 cells formed an increased number of single strand breaks in response to 
treatment with camptothecin compared to the AA8 cell line. This increase could 
explain the hypersensitivity of these cells to camptothecin. However, a difference in the 
level of DNA single strand breaks was not shown by Plo et aI, (2003), comparing the 
effects of a one hour exposure to 1 !J.M camptothecin in EM9 and XRCC 1-
complemented EM9 cells. The difference in these findings may be due to the cell lines 
used and the different experimental procedure used. 
The EM9 cells have been reported to be deficient in the repair of single strand breaks 
(Thompson et aI., 1982). However, under the conditions used here (measurement of 
DNA breaks 60 mins after a 30 min pulse with 10 !J.M camptothecin) the repair of single 
strand breaks in the EM9 cells was similar to that seen in the AA8 cells i.e. 70-75%. 
This is in opposition to Plo et aI., (2003), who showed that repair was delayed in the 
EM9 cells compared to the XRCCI-complemented cells after 15 and 30 mins. It is 
possible that the time point that was used in this study was too long after drug removal, 
and the BER dependent stage of repair occurred immediately following drug exposure 
therefore accounting for the conflicting studies. Comparable experiments with P ARP-l 
wild type and null cells also exposed to a 30 min pulse with 10 !J.M camptothecin 
indicated that only 50-60% of the DNA strand breaks had been resolved by 60 mins, 
which is similar to the results obtained with the AA8 and EM9 cells. Therefore, the 
proportion of DNA breaks remaining at different times may be due to the concentration 
of camptothecin used and hence the initial level of breaks. Much more rapid repair was 
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seen after 10 min repair in the K562 cells exposed to 30 nM camptothecin (chapter 5) in 
which 80% of the damage was repaired within 10 mins following drug removal. The 
observation that DNA breaks immediately after camptothecin-exposure (without repair 
incubation) were -30% higher in the EM9 cells than the AA8 cells may be due to 
reduced repair, if there is a dynamic equilibrium between induction and repair of 
camptothecin-induced DNA strand breaks. If the rate of induction of breaks was the 
same in both cell lines but the rate of repair was slower in the EM9 cells then more 
breaks would accumulate in these cells. 
AG 14361 caused a significant increase in the number of single strand breaks remaining 
at 60 min after camptothecin removal in the AA8 cell line. This is consistent with data 
presented for the K562 and P ARP-l wild type cells in this thesis (see chapter 5). 
AG 14361 also caused a similar increase in the EM9 cells but this was not statistically 
significant. This combined with the lack of statistically significant potentiation of 
camptothecin in EM9 cells could implicate PARP-l in XRCCI-dependent (presumably 
BER) pathways of DNA repair. However, the fact that both retardation of DNA repair 
and increased cytotoxicity was observed suggests the involvement of P ARP-l in other 
DNA repair pathways, such as NJEJ and HR, possibly to a lesser extent then BER. The 
involvement of P ARP-l in these repair pathways is described in the introduction of this 
chapter. 
Summary. 
1. V3, EM9 and irslSF cells are 1.5, 4.5 and 9-fold more sensitive to camptothecin 
than AA8 cells indicating that HR is the most important pathway for repair of 
camptothecin-induced DNA damage, followed by BER, with NHEJ playing a minor 
role. 
2. AG 14361 significantly potentiates the cytotoxicity of camptothecin to a similar 
extent in the AA8 and V3 cell lines, therefore suggesting that P ARP-l is involved in 
NHEl-independent pathways. 
3. AG 14361 potentiated camptothecin-induced cytotoxicity in EM9 cells to a lesser 
degree than the other cell lines and the potentiation was not statistically significant. 
Retardation of repair of camptothecin-induced DNA damage in EM9 cells, although 
apparently similar to the retardation of repair in AA8 cells, was also not statistically 
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significant. These data would suggest that P ARP-1 is involved in BER-mediated 
repair of topo I poison-induced DNA damage, consistent with its well known role in 
this pathway in response to IR and alkylating agent-induced DNA damage. 
Nevertheless, the fact that repair does appear to be retarded and cytotoxicity 
potentiated by AG14361 (albeit without statistical significance) suggests a role for 
P ARP-1 in other pathways as well. 
4. irs 1 SF, HR deficient, cells are hypersensitive to AG 14361 and this is not due to 
altered P ARP-1 activity in these cells or sensitivity to inhibition by AG 14361. 
5. AG14361 does not significantly potentiate camptothecin-induced cytotoxicity in 
irs 1 SF cells, this may suggest that P ARP-1 may playa role in the HR pathway or 
that the concentration of AG14361 was too low. 
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The cytotoxicity and anti-tumour effects of topo I pOIsons such as camptothecin. 
topotecan and irinotecan can be enhanced by inhibition of P ARP-l in vitro and in vi\'O, 
As new combinations of chemotherapy are always being sought to overcome the 
problems of resistance and reduce side effects, the combination of topo I poison and 
P ARP-l inhibitor may have a role in the clinic. In order to design studies that may 
enable the clinical use of this combination to be optimised, the molecular mechanisms 
underlying this potentiation of cytotoxicity need to be elucidated. 
There were two hypotheses put forward to explain the effect of P ARP-l on topo I 
poison mediated cytotoxicity. Firstly that P ARP-l inhibited the activity of topo I via 
poly(ADP-ribosylation) which, by virtue of the negative charge conferred by the 
polymer on the enzyme, caused topo I to be repelled from the DNA. The second 
hypothesis was that P ARP-l was involved in the repair of topo I poison-mediated DNA 
damage, probably via its role in the base excision repair pathway. In this study these 
hypotheses have been tested using AG14361, a novel potent inhibitor of PARP-l, 
developed by the Experimental Therapeutics group at the Northern Institute for Cancer 
Research, University of Newcastle upon Tyne in collaboration with Pfizer GRD. 
A role for P ARP-l in the response to topo I poison-induced cytotoxicity and growth 
inhibition has been confinued. The inhibition ofPARP-l by AG14361 caused a -2-fold 
potentiation of topo I poison-induced cytotoxicity or growth inhibition in all of the wild 
type cells used in this thesis (P ARP-l wild type MEFs, K562 and AA8 cells, see figures 
3.8, 3.12 and 6.4). This effect was achieved at a concentration of AG14361 (0.4 ~M) 
that inhibited P ARP-1 activity by >90% without affecting cellular proliferation or 
survival (table 3.2). P ARP-1 null MEF cells were 2 to 3-fold hypersensitive to 
topotecan, a similar degree to that seen in P ARP-l wild-type cells treated with 
AG1436l (figure 3.8). This confinus a role for PARP-l in the response to topo I 
poisons. AG 14361 was unable to significantly potentiate the cytotoxicity of topotecan 
in P ARP-1 null cells. However, the residual P ARP activity that was detected in the null 
cells, possibly due to PARP-2, could be inhibited by AG14361 (table 3.2). 
AG 14361 was able to significantly potentiate camptothecin-mediated growth inhibition 
in K562 cells following a 16 hour exposure. However, after 30 mins exposure. 
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AG 14361 did not significantly reduce the GI50 for camptothecin. This suggested that 
the effect of P ARP-1 on topo I poison-mediated growth inhibition was time dependent. 
The difference in potentiation between these two time points was not related to 
modulation of topo I activity. Topo I activity was determined by measurement of DNA 
relaxation activity; and levels of cleavable complexes were measured using the 
TARDIS and K-SDS assays. Using the relaxation assay AG14361 did not significantly 
alter topo I activity following either a 30 min and 16 hour exposure (figure 4.1 and 4.2). 
Cleavable complexes were not increased by AG 14361 following exposure to 
camptothecin for either 30 mins (figure 4.6 and 4.9) or 16 hours (figure 4.10). Neither 
was the persistence of the complexes following drug removal (table 4.1 and figure 
4.11). It had previously been reported that P ARP-1 poly(ADP-ribosylated) topo I 
following IR (Boothman et al., 1994), however exposure to IR prior to treatment with 
camptothecin had no significant effect on the level of cleavable complexes (figure 4.8). 
Neither did AG14361 have an effect on the level of cleavable complexes produced by 
exposure to IR and camptothecin compared to treatment with camptothecin alone. This 
suggested that P ARP-1 did not exert its effect on topo I poison-mediated cytotoxicity by 
modulation of to po I activity via poly(ADP-ribosylation). 
To address the second hypothesis, that P ARP-l is involved in the repair of topo I 
poison-mediated DNA damage, the levels of DNA single strand breaks were measured 
in response to treatment with camptothecin. AG14361 significantly increased the level 
of single strand breaks by -30 % following a 16 hour exposure to camptothecin (table 
5.1). There was no detectable difference in DNA single strand breaks induced by a 30 
minute exposure to camptothecin verses camptothecin and AG 14361 (table 5.2). This 
was consistent with the growth inhibition data where there was no reduction in the GI50 
for camptothecin by AG14361 after only 30 mins (figure 3.11). A study of different 
schedules of exposure 30 min exposure to camptothecin with or without 16 hours 
exposure to AG14361 showed that AG14361 increased the level of strand breaks when 
cells were treated with AG 14361 after camptothecin but not when the exposure to 
AG 14361 preceded camptothecin (table 5.3 and 5.4). Thus, the increase in strand 
breaks was shown to be a reflection of decreased repair of strand breaks rather than 
increased formation. The repair of camptothecin-induced strand breaks following a 10 
min repair interval was significantly retarded by AG 14361 such that there were 28% 
more strand breaks remaining in those cells incubated in AG 14361-containing medium, 
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compared to control medium, following a 30 min pulse with camptothecin (figure 5.9). 
Thus it would seem that P ARP-l has a role in the repair of DNA damage caused by 
camptothecin. 
DNA single strand break levels were also studied in the P ARP-l wild type and null 
cells. Exposure to camptothecin for 30 mins resulted in the accumulation of ~200 ~ 
more DNA single strand breaks in the PARP-l null cells compared to the PARP-l wild 
type cells (table 5.7), showing that PARP-l is involved in increasing the levels of DNA 
strand breaks in response to treatment with camptothecin. This may provide the 
explanation for the differential sensitivities of the P ARP-l wild type and null cells 
treated with topotecan (figure 3.8). The increase in DNA strand breaks caused by 
AG14361 in camptothecin treated PARP-l wild type cells was surprising as inhibition 
of PARP-l by AG14361 did not significantly increase the levels of strand breaks 
following a 30 min exposure in K562 cells although small increases were detectable in 
these cells. It may therefore be that difference between strand break levels in K562 
cells treated with camptothecin and AG41361 were not high enough to be significantly 
different to those treated with camptothecin alone. AG14361 significantly increased the 
levels of DNA strand breaks remaining 60 mins after drug removal in P ARP-l wild type 
cells. AG 14361 did not increase the persistence of strand breaks in the P ARP-l null 
cells therefore confirming that AGl4361-induced accumulation of DNA single strand 
breaks was due to P ARP-l inhibition. The increased strand breakage caused by 
AG 14361 observed in the P ARP-l wild type cells was very small compared to those in 
the K562 cells, which may be a reflection of the cell type, or due to differences in the 
repair period (60 verses 10 mins). Had more time been available the conditions might 
have been optimised to enable better detection of the effect of AG14361 or lack of 
P ARP-l on rate of repair. 
The lack of a significant effect of AG14361 on camptothecin-induced strand breaks in 
K562 cells following a 30 min exposure may be due to the limits of sensitivity of the 
assay. The level of strand breaks is a reflection of both the rate of formation and 
reversal/repair. Therefore, after a 30 min exposure the decreased repair of the breaks in 
P ARP-l inhibited cells may not be detectable if the rate of formation of the breaks is 
equivalent or greater than the rate of repair. Over time the balance between fom1ation 
and rc\'t~rsal will result in an accumulation of strand breaks if the breaks are not repaired 
1'1 
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as fast as they are fonned. The greater accumulation of camptothecin-induced breaks in 
the presence of AG 14361 most likely arises from an inhibition of repair, thus tipping the 
balance in favour of fonnation. Similarly, in the cytotoxicity assays, in the 30 min 
exposure period there may be insufficient time to accumulate a greater number of 
breaks in P ARP-l inhibited cells (compared to control) that could lead to an increase in 
cytotoxicity following drug removal. 
The P ARP-l null cells were not deficient in the repair of camptothecin-induced strand 
breaks as might be expected. Extracts from P ARP-l null cells have been shown 
previously to be able to repair single strand plasmid DNA damage by Vodenicharov et 
al., 2000, and Allinson et at., 2003, in a NAD+ -independent manner. This would 
suggest that P ARP-I is not essential for BER. This has been shown by Satoh et al., 
(1993) where P ARP-I deficient cell extracts were able to conduct BER in an NAD-
independent manner. However, extracts containing inhibited PARP-I (either by 3-AB 
or NAD+ -depletion) were unable to conduct efficient BER, this was thought to be due to 
obstruction of access of the repair proteins to the site of damage as P ARP-I is unable to 
be removed from the nick site via poly(ADP-ribosylation). In this study, it has been 
demonstrated that repair of camptothecin-induced DNA strand breaks is possible in the 
presence of inhibited PARP-I, opposing the results of Satoh et al., prompting the need 
for alternative explanations. The BER pathway has two sub-pathways that can cross 
over therefore it is possible that BER could be accomplished in the absence of P ARP-l 
by using an alternative mechanism. P ARP-2 is also able to perfonn the same role in 
BER as P ARP-l, therefore a NAD+ -dependent BER could still function in the absence 
of P ARP-I. It has been shown by Dantzer et al., (2000) that P ARP-l null cells 
demonstrate a 90% deficiency in long patch BER, but still retain 500/0 of the short patch 
capacity compared to the wild type cells. This confinns the data presented in this thesis 
showing that BER does function in the absence of P ARP-l activity. In addition, as 
there are a number of different lesions produced in response to treatment with 
camptothecin (single, double and protein-linked strand breaks), it is possible that 
camptothecin-induced DNA damage could be repaired by a variety of different 
pathways including BER, HR and NHEJ. 
The mechanism by which P ARP-l may be exerting its effect on the repair of topo I 
poison-mediated cytotoxicity was also investigated. PARP-l has been shown to be 
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involved in the BER pathway. There are also reports suggesting that it may function in 
the HR and NHEJ pathways as well. To investigate which pathway or pathways are 
involved in the cellular response to camptothecin and in which P ARP-l acts by, cells 
deficient in BER, (EM9) HR (irslSF) and NHEJ (V3) were used. All of these cell lines 
were hypersensitive to camptothecin compared to the parental AA8 cell line. The 
irslSF were most sensitive (9-fold), followed by EM9 (4.5-fold) and then V3 (1.5-fold) 
(figures 6.4, 6.5 and 6.6) consistent with results obtain previously by Caldecott and 
Jeggo, (1991), Amaudeau et al (2001) and Hinz et al (2003). This suggested that the 
HR pathway was the most important pathway in the repair of topo I poison mediated 
DNA damage, followed by BER and NHEJ. AG14361 was able to potentiate the 
cytotoxicity of camptothecin in the V3 cells suggesting that P ARP-l-dependent repair 
of camptothecin-induced DNA damage did not overlap with the NHEJ pathway. 
AG14361 did not significantly potentiate the cytotoxicity of camptothecin or 
significantly retard repair of camptothecin-induced DNA strand breaks in the EM9 cells 
(table 6.2). Therefore this suggests that P ARP-l is involved in the repair of 
camptothecin-induced DNA strand breaks via the BER pathway. However, since 
AG 14361 caused a modest (not significant) potentiation of camptothecin-induced 
cytotoxicity and retardation of repair of camptothecin-induced DNA single strand 
breaks, it is possible that P ARP-1 is involved in other pathways as well. 
AG14361 did not potentiate the cytotoxicity of camptothecin in the HR deficient cells 
(table 6.3). Although, these results are hard to interpret as lower concentrations of 
AG 14361 had to be used due to the sensitivity of HR -deficient cells to treatment with 
AG14361 alone. This may suggest that PARP-1 is involved in the HR pathway, as has 
been suggested by Schultz et al (2003) where it was proposed that P ARP-1 may serve to 
control the DNA damage recognised by the HR pathway. It may also suggest that in the 
absence ofPARP-1, HR acts to repair damage normally repaired by PARP-1-dependent 
pathways, and thus in the absence of both pathways there is hypersensitivity. It may 
also be that the concentration of camptothecin used was too low to exert an effect. To 
determine whether this was the case it would have been useful to conduct cytotoxicity 
assays with the lower concentration of AG 14361 used with the irs 1 SF cells on other 
wild type cells to see if this concentration was sufficient to potentiate cytotoxicity. The 
results from this would help to detemline whether AG 14361 had an effect on 
camptothecin induced cytotoxicity in these cells. 
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Possibly the most plausible mechanism by which P ARP-1 can modulate topo I 
cytotoxicity is via its role in BER. As has been shown here there was no significant 
potentiation of cytotoxicity or retardation of strand break repair in cells deficient in 
BER. The BER pathway may repair the single strand break formed on collision with 
the replication fork, or it may be involved in processing the single strand break fonned 
following removal of the cleavable complex. The last proposal is supported by the 
observation that the tyrosyl DNA phosphodiesterase (TDP) responsible for the removal 
of the topo I cleavable complex associates with the BER scaffold protein XRCC 1 (Plo 
et al., 2003). Thus P ARP-l may be involved in the processing of the strand break via 
the BER pathway, and through its association with XRCC1 as PARP-1 has been shown 
to be necessary for the formation of XRCC1 nuclear foci, in response to DNA damage 
(EI-Khamisy et al., 2003). This theory would be consistent with the increased strand 
breaks seen 10 mins after removal of camptothecin in those cells treated with AG 14361 
(figure 5.9). The level of complexes in those cells treated with AG 14361 would be the 
same as those treated with camptothecin alone as the action of the TDP should be the 
same in the presence or absence of AG 14361, which is also consistent with the 
observations made in this study. P ARP-1 could be involved in the recruitment of 
XRCC1 to the break formed following or prior to removal of the complex by TDP, or 
down stream of XRCC1 in the recruitment of other repair enzymes (illustrated in figure 
7.1). To further determine whether this was the case it would be interesting to see if 
there was any interaction between P ARP-1 and TDP. This could be investigated by 
immunoprecipitation, or by searching the amino acid sequence of TDP to see if there 
was a poly(ADP-ribose) binding motif, although, actual interaction between these 
proteins may not actually be necessary, as both proteins interact with XRCC 1. It may 
also be interesting to see if P ARP-1 locates to the sites of damage repaired by TDP, by 
studying the foci formed in response to damage caused by topo I poisons. 
The increased potentiation of cytotoxicity seen after 16 hours may just be due to the 
accumulation of damage, but may also be a reflection of the involvement of P ARP-l in 
other repair pathways apart from BER. After a 16 hour exposure collision of the 
camptothecin-stabilised cleavable complex with the replication fork is likely to have 
occurred in at the least 50%) of the cells as the doubling time for K562 cells is -20 
hours, therefore there will be double stand breaks as well as single strand breaks. :\s 
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was demonstrated by the hypersensitivity of the irslSF cells to camptothecin and their 
lack of potentiation by AG14361, there may be a role for PARP in the HR pathway, As 
mentioned previously, Schultz et al (2003) has suggested that P ARP-l may serve to 
control the repair recognised by HR. This hypothesis could be tested by studying the 
repair of double strand breaks following 16 hours incubation. If P ARP-l was invoh'ed 
in this pathway then AG14361 may increase double strand breaks. Similarly the irslSF 
cells could be used to compare the effect of camptothecin on this pathway in 
comparison with the AA8 cells in the same way that single strand breaks have been 
studied in the EM9 cells compared to the AA8 cells. Although there may be difficulties 
in obtaining meaningful results as the irsl SF cells are hypersensitive to AG 14361 
therefore other cell lines deficient in HR could be used. 
It would be interesting to investigate the intrinsic sensitivity of the irs 1 SF cells to 
AG 14361. It has been shown in this study that the levels of P ARP-l activity in these 
cells is comparable to other wild type cells such as the K562 and P ARP-l wild-type 
therefore the sensitivity of these cells is not due to decreased P ARP-l activity. P ARP-1 
could be involved in the repair pathways that do function in these cells, or HR could be 
a back-up mechanism that acts in the absence of P ARP-l. Further characterisation of 
the repair pathways functioning and the levels of the repair proteins in P ARP-l null 
cells may provide insight into the sensitivity of these cells to AG 14361. 
To summarise, the studies contained within this thesis show that P ARP-l is involved in 
the response to topo I poisons. This is likely to be via repair of the single strand breaks 
formed on removal of the topo I from the DNA, via the base excision repair pathway. 
There are also indications that other pathways may be involved, in particular the 
homologous recombination pathway. These possible methods of interaction of P ARP-l 
in the response to topo I poisons are summarised in figure 7.1. 
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Figure 7.1 The role of PARP-l in topo I poison-mediated cytotoxicity. 
(1) Topo I binds to DNA forming a protein linked single strand break that can be 
stabilised by camptothecin. (2) Persistence of strand breaks may cause collision of the 
complex with the replication fork. Double strand breaks are formed that can be repaired 
by HR. In the absence ofPARP-l this damage may be repaired by the HR pathway. (3) 
P ARP-l may be stimulated in response to topo I-related DNA single strand breaks. 
Poly(ADP-ribose) polymers are formed and recruit XRCCI. TDP via its association 
with XRCCI may be recruited to remove the topo I. The remaining gap may then be 
repaired by PNK, pol ~ and ligase III, according to the BER pathway. Inhibition of 
PARP-I would prevent the recruitment of the DNA repair enzymes. (4) An alternative 
pathway may involve the removal of topo I by TDP, and the remaining single strand 
break may be repaired by XRCC 1 and the other members of the BER pathway 
involving PARP-l. Inhibition ofPARP-l may delay repair (4) and cause persistence of 
the strand break, which Inay collide with the replication fork causing double strand 
breaks and eventual cell death. 
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